var title_f29_4_29760="Normal lateral elbow radiograph child";
var content_f29_4_29760=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal lateral radiograph of the elbow of a 2-year-old child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The anterior fat pad is readily seen (arrow); the posterior fat pad is not visible. A line drawn along the anterior cortex of the humerus intersects the capitellum in its middle third (solid line). A line drawn along the axis of the radius also passes through the center of the capitellum (dashed line).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bachman D, Santora S. Orthopedic trauma. In: Textbook of pediatric emergency medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_4_29760=[""].join("\n");
var outline_f29_4_29760=null;
var title_f29_4_29761="Macular erythema in toxic shock syndrome";
var content_f29_4_29761=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Toxic shock syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Macular erythema in toxic shock syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_4_29761=[""].join("\n");
var outline_f29_4_29761=null;
var title_f29_4_29762="Patient information: When your cancer treatment makes you tired (The Basics)";
var content_f29_4_29762=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16250\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?15/45/16093\">",
"         General ways to save your energy",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_table\" href=\"UTD.htm?42/49/43804\">",
"          Specific ways to save your energy",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?14/15/14588\">",
"           Tips for sleeping better at night",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?23/35/24114\">",
"         Patient information: Brachytherapy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/40/1667\">",
"         Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/36/579\">",
"         Patient information: Managing pain when you have cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/57/19346\">",
"         Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/32/40450\">",
"         Patient information: Radiation therapy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: When your cancer treatment makes you tired (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/when-your-cancer-treatment-makes-you-tired-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H2082240\">",
"      <span class=\"h1\">",
"       What causes people to feel tired during cancer treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Feeling tired is a common side effect of cancer treatments such as chemotherapy, radiation, and certain medicines. Also, people who have surgery usually feel tired afterward.",
"     </p>",
"     <p>",
"      Other factors can make people feel tired. People might feel tired, weak, or have no energy because they:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Are sad, worried, or stressed",
"       </li>",
"       <li>",
"        Aren&rsquo;t eating enough",
"       </li>",
"       <li>",
"        Have trouble sleeping or do not get enough sleep",
"       </li>",
"       <li>",
"        Have pain",
"       </li>",
"       <li>",
"        Have a condition called anemia, in which their body has too few red blood cells. When a person has too few red blood cells, his or her body doesn&rsquo;t get all the oxygen it needs.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2082247\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor will ask about your symptoms and daily activities. He or she might do blood tests to check for conditions that could cause you to feel tired but can be treated.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2082254\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own so that I don&rsquo;t feel so tired?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. There are many things you can do so that you don&rsquo;t feel so tired. You can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Exercise &mdash; Exercise can increase your energy and help improve your appetite. Try to exercise every day, even if it&rsquo;s just a short walk.",
"       </li>",
"       <li>",
"        Do yoga &mdash; Doing gentle yoga with breathing exercises helps many people feel less tired and sleep better at night.",
"       </li>",
"       <li>",
"        Lower your stress &mdash; To lower the stress in your life, you can:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Not try to do too much. Instead, ask your family and friends to help you get your chores done.",
"       </li>",
"       <li>",
"        Take time off from work or work fewer hours",
"       </li>",
"       <li>",
"        Do relaxation exercises or meditate",
"       </li>",
"       <li>",
"        Talk with a mental health expert or go to a support group",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Save your energy &mdash; To avoid using too much energy, you can change your daily routines and how you go about your activities. For example, try to plan ahead, rest often, and use devices to help you reach things.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      For general and specific tips on ways to save your energy, see the tables: (",
"      <a class=\"graphic graphic_table graphicRef80431 \" href=\"UTD.htm?15/45/16093\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef61916 \" href=\"UTD.htm?42/49/43804\">",
"       table 2",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Improve your sleep habits &mdash; Try to get at least 8 hours of sleep every night. If you have trouble sleeping, you can do things to improve your sleep habits. For example, you can:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Avoid drinking alcohol or caffeine in the late afternoon or evening",
"       </li>",
"       <li>",
"        Go to bed and wake up at the same time every day",
"       </li>",
"       <li>",
"        Limit your naps during the day, and don&rsquo;t nap more than 30 minutes at a time",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      For more tips on ways to improve your sleep habits, see the table: (",
"      <a class=\"graphic graphic_table graphicRef67141 \" href=\"UTD.htm?14/15/14588\">",
"       table 3",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Make sure to eat and drink enough each day. You can also ask your doctor or nurse about taking a daily vitamin.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2082261\">",
"      <span class=\"h1\">",
"       When should I call my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your doctor or nurse if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feel dizzy or very weak",
"       </li>",
"       <li>",
"        Are so tired that you can&rsquo;t do your daily activities, including bathing, getting dressed, and eating",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2082268\">",
"      <span class=\"h1\">",
"       Are there treatments that might help my symptoms?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Different types of treatments might help, depending on your symptoms and other conditions. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Treatments for anemia, if you have anemia &mdash; Doctors can treat certain kinds of anemia with medicines. They can also treat it with a procedure called a &ldquo;blood transfusion.&rdquo; During a blood transfusion, a person gets blood (into their vein) that has been donated by someone else.",
"       </li>",
"       <li>",
"        Medicines called &ldquo;stimulants&rdquo; &mdash; These medicines can increase a person&rsquo;s energy. Doctors usually prescribe these medicines only to people who are severely tired and weak.",
"       </li>",
"       <li>",
"        Medicines to treat depression &mdash; Depression is when people feel very sad. People with depression often feel tired and don&rsquo;t sleep well at night. If you are depressed, your doctor might prescribe medicines called &ldquo;antidepressants.&rdquo;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2082275\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=see_link\">",
"       Patient information: Managing pain when you have cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/40/1667?source=see_link\">",
"       Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=see_link\">",
"       Patient information: Radiation therapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/35/24114?source=see_link\">",
"       Patient information: Brachytherapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/57/19346?source=see_link\">",
"       Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?29/4/29762?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16250 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-259ED97FEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_4_29762=[""].join("\n");
var outline_f29_4_29762=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2082240\">",
"      What causes people to feel tired during cancer treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2082247\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2082254\">",
"      Is there anything I can do on my own so that I don&rsquo;t feel so tired?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2082261\">",
"      When should I call my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2082268\">",
"      Are there treatments that might help my symptoms?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2082275\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16250\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/45/16093\">",
"      General ways to save your energy",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_table\" href=\"UTD.htm?42/49/43804\">",
"       Specific ways to save your energy",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_table\" href=\"UTD.htm?14/15/14588\">",
"        Tips for sleeping better at night",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/35/24114?source=related_link\">",
"      Patient information: Brachytherapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/40/1667?source=related_link\">",
"      Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/57/19346?source=related_link\">",
"      Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=related_link\">",
"      Patient information: Radiation therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_4_29763="Retapamulin: Patient drug information";
var content_f29_4_29763=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Retapamulin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/47/4851?source=see_link\">",
"     see \"Retapamulin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F4599865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Altabax&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702864",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to retapamulin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697759",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care when a large part of the skin is involved or where there are open wounds.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694771",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695952",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The treated part may be covered with a dressing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11910 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-221.10.40.232-29E1B55F6D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_4_29763=[""].join("\n");
var outline_f29_4_29763=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4599865\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013056\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013055\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013060\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013061\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013063\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013058\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013059\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013064\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013065\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/47/4851?source=related_link\">",
"      Retapamulin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_4_29764="Algorithm - acute abdominal pain boys and premenarchal girls";
var content_f29_4_29764=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 591px\">",
"   <div class=\"ttl\">",
"    Acute abdominal pain: males and premenarchal females",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 571px; height: 750px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_4_29764=[""].join("\n");
var outline_f29_4_29764=null;
var title_f29_4_29765="Fluconazole: Patient drug information";
var content_f29_4_29765=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fluconazole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     see \"Fluconazole: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=see_link\">",
"     see \"Fluconazole: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F171677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Diflucan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F171678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Fluconazole&reg;;",
"     </li>",
"     <li>",
"      CanesOral&reg;;",
"     </li>",
"     <li>",
"      CO Fluconazole;",
"     </li>",
"     <li>",
"      Diflucan&reg;;",
"     </li>",
"     <li>",
"      Dom-Fluconazole;",
"     </li>",
"     <li>",
"      Fluconazole Injection;",
"     </li>",
"     <li>",
"      Fluconazole Omega;",
"     </li>",
"     <li>",
"      Monicure;",
"     </li>",
"     <li>",
"      Mylan-Fluconazole;",
"     </li>",
"     <li>",
"      Novo-Fluconazole;",
"     </li>",
"     <li>",
"      PHL-Fluconazole;",
"     </li>",
"     <li>",
"      PMS-Fluconazole;",
"     </li>",
"     <li>",
"      PRO-Fluconazole;",
"     </li>",
"     <li>",
"      Riva-Fluconazole;",
"     </li>",
"     <li>",
"      Taro-Fluconazole;",
"     </li>",
"     <li>",
"      ZYM-Fluconazole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691491",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat yeast infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fluconazole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696367",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699444",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) at room temperature or in a refrigerator. Do not freeze. Throw away any part not used after 2 weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store shot as you have been told by the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12475 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.218.100.194-EFEE8658EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_4_29765=[""].join("\n");
var outline_f29_4_29765=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171677\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171678\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027548\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027550\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027549\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027554\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027555\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027557\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027552\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027553\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027558\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027559\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=related_link\">",
"      Fluconazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/43/26297?source=related_link\">",
"      Fluconazole: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_4_29766="Adjuvant chemotherapy for muscle invasive urothelial (transitional cell) carcinoma of the bladder";
var content_f29_4_29766=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adjuvant chemotherapy for muscle invasive urothelial (transitional cell) carcinoma of the bladder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/4/29766/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/4/29766/contributors\">",
"     Jonathan E Rosenberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/4/29766/contributors\">",
"     Joaquim Bellmunt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/4/29766/contributors\">",
"     Cora N Sternberg, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/4/29766/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/4/29766/contributors\">",
"     Derek Raghavan, MD, PhD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/4/29766/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/4/29766/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/4/29766/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder cancer is the most common malignancy involving the urinary system. Urothelial (transitional cell) carcinoma is the predominant histologic type in the United States and Europe, where it accounts for 90 percent of all bladder cancers. In other areas of the world, non-urothelial carcinomas are more frequent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The identification of active chemotherapy regimens in patients with metastatic urothelial carcinoma resulted in the use of both neoadjuvant and adjuvant chemotherapy. Neoadjuvant chemotherapy is associated with a survival advantage for patients with locally advanced bladder cancer, but it does not allow for the selection of patients most likely to benefit from treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29766/abstract/1\">",
"     1",
"    </a>",
"    ]. As a result, many patients and clinicians opt for definitive surgery rather than neoadjuvant chemotherapy. For those patients who undergo primary surgery, patients at high risk for recurrence based on pathologic staging may be candidates for adjuvant treatment.",
"   </p>",
"   <p>",
"    The role of adjuvant chemotherapy in patients with locally advanced urothelial carcinoma of the bladder will be reviewed here. The surgical approach to bladder cancer and the role of neoadjuvant chemotherapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/44/2759?source=see_link\">",
"     \"Overview of the management of urothelial (transitional cell) bladder cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/39/634?source=see_link\">",
"     \"Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41992?source=see_link\">",
"     \"Neoadjuvant treatment and bladder preservation options for muscle-invasive urothelial (transitional cell) bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H289481328\">",
"    <span class=\"h1\">",
"     RATIONALE FOR ADJUVANT CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with muscle invasive bladder cancer, cystectomy alone is associated with a 50 to 65 percent overall survival rate, which may be as high as 80 percent in patients who have pT2 disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29766/abstract/2\">",
"     2",
"    </a>",
"    ]. However, patients with locally advanced disease are at risk for worse outcomes. The five-year survival rate in patients with invasion beyond the bladder muscle is approximately 40 percent, while the survival for patients with lymph node involvement does not exceed 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29766/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the benefit of chemotherapy in the neoadjuvant setting and the poor prognosis of patients following surgical resection, adjuvant chemotherapy is often used in patients with high-risk bladder cancer.",
"   </p>",
"   <p>",
"    Although this rationale provides the justification for the use of adjuvant chemotherapy, the available data from randomized trials provide little conclusive evidence that adjuvant therapy improves survival outcomes. In addition, approximately 30 percent of patients experience complications following radical cystectomy that preclude them from receiving adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29766/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H289481448\">",
"    <span class=\"h1\">",
"     DOES ADJUVANT CHEMOTHERAPY IMPROVE SURVIVAL?",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is low quality evidence to support the use of adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29766/abstract/4\">",
"     4",
"    </a>",
"    ]. Therefore, we suggest against administration of adjuvant chemotherapy to patients with bladder cancer. However, for patients with high-risk (T3 or higher and especially in patients with pathologic node involvement) bladder cancers who are candidates for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based combination chemotherapy and are willing to accept the risk for treatment-related toxicities in the absence of a proven survival benefit, adjuvant chemotherapy is a reasonable option. If adjuvant chemotherapy is administered, we prefer a cisplatin-based combination outside of a protocol setting. Given their activity in patients with metastatic disease, our practice is to administer three to four cycles of chemotherapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and cisplatin (M-VAC) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    and cisplatin (GC). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19897?source=see_link\">",
"     \"Treatment of metastatic urothelial cancer of the bladder and urinary tract\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The impact of adjuvant chemotherapy for locally advanced bladder cancer is unclear. Although two trials demonstrated a survival advantage, each enrolled fewer than 100 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29766/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In addition, in one of these studies, patients enrolled in the observation arm never received treatment at the time of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29766/abstract/5\">",
"     5",
"    </a>",
"    ]. A 2012 systematic review (that included these two studies) found no evidence that adjuvant chemotherapy improved survival outcomes, even among selected patients with pathologic extravesical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    node-positive disease. Of note, only four of the eight adjuvant trials included in this review completed target accrual [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29766/abstract/7\">",
"     7",
"    </a>",
"    ]. Despite this, a large international collaborative dataset (n=3947) showed that adjuvant chemotherapy was independently associated with improved survival, particularly in patients at highest risk for disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29766/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1072936968\">",
"    <span class=\"h2\">",
"     Contemporary trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several contemporary randomized trials were not included in the meta-analysis discussed above. While these trials attempted to establish a role for adjuvant chemotherapy in high-risk urothelial cancer of the bladder and urinary tract, each failed to meet its original accrual goals and all were prematurely terminated. Therefore, the benefit of adjuvant chemotherapy remains uncertain. These studies are reviewed below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Spanish Oncology GU Group Trial",
"       <span class=\"nowrap\">",
"        99/01",
"       </span>",
"      </strong>",
"      &mdash; The Spanish Oncology Genitourinary Group trial",
"      <span class=\"nowrap\">",
"       99/01",
"      </span>",
"      planned to randomly assign 340 patients with T3-T4 or node positive disease to treatment using four cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (PGC) or observation [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29766/abstract/9\">",
"       9",
"      </a>",
"      ]. However, the trial was terminated in 2007 because of poor accrual after only 142 patients were enrolled. The preliminary results of this trial were presented at the 2010 American Society of Clinical Oncology (ASCO) meeting. At a median follow-up of 51 months, adjuvant PGC resulted in a significant increase in overall survival (OS) at five years compared to no chemotherapy (60 versus 30 percent, hazard ratio [HR] 0.44). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19897?source=see_link&amp;anchor=H973607999#H973607999\">",
"       \"Treatment of metastatic urothelial cancer of the bladder and urinary tract\", section on 'PGC (paclitaxel plus GC)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      <strong>",
"       plus",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      <strong>",
"       (GC)",
"      </strong>",
"      &mdash; In an Italian trial, 194 patients with pT2 (grade 3) or pT3-4, N0-2 urothelial bladder carcinoma were randomly assigned to four cycles of GC or observation. Patients on the GC arm were also randomly assigned receive gemcitabine 1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1, 8 and 15 and cisplatin 70",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      day 2 or gemcitabine as above plus cisplatin 70",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      day 15, every 28 days [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29766/abstract/10\">",
"       10",
"      </a>",
"      ]. For patients on observation, GC was administered at the time of disease progression. The trial was prematurely closed due to poor accrual. At a median follow-up of 35 months, there was no difference in either overall survival (HR 1.29, 95% CI 0.84-2.00) or disease-free survival (HR 1.08, 95% CI 0.73-1.59) compared to observation. However, the study was underpowered to show the impact of treatment on either endpoint.",
"     </li>",
"     <li>",
"      <strong>",
"       EORTC Trial",
"      </strong>",
"      &mdash; A very different phase III study was performed by the European Organization for Research and Treatment of Cancer (EORTC), which aimed to randomly assign 660 patients to observation or treatment with adjuvant chemotherapy (either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      [M-VAC] or High Dose M-VAC [HD-MVAC] or GC at the discretion of the treating physician). After enrollment of 248 patients, the trial was closed due to slow accrual (though this surpasses the accrual of patients in other contemporary trials). Following a futility analysis, the trial remains open to follow-up with results expected in 2013 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29766/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Selection by p53",
"      </strong>",
"      <strong>",
"       status",
"      </strong>",
"      &mdash; In a trial led by the University of Southern California and the Southwest Oncology Group, 499 patients with pT1N0 or pT2N0 urothelial cancer who underwent radical cystectomy had their tumors analyzed by immunohistochemistry (IHC) for p53 expression [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29766/abstract/12\">",
"       12",
"      </a>",
"      ]. Patients whose tumors were p53 negative (227 of 499, 45 percent) were managed with observation. IHC was positive for p53 in 272 (55 percent), and 114 of these agreed to randomization to either three cycles of adjuvant M-VAC chemotherapy or observation. The study was halted at an interim analysis based on futility. The final results showed that among p53 positive patients, adjuvant M-VAC did not improve recurrence-free or overall survival compared to surgery alone. However, the high rate of non-compliance with the original study design complicates interpretation of these results.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1490335963\">",
"    <span class=\"h2\">",
"     Is there a role for single-agent cisplatin?",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited information on the use of single-agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    in the adjuvant setting for urothelial carcinoma. Two small studies evaluating cisplatin alone in the neoadjuvant and the adjuvant setting did not show a survival advantage compared to surgery alone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29766/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. As an example, in one trial, 77 patients with muscle-invasive bladder cancer treated with cystectomy were randomly assigned to expectant observation or cisplatin (90",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for three days monthly for three cycles) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29766/abstract/13\">",
"     13",
"    </a>",
"    ]. There was no improvement in the five-year overall survival with adjuvant cisplatin chemotherapy (57 versus 54 percent with observation).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1490335970\">",
"    <span class=\"h2\">",
"     Use of other platinum agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     Carboplatin",
"    </a>",
"    is an alternative platinum agent associated with less renal toxicity than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    . However, the available data on its efficacy in the adjuvant setting are extremely limited but suggest no disease-specific survival advantage in high-risk patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29766/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1490335977\">",
"    <span class=\"h2\">",
"     Non-platinum based treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limited data suggest that non-platinum therapy should not be administered in the adjuvant setting.",
"   </p>",
"   <p>",
"    In one phase III study, 115 patients who underwent a radical cystectomy and were not candidates for adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    were randomly assigned treatment with adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    or to gemcitabine at the time of disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29766/abstract/16\">",
"     16",
"    </a>",
"    ]. All patients had locally advanced bladder cancer with up to five pathologically involved positive nodes at initial diagnosis of bladder cancer. As presented at the 2013 Genitourinary Cancers Symposium, compared to the administration of gemcitabine at the time of disease progression, the use of adjuvant gemcitabine resulted in higher rates of progression-free, cancer specific, and overall survival at three years, although none of these outcomes reached statistical significance. Treatment also resulted in serious (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    leukopenia. The lack of statistical significance and a notable imbalance in the proportion of patients with node-positive disease randomized to adjuvant treatment rather than treatment on progression (52 versus 38 percent, respectively) limit the generalizability of this study. Therefore, this study should not be used to justify the administration of adjuvant chemotherapy in patients with muscle-invasive bladder cancer. It does support continued evaluation of non-platinum therapy in the adjuvant setting, particularly for patients who are not candidates for platinum treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H653456658\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have undergone surgery for urothelial carcinoma are eligible for adjuvant chemotherapy if they are medically fit for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based combination chemotherapy and their cancers have high-risk tumor characteristics (",
"    <a class=\"graphic graphic_table graphicRef53395 \" href=\"UTD.htm?25/52/26445\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H1072937211\">",
"     'Medical fitness'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1490336099\">",
"     'Definition of high risk'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1072937211\">",
"    <span class=\"h2\">",
"     Medical fitness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urothelial cancer predominantly occurs in older patients, with a median age at diagnosis of 73 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29766/abstract/17\">",
"     17",
"    </a>",
"    ]. Given that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based therapy is the standard of care and that renal dysfunction and systemic comorbidities increase with age, the following criteria are used to select patients for adjuvant therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29766/abstract/18\">",
"     18",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19897?source=see_link&amp;anchor=H1495808759#H1495808759\">",
"     \"Treatment of metastatic urothelial cancer of the bladder and urinary tract\", section on 'Defining medical fitness'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      World Health Organization",
"      <span class=\"nowrap\">",
"       (WHO)/Eastern",
"      </span>",
"      Cooperative Group (ECOG) performance status &lt;2 (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"       table 2",
"      </a>",
"      ) or a Karnofsky performance status &gt;70 (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Creatinine clearance &ge;60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"     </li>",
"     <li>",
"      No evidence of hearing loss",
"     </li>",
"     <li>",
"      Peripheral neuropathy &le;grade 1",
"     </li>",
"     <li>",
"      Absence of congestive heart failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, if the impairment in renal function is due to renal tract obstruction, the obstruction should be addressed and creatinine clearance re-checked before a final therapeutic decision is made.",
"   </p>",
"   <p>",
"    The impact of performance status on outcome was demonstrated in a series of 381 patients (30 percent over 70 years) that assessed treatment outcomes after platinum-based combination chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29766/abstract/19\">",
"     19",
"    </a>",
"    ]. Among patients 70 years or older, performance status &ge;2 was significantly associated with an increased risk of death (hazard ratio for mortality, 2.5).",
"   </p>",
"   <p>",
"    Patients who do not meet the above criteria for medical fitness are considered &ldquo;medically frail&rdquo;. These patients are at a high risk for toxicity from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy, and they have been excluded from adjuvant chemotherapy clinical trials. For medically frail patients, we suggest observation following surgical treatment and not administering adjuvant chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1490336099\">",
"    <span class=\"h2\">",
"     Definition of high risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The eligibility criteria used to define a high-risk subgroup of patients with urothelial carcinoma for adjuvant clinical trials are also used in clinical practice to select patients who are candidates for adjuvant therapy off protocol. High-risk features include tumor that extends beyond the muscle (pathologic T3 or T4 disease) (",
"    <a class=\"graphic graphic_table graphicRef53395 \" href=\"UTD.htm?25/52/26445\">",
"     table 1",
"    </a>",
"    )",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pathologic node involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29766/abstract/2\">",
"     2",
"    </a>",
"    ]. The five-year overall survival rate among patients with these high-risk features ranges from 10 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29766/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite potentially curative-intent surgery, many patients who undergo cystectomy for muscle invasive urothelial cancer relapse and subsequently die of their disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with muscle-invasive bladder cancer (T2 or higher), we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based neoadjuvant chemotherapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). This approach is associated with a survival advantage. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41992?source=see_link&amp;anchor=H210939438#H210939438\">",
"       \"Neoadjuvant treatment and bladder preservation options for muscle-invasive urothelial (transitional cell) bladder cancer\", section on 'Neoadjuvant chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with bladder cancer who were not treated with neoadjuvant chemotherapy, we suggest not routinely administering chemotherapy following cystectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, for patients with high-risk (T3 or higher, pathologic node involvement) urothelial carcinomas who are candidates for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based combination chemotherapy and are willing to accept the risk for treatment-related toxicities in the absence of high level of evidence, adjuvant chemotherapy is a reasonable option. If administered, we prefer to use a cisplatin-based combination. (See",
"      <a class=\"local\" href=\"#H1490336099\">",
"       'Definition of high risk'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29766/abstract/1\">",
"      Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29766/abstract/2\">",
"      Sternberg CN, Donat SM, Bellmunt J, et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 2007; 69:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29766/abstract/3\">",
"      Donat SM, Shabsigh A, Savage C, et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol 2009; 55:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29766/abstract/4\">",
"      Sternberg CN, Bellmunt J, Sonpavde G, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol 2013; 63:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29766/abstract/5\">",
"      St&ouml;ckle M, Meyenburg W, Wellek S, et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 1992; 148:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29766/abstract/6\">",
"      Skinner DG, Daniels JR, Russell CA, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991; 145:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29766/abstract/7\">",
"      Meeks JJ, Bellmunt J, Bochner BH, et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2012; 62:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29766/abstract/8\">",
"      Svatek RS, Shariat SF, Lasky RE, et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res 2010; 16:4461.",
"     </a>",
"    </li>",
"    <li>",
"     Paz-Ares LG, Solsona E, Esteban E, et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study (abstract #LBA4518). J Clin Oncol 2010; 28:18s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29766/abstract/10\">",
"      Cognetti F, Ruggeri EM, Felici A, et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol 2012; 23:695.",
"     </a>",
"    </li>",
"    <li>",
"     Personal communication with Dr. Sternberg, June 5, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29766/abstract/12\">",
"      Stadler WM, Lerner SP, Groshen S, et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol 2011; 29:3443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29766/abstract/13\">",
"      Studer UE, Bacchi M, Biedermann C, et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 1994; 152:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29766/abstract/14\">",
"      Martinez-Pi&ntilde;eiro JA, Gonzalez Martin M, Arocena F, et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 1995; 153:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29766/abstract/15\">",
"      Gallagher DJ, Milowsky MI, Iasonos A, et al. Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma. Cancer 2009; 115:5193.",
"     </a>",
"    </li>",
"    <li>",
"     Lehmann J, Kuehn M, Fischer C, et al. Randomized phase III study of adjuvant versus progression-triggered treatment with gemcitabine (G) after radical cystectomy (RC) for locally advanced bladder cancer (LABC) in patients not suitable for cisplatin-based chemotherapy (CBC) (AUO-trial AB22/00). J Clin Oncol 21, 2013 (suppl 6; abstr 250).",
"    </li>",
"    <li>",
"     Cancer of the Urinary Bladder- SEER Stat Facts file://seer.cancer.gov/statfacts/html/urinb.html (Accessed on April 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29766/abstract/18\">",
"      Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 2011; 12:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29766/abstract/19\">",
"      Bamias A, Efstathiou E, Moulopoulos LA, et al. The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Ann Oncol 2005; 16:307.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2966 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-BD9846CABD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_4_29766=[""].join("\n");
var outline_f29_4_29766=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H289481328\">",
"      RATIONALE FOR ADJUVANT CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H289481448\">",
"      DOES ADJUVANT CHEMOTHERAPY IMPROVE SURVIVAL?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1072936968\">",
"      Contemporary trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1490335963\">",
"      Is there a role for single-agent cisplatin?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1490335970\">",
"      Use of other platinum agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1490335977\">",
"      Non-platinum based treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H653456658\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1072937211\">",
"      Medical fitness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1490336099\">",
"      Definition of high risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2966\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2966|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/52/26445\" title=\"table 1\">",
"      TNM staging bladder CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 2\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 3\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=related_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41992?source=related_link\">",
"      Neoadjuvant treatment and bladder preservation options for muscle-invasive urothelial (transitional cell) bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/44/2759?source=related_link\">",
"      Overview of the management of urothelial (transitional cell) bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/39/634?source=related_link\">",
"      Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19897?source=related_link\">",
"      Treatment of metastatic urothelial cancer of the bladder and urinary tract",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_4_29767="Amiodarone pulmonary toxicity";
var content_f29_4_29767=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Amiodarone pulmonary toxicity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/4/29767/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/4/29767/contributors\">",
"     Edward D Chan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/4/29767/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/4/29767/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/4/29767/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/4/29767/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/4/29767/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/4/29767/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    is an iodinated benzofuran derivative that is highly effective in suppressing ventricular and supraventricular tachyarrhythmias. Adverse side effects are common and include photosensitivity, blue-gray discoloration of the skin, thyroid dysfunction, corneal deposits, abnormal liver function tests, and bone marrow suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/1\">",
"     1",
"    </a>",
"    ]. Pulmonary toxicity is the most serious adverse effect of amiodarone.",
"   </p>",
"   <p>",
"    The types, pathogenesis, risk factors, diagnosis, and treatment of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    pulmonary toxicity will be reviewed here. The other major side effects of amiodarone are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several forms of pulmonary disease occur among patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , including chronic interstitial pneumonitis, organizing pneumonia, acute respiratory distress syndrome, and a solitary pulmonary mass. The incidence of pulmonary toxicity from amiodarone is not precisely known but is likely to be approximately 5 percent.",
"   </p>",
"   <p>",
"    A characteristic finding in all patients exposed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is the presence of numerous foamy macrophages in the air spaces (",
"    <a class=\"graphic graphic_picture graphicRef53653 \" href=\"UTD.htm?20/60/21441\">",
"     picture 1",
"    </a>",
"    ), which are filled with amiodarone-phospholipid complexes (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64923 \" href=\"UTD.htm?33/27/34230\">",
"     image 1",
"    </a>",
"    ). Like other amphiphilic compounds, amiodarone can cause an accumulation of phospholipids within lysosomes in the lungs and other tissues due to the inhibition of phospholipase A [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/1\">",
"     1",
"    </a>",
"    ]. Ultrastructural studies show myelinoid inclusion bodies in the affected tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Chronic interstitial pneumonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic interstitial pneumonitis is the most common presentation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    -induced pulmonary disease. It is characterized by the insidious onset of nonproductive cough, dyspnea, and weight loss. The chest radiograph reveals focal or diffuse interstitial opacities. Interstitial pneumonitis is usually recognized after two or more months of therapy, especially in patients in whom the dose of amiodarone exceeds 400 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/2\">",
"     2",
"    </a>",
"    ]. These manifestations are due to a nonspecific interstitial pneumonitis predominantly composed of mononuclear cells, foamy alveolar macrophages, type II cell hyperplasia, and fibrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Organizing pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;An organizing pneumonia with or without bronchiolitis obliterans (BOOP pattern) is seen in approximately 25 percent of cases of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    pulmonary toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The presentation of organizing pneumonia is more acute than that of interstitial pneumonitis. It is characterized by a nonproductive cough, pleuritic chest pain, fever, dyspnea, and patchy alveolar opacities on chest radiograph. These findings mimic an infectious pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/5\">",
"     5",
"    </a>",
"    ]. Pulmonary auscultation typically reveals crackles and a pleural rub. Pathology demonstrates organizing pneumonia with intraluminal polyps.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Acute respiratory distress syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute respiratory distress syndrome (ARDS) is a rare but potentially fatal form of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    pulmonary toxicity and is usually characterized by diffuse alveolar damage with an acute interstitial pneumonitis and hyaline membranes (",
"    <a class=\"graphic graphic_picture graphicRef78032 \" href=\"UTD.htm?13/47/14074\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/3\">",
"     3",
"    </a>",
"    ]. It has been reported in patients being treated with amiodarone who have undergone surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/6-8\">",
"     6-8",
"    </a>",
"    ] or pulmonary angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/9\">",
"     9",
"    </a>",
"    ]. In the reports describing surgical patients, acute lung injury (consistent with ARDS) developed within one to four days after extubation. In comparison, the report of two patients with fatal ARDS following pulmonary angiography, described respiratory deterioration within 30 minutes of the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/9\">",
"     9",
"    </a>",
"    ]. It has been hypothesized that amiodarone may sensitize these individuals to either high concentrations of inspired oxygen or to iodinated contrast media.",
"   </p>",
"   <p>",
"    Consequently, it is recommended that the arterial oxygen saturation (SaO",
"    <sub>",
"     2",
"    </sub>",
"    ) and oxygen concentration (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ) be closely monitored in patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    . Caution should be used when considering patients using amiodarone for surgery, especially if there exists preoperative pulmonary dysfunction. The concerns about performing surgery on a patient taking amiodarone must be weighed against the alternative concern that withdrawal before surgery implies delaying the operation for several weeks (because amiodarone has a very long half-life), which may put the patient at increased risk of malignant dysrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20759678\">",
"    <span class=\"h2\">",
"     Diffuse alveolar hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraalveolar hemorrhage is a rare complication of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. It may occur abruptly in the first few days or months (average six months) after initiation of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/3,13\">",
"     3,13",
"    </a>",
"    ]. The patients commonly present with an acute onset of cough, shortness of breath, fever, and hemoptysis. Many of the patients have pre-existing chronic lung disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Solitary pulmonary mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;A solitary pulmonary mass simulating a pulmonary malignancy has also been reported as a complication of therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms involved in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    -induced pulmonary injury are incompletely understood. Two major hypotheses have been suggested, a direct toxic injury to lung cells and an indirect immunologic reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/17\">",
"     17",
"    </a>",
"    ]. Genetic susceptibility of certain individuals may play an additional role in determining the type of injury that ensues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cytotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A direct toxic reaction in the lung is supported by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      has a long half-life and a high tissue affinity for the lung. In addition, an active metabolite of amiodarone, monodesethylamiodarone (DEA), exhibits cytotoxic activity and tends to accumulate in the lungs even more than amiodarone [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is an accumulation of cellular drug-phospholipid complexes that interferes with normal cellular metabolic pathways and ultimately leads to direct cell injury and death. Both apoptotic and necrotic cell death have been implicated [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      alters the phospholipid bilayer, which in turn disrupts cellular and organelle membrane function.",
"     </li>",
"     <li>",
"      Toxic oxygen species resulting in tissue injury are generated by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chronic inflammation results from cellular injury; persistent insults can ultimately lead to fibrosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hypersensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;An immunologic reaction is suggested by several patients who presented with features of a hypersensitivity pneumonitis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lymphocytic infiltration, often with \"intraalveolar buds\" (BOOP-like reaction)",
"     </li>",
"     <li>",
"      CD8 T-cell lymphocytosis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Positive IgG immunofluorescence in the lung",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    pulmonary toxicity are uncertain but may include a high cumulative dose, a daily dose greater than 400",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    a duration of therapy exceeding two months, increased patient age, preexisting lung disease, thoracic or nonthoracic surgery, and pulmonary angiography. In a retrospective analysis of over 200 patients with amiodarone lung toxicity, patients &gt; 60 years old and those on amiodarone for 6 to 12 months had the highest risks [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cumulative dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary toxicity correlates more closely with the total cumulative dose than with serum drug levels. Consistent with this observation, pulmonary toxicity usually occurs several months to several years after the initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/2\">",
"     2",
"    </a>",
"    ]. However, there exist anecdotal cases of severe pulmonary toxicity developing within two to three weeks of therapy with low cumulative doses [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Daily dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early reports (when patients were usually treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    doses &ge;400",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    noted a 5 to 15 percent incidence of pulmonary toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/1,23,24\">",
"     1,23,24",
"    </a>",
"    ]. The incidence appears to be lower with smaller maintenance doses [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/2,24,25\">",
"     2,24,25",
"    </a>",
"    ]. As an example, one study of 573 patients demonstrated that patients who developed pulmonary toxicity took higher daily doses than those who did not develop pulmonary disease (517 versus 409",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/24\">",
"     24",
"    </a>",
"    ]. There were no cases of pulmonary toxicity when the maintenance dose was below 305",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the likelihood of pulmonary toxicity may be less in patients receiving smaller daily doses, pulmonary toxicity may still occur at low doses, albeit infrequently. In a meta-analysis of four trials (1465 patients) that randomly assigned patients to receive a low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    (150 to 330",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo for a minimum of one year, there was an increased incidence of pulmonary toxicity with amiodarone that was not statistically significant (1.9 versus 0.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/25\">",
"     25",
"    </a>",
"    ]. In a retrospective series of 500 Japanese patients, daily doses as low as approximately 140 mg per day were associated with a cumulative incidence of amiodarone lung toxicity of approximately 4 to 11 percent at 1 to 5 years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Preexisting lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between preexisting lung disease and the development of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    pulmonary toxicity has been reported in some series. However, it is possible that these patients merely have limited pulmonary reserve and thus become symptomatic earlier in their course than other individuals. The following two studies illustrate the conflicting literature:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One randomized, placebo-controlled trial of 519 patients with heart failure found no accelerated loss of diffusing capacity among patients with chronic obstructive pulmonary disease who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      compared to those who received placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, a separate randomized, controlled trial demonstrated that patients with preexisting pulmonary disease had an increased risk of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      pulmonary toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/28\">",
"       28",
"      </a>",
"      ]. However, amiodarone use did not increase pulmonary death or all-cause mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PREDICTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no adequate predictors of pulmonary toxicity due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    . Serial pulmonary function testing with diffusion capacity (DLCO) is the approach most frequently proposed for monitoring patients taking amiodarone because DLCO is generally decreased in patients with amiodarone toxicity. However, serial pulmonary function tests are not helpful because there are generally no premonitory changes in DLCO [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. One study prospectively evaluated the usefulness of serial DLCO and spirometry measurements in 91 patients who were receiving amiodarone therapy for refractory arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/30\">",
"     30",
"    </a>",
"    ]. Most of the asymptomatic patients whose DLCO decreased more than 20 percent did not develop pulmonary toxicity over the next year despite continued amiodarone therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115635386\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, a nonproductive cough and dyspnea are present in 50 of 75 percent of individuals at presentation. Pleuritic pain, weight loss, fever (33 to 50 percent of cases), and malaise can also occur.",
"   </p>",
"   <p>",
"    The physical examination often reveals bilateral inspiratory crackles, while clubbing is not seen. These findings frequently must be distinguished from heart failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    -induced pulmonary toxicity is one of exclusion. The differential diagnosis of pulmonary processes that can present similarly to amiodarone toxicity includes heart failure, infectious pneumonia, pulmonary embolism, and malignancy.",
"   </p>",
"   <p>",
"    The presence of three or more of the following suggests the \"clinical diagnosis\" of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    pulmonary toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      New or worsening symptoms or signs",
"     </li>",
"     <li>",
"      New abnormalities on chest roentgenogram",
"     </li>",
"     <li>",
"      A decline in total lung capacity (&ge;15 percent) or in DLCO (&gt;20 percent)",
"     </li>",
"     <li>",
"      Presence of phospholipidosis in lung cells",
"     </li>",
"     <li>",
"      A marked CD8+ lymphocytosis in lavage fluid",
"     </li>",
"     <li>",
"      A lung biopsy that reveals diffuse alveolar damage, organizing pneumonia, interstitial pneumonitis, or fibrosis",
"     </li>",
"     <li>",
"      Improvement in lung manifestations following withdrawal of the drug (with or without steroid therapy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral blood findings are nonspecific but include elevations of the white blood cell count, the serum lactate dehydrogenase (LDH) level, and the erythrocyte sedimentation rate [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/2\">",
"     2",
"    </a>",
"    ]. Eosinophilia and antinuclear antibodies are not typically seen.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    levels are usually within the normal range and are not predictive or diagnostic of pulmonary toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Measurement of serum concentrations of KL-6, a mucin-like high molecular weight glycoprotein secreted by proliferating type II pneumocytes, shows promise as a marker of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    pulmonary toxicity. As an example, one report of 7 patients treated with amiodarone described serum concentrations of KL-6 of 4 to 6 times the upper limit of normal in 2 patients who developed drug-related pneumonitis but none of the other 5 patients, despite their development of bacterial pneumonia, heart failure, or lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Chest imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest radiograph in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    pulmonary toxicity may reveal diffuse or localized interstitial, alveolar, or mixed opacities [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/3\">",
"     3",
"    </a>",
"    ]; these changes may be migratory, and can occur in the absence of symptoms (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50428 \" href=\"UTD.htm?14/11/14512\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/32\">",
"     32",
"    </a>",
"    ]. Pleural effusions are very rare.",
"   </p>",
"   <p>",
"    Computed tomographic scans of the chest and upper abdomen may show increased attenuation in the lungs, liver, and spleen due to the accumulation of the iodinated drug in tissue macrophages (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58121 \" href=\"UTD.htm?20/0/20485\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/33\">",
"     33",
"    </a>",
"    ]. Although this finding is specific for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , it does not discriminate actual pulmonary toxicity from \"normal\" drug accumulation.",
"   </p>",
"   <p>",
"    Increased gallium uptake in the lung has been suggested as a sensitive marker of the presence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    pneumonitis. Changes in gallium lung uptake, however, do not always mirror the course of the disease. As an example, one study evaluated the uptake of gallium scanning before and after the discontinuation of amiodarone in six patients in whom amiodarone-induced pulmonary toxicity had been diagnosed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/34\">",
"     34",
"    </a>",
"    ]. After stopping amiodarone, gallium uptake in the lung remained elevated in three of the six patients despite the absence of ongoing clinical disease as determined by symptoms, radiographic abnormalities, and bronchoalveolar lavage.",
"   </p>",
"   <p>",
"    Gallium scanning may be of some value in distinguishing the inflammatory and immune response associated with pulmonary toxicity from the interstitial edema associated with congestive failure. However, it is rarely performed because of its high cost, high radiation dose, prolonged testing interval of 48 to 72 hours, limited utility, and difficulty in interpretation and quantification of the gallium uptake [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Bronchoalveolar lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bronchoalveolar lavage (BAL) pattern in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    pneumonitis is highly variable. Reported findings in lavage fluid include [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lymphocytosis",
"     </li>",
"     <li>",
"      Neutrophilia",
"     </li>",
"     <li>",
"      Eosinophilia",
"     </li>",
"     <li>",
"      Normal BAL cellular counts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Certain BAL findings, however, may point to a diagnosis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    pulmonary toxicity: the detection of foam cells, a CD8 predominant lymphocytic or neutrophilic alveolitis, and an increased phospholipid content [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/2\">",
"     2",
"    </a>",
"    ]. No particular BAL cellular pattern appears predictive of outcome.",
"   </p>",
"   <p>",
"    The presence of foam cells in biopsy specimens or in bronchoalveolar fluid is not pathognomonic of pulmonary toxicity because even exposed patients without signs or symptoms of toxicity may have these findings. The absence of foam cells, however, makes the diagnosis of pulmonary toxicity unlikely [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients presenting with acute onset and progressive respiratory distress, BAL may reveal alveolar hemorrhage with sequentially more hemorrhagic lavage returns",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a high concentration of hemosiderin-laden macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link&amp;anchor=H18#H18\">",
"     \"The diffuse alveolar hemorrhage syndromes\", section on 'Bronchoalveolar lavage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Lung biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transbronchial lung biopsy may be useful in identifying the typical changes found in the lungs of patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    . The biopsy may reveal parenchymal lung changes consistent with nonspecific interstitial pneumonitis, organizing pneumonia, or diffuse alveolar damage. Most importantly, the biopsy may identify another potential cause of the observed pulmonary injury, particularly infection or malignancy.",
"   </p>",
"   <p>",
"    Due to the concerns regarding the development of ARDS following any surgical procedure in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , open or thoracoscopic lung biopsies are only performed when all other efforts to diagnose the illness have been exhausted. This includes a trial of drug withdrawal and glucocorticoid treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pulmonary function testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung function studies are not diagnostic of pulmonary toxicity because they are frequently abnormal in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    . However, a documented decline in the DLCO of greater than 20 percent is useful in suggesting the need for closer monitoring or for further diagnostic testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    pulmonary toxicity consists primarily of stopping amiodarone. Alternative medications and procedures are available to treat supraventricular arrhythmias, and the implantable cardioverter-defibrillator is an increasingly used alternative for potentially life-threatening ventricular arrhythmias. Due to the accumulation of amiodarone in fatty tissues and its long elimination half-life (approximately 45 days), pulmonary toxicity may initially progress despite drug discontinuation.",
"   </p>",
"   <p>",
"    For the majority of patients with symptomatic lung toxicity, we initiate systemic glucocorticoid therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    40 to 60 mg per day). In a number of case reports, glucocorticoid therapy has been associated with dramatic improvement even in cases of severe disease. We suggest slow tapering glucocorticoid therapy, as tolerated, over two to six months. If symptoms and signs recur, the glucocorticoid dose is returned to the last effective dose and further tapering is slower, over approximately 12 months. Recurrent pulmonary toxicity during tapering of glucocorticoids may be due greater body stores of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    associated with greater body mass indices",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    amounts of body fat [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest NOT resuming",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    in patients who have recovered from amiodarone induced pulmonary toxicity due to the risk of recurrent disease and progressive pulmonary fibrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    lung disease is generally favorable. In one study, for example, three-fourths of patients stabilized or improved after withdrawal of the drug with or without glucocorticoid treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/36\">",
"     36",
"    </a>",
"    ]. Death attributable to amiodarone pneumonitis occurred in 10 percent of cases reported in the literature, although the actual mortality in clinical practice is probably less. However, patients in whom ARDS develops have a much higher mortality rate of approximately 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29767/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several forms of pulmonary disease occur among patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , including chronic interstitial pneumonitis, organizing pneumonia, acute respiratory distress syndrome, and a solitary pulmonary mass. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Types of disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanisms of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      -induced pulmonary injury are incompletely understood. Two major hypotheses include direct cytotoxicity and a hypersensitivity reaction. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      pulmonary toxicity include a daily dose greater than 400",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      a duration of therapy exceeding two months, increased patient age, preexisting lung disease, thoracic or nonthoracic surgery, and pulmonary angiography. Although it is commonly cited that pulmonary toxicity is seen only with drug doses greater than 400",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      lower daily doses may also cause pulmonary toxicity. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      pulmonary toxicity is a diagnosis of exclusion. The presence of foamy macrophages is suggestive of amiodarone pulmonary toxicity, but not diagnostic. Increased lung attenuation on computed tomography, increased gallium uptake, and abnormal pulmonary function tests are nonspecific. Lung biopsy may be helpful in excluding alternative etiologies and may be helpful in identifying the pathologic type of disease (eg, chronic interstitial pneumonitis), but is also nonspecific for amiodarone-induced disease. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Discontinuation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      is the primary therapy for amiodarone toxicity. In addition, for patients with symptomatic lung toxicity, we typically initiate systemic glucocorticoid therapy (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      40 to 60 mg per day). Due to the long elimination half-life (approximately 45 days) of amiodarone, pulmonary toxicity may initially progress despite drug discontinuation and may recur upon glucocorticoid withdrawal. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      lung disease is generally favorable, when amiodarone is discontinued. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/1\">",
"      Mason JW. Amiodarone. N Engl J Med 1987; 316:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/2\">",
"      Martin WJ 2nd, Rosenow EC 3rd. Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part I). Chest 1988; 93:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/3\">",
"      Dean PJ, Groshart KD, Porterfield JG, et al. Amiodarone-associated pulmonary toxicity. A clinical and pathologic study of eleven cases. Am J Clin Pathol 1987; 87:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/4\">",
"      Valle JM, Alvarez D, Ant&uacute;nez J, Vald&eacute;s L. Bronchiolitis obliterans organizing pneumonia secondary to amiodarone: a rare aetiology. Eur Respir J 1995; 8:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/5\">",
"      Zitnik, RJ. Drug-induced lung disease: Antiarrhythmic agents. J Respir Dis 1996; 17:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/6\">",
"      Greenspon AJ, Kidwell GA, Hurley W, Mannion J. Amiodarone-related postoperative adult respiratory distress syndrome. Circulation 1991; 84:III407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/7\">",
"      Kay GN, Epstein AE, Kirklin JK, et al. Fatal postoperative amiodarone pulmonary toxicity. Am J Cardiol 1988; 62:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/8\">",
"      Van Mieghem W, Coolen L, Malysse I, et al. Amiodarone and the development of ARDS after lung surgery. Chest 1994; 105:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/9\">",
"      Wood DL, Osborn MJ, Rooke J, Holmes DR Jr. Amiodarone pulmonary toxicity: report of two cases associated with rapidly progressive fatal adult respiratory distress syndrome after pulmonary angiography. Mayo Clin Proc 1985; 60:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/10\">",
"      Iskandar SB, Abi-Saleh B, Keith RL, et al. Amiodarone-induced alveolar hemorrhage. South Med J 2006; 99:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/11\">",
"      Vizioli LD, Cho S. Amiodarone-associated hemoptysis. Chest 1994; 105:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/12\">",
"      Borders CW 3rd, Bennett S, Mount C, Claassen SL. A rare case of acute diffuse alveolar hemorrhage following initiation of amiodarone: a case report. Mil Med 2012; 177:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/13\">",
"      Tanawuttiwat T, Harindhanavudhi T, Hanif S, Sahloul MZ. Amiodarone-induced alveolar haemorrhage: a rare complication of a common medication. Heart Lung Circ 2010; 19:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/14\">",
"      Piccione W Jr, Faber LP, Rosenberg MS. Amiodarone-induced pulmonary mass. Ann Thorac Surg 1989; 47:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/15\">",
"      Arnon R, Raz I, Chajek-Shaul T, et al. Amiodarone pulmonary toxicity presenting as a solitary lung mass. Chest 1988; 93:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/16\">",
"      Azzam I, Tov N, Elias N, Naschitz JE. Amiodarone toxicity presenting as pulmonary mass and peripheral neuropathy: the continuing diagnostic challenge. Postgrad Med J 2006; 82:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/17\">",
"      Martin, WJ, and Rosenow, EC. Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part 2). Chest 1988; 93:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/18\">",
"      Seki S, Itagaki S, Kobayashi M, et al. Amiodarone increases the accumulation of DEA in a human alveolar epithelium-derived cell line. Biol Pharm Bull 2008; 31:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/19\">",
"      Yano T, Itoh Y, Yamada M, et al. Combined treatment with L-carnitine and a pan-caspase inhibitor effectively reverses amiodarone-induced injury in cultured human lung epithelial cells. Apoptosis 2008; 13:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/20\">",
"      Akoun GM, Gauthier-Rahman S, Milleron BJ, et al. Amiodarone-induced hypersensitivity pneumonitis. Evidence of an immunological cell-mediated mechanism. Chest 1984; 85:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/21\">",
"      Ernawati DK, Stafford L, Hughes JD. Amiodarone-induced pulmonary toxicity. Br J Clin Pharmacol 2008; 66:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/22\">",
"      Kharabsheh S, Abendroth CS, Kozak M. Fatal pulmonary toxicity occurring within two weeks of initiation of amiodarone. Am J Cardiol 2002; 89:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/23\">",
"      Greene HL, Graham EL, Werner JA, et al. Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias. J Am Coll Cardiol 1983; 2:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/24\">",
"      Dusman RE, Stanton MS, Miles WM, et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation 1990; 82:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/25\">",
"      Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997; 30:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/26\">",
"      Yamada Y, Shiga T, Matsuda N, et al. Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. Circ J 2007; 71:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/27\">",
"      Singh SN, Fisher SG, Deedwania PC, et al. Pulmonary effect of amiodarone in patients with heart failure. The Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy (CHF-STAT) Investigators (Veterans Affairs Cooperative Study No. 320). J Am Coll Cardiol 1997; 30:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/28\">",
"      Olshansky B, Sami M, Rubin A, et al. Use of amiodarone for atrial fibrillation in patients with preexisting pulmonary disease in the AFFIRM study. Am J Cardiol 2005; 95:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/29\">",
"      Mason JW. Prediction of amiodarone-induced pulmonary toxicity. Am J Med 1989; 86:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/30\">",
"      Gleadhill IC, Wise RA, Schonfeld SA, et al. Serial lung function testing in patients treated with amiodarone: a prospective study. Am J Med 1989; 86:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/31\">",
"      Endoh Y, Hanai R, Uto K, et al. KL-6 as a potential new marker for amiodarone-induced pulmonary toxicity. Am J Cardiol 2000; 86:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/32\">",
"      Standertskj&ouml;ld-Nordenstam CG, Wandtke JC, Hood WB Jr, et al. Amiodarone pulmonary toxicity. Chest radiography and CT in asymptomatic patients. Chest 1985; 88:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/33\">",
"      Kuhlman, JE, Teigen, C, Ren, H, et al. Amiodarone pulmonary toxicity: CT findings in symptomatic patients. Radiology 1990; 177:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/34\">",
"      Xaubet A, Roca J, Rodriguez-Roisin R, et al. Bronchoalveolar lavage cellular analysis and gallium lung scan in the assessment of patients with amiodarone-induced pneumonitis. Respiration 1987; 52:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/35\">",
"      Ohar JA, Jackson F, Dettenmeier PA, et al. Bronchoalveolar lavage cell count and differential are not reliable indicators of amiodarone-induced pneumonitis. Chest 1992; 102:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/36\">",
"      Coudert B, Bailly F, Lombard JN, et al. Amiodarone pneumonitis. Bronchoalveolar lavage findings in 15 patients and review of the literature. Chest 1992; 102:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/37\">",
"      Okayasu K, Takeda Y, Kojima J, et al. Amiodarone pulmonary toxicity: a patient with three recurrences of pulmonary toxicity and consideration of the probable risk for relapse. Intern Med 2006; 45:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29767/abstract/38\">",
"      Myers JL, Kennedy JI, Plumb VJ. Amiodarone lung: pathologic findings in clinically toxic patients. Hum Pathol 1987; 18:349.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4364 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-E57427EB1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_4_29767=[""].join("\n");
var outline_f29_4_29767=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Chronic interstitial pneumonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20759678\">",
"      Diffuse alveolar hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Solitary pulmonary mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cytotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hypersensitivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cumulative dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Daily dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Preexisting lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PREDICTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H115635386\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Chest imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Lung biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pulmonary function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4364\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4364|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/27/34230\" title=\"diagnostic image 1\">",
"      Amiodarone toxicity EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/11/14512\" title=\"diagnostic image 2\">",
"      Amiodarone toxicity chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/0/20485\" title=\"diagnostic image 3\">",
"      Amiodarone pneumonitis CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4364|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/60/21441\" title=\"picture 1\">",
"      BAL amiodarone lung",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/47/14074\" title=\"picture 2\">",
"      Amiodarone lung micrograph",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=related_link\">",
"      The diffuse alveolar hemorrhage syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_4_29768="Pathogenesis of Vibrio cholerae infection";
var content_f29_4_29768=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of Vibrio cholerae infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/4/29768/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/4/29768/contributors\">",
"     Joan R Butterton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/4/29768/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/4/29768/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/4/29768/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/4/29768/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/4/29768/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 16, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholera is a diarrheal illness caused by infection with the gram-negative bacterium Vibrio cholerae. Cholera is characterized by severe, watery diarrhea, which can rapidly lead to dehydration and death in untreated patients.",
"   </p>",
"   <p>",
"    V. cholerae of the O1 and O139 serotypes are responsible for epidemic cholera in humans. All other serotypes are grouped as \"non-O1\" strains; they are associated with sporadic cases of gastroenteritis. V. cholerae O1 occurs in two biotypes, classical and El Tor, which differ in biochemical characteristics and phage susceptibility [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of infection with epidemic V. cholerae of the O1 and O139 serotypes will be reviewed here. The clinical approach to patients with V. cholerae infection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=see_link\">",
"     \"Overview of Vibrio cholerae infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16786065\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of Vibrio cholerae infection serves as a paradigm for many classic features of bacterial virulence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      V. cholerae is both an environmental organism and a human intestinal pathogen.",
"     </li>",
"     <li>",
"      The organism produces a prototypical enterotoxin.",
"     </li>",
"     <li>",
"      A pilus is required for colonization of the small intestine.",
"     </li>",
"     <li>",
"      Genes encoding virulence factors are clustered in two regions of the chromosome, on a pathogenicity island and on a filamentous bacteriophage; this suggests that horizontal gene transfer may lead to the development of new epidemic strains.",
"     </li>",
"     <li>",
"      Multiple virulence genes are coordinately regulated by environmental conditions.",
"     </li>",
"     <li>",
"      Biofilm formation is important in both infectivity and environmental persistence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Steps in the pathogenesis of infection include transmission of bacteria, intestinal colonization, production of virulence factor, and environmental persistence; these are discussed in the following sections (",
"    <a class=\"graphic graphic_figure graphicRef69278 \" href=\"UTD.htm?31/56/32644\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with V. cholerae occurs after ingestion of contaminated food or water. Water has been understood to be a major route for cholera transmission since the seminal observations by John Snow during the cholera epidemic in London in 1854 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Similarly, contamination of municipal water supplies in Peru led to the majority of cases during the epidemics of the early 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Contaminated food can also transmit disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/1\">",
"     1",
"    </a>",
"    ]. Direct person-to-person spread is rare but has been implicated in hospital outbreaks and during burial ceremonies requiring handling of intestinal contents. V. cholerae also colonizes arthropods, and flies have been postulated as potential hosts and possible disease vectors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ingested bacteria must survive the gastric acid barrier of the stomach in order to reach the small intestine. V. cholerae are sensitive to gastric acid, and are rapidly killed at pH &lt;2.4. Organisms may survive transit through the stomach by virtue of protection within food, low gastric acidity of a compromised host, rapid gastric emptying, or a large inoculum size. If, for example, organisms are ingested with food or antacids, the infectious dose is reduced from 10(9) organisms to 10(4) to 10(6) organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, individuals with low gastric acidity from disease or medications are at increased risk for infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanisms of intestinal colonization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonization of the small intestinal epithelium is necessary for V. cholerae to cause disease. Factors that may contribute to this process include bacterial pili, hemagglutinins, an accessory colonizing factor, porin-like proteins, rfb-encoded enzymes, and a chitin-binding protein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Pili",
"    </span>",
"    &nbsp;&mdash;&nbsp;V. cholerae produces a pilus, the toxin-coregulated pilus (TCP), which is absolutely required for colonization of the small intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The major structural subunit of TCP is encoded by the tcpA gene, which lies within a cluster of genes that participate in the synthesis and function of the mature pilus. The tcp gene cluster lies next to other virulence gene clusters, and is located on an approximately 40 kb pathogenicity island on the V. cholerae chromosome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of TCP can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibodies to TcpA are protective in an infant mouse model, and inhibit attachment of bacteria to epithelial cells in vitro [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/12-14\">",
"       12-14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      V. cholerae strains that do not express TCP do not colonize the intestines of human volunteers and do not induce anti-TCP immune responses [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both the classical and El Tor biotypes have the tcpA gene, but the expression of pili in response to environmental conditions varies by biotype. The importance of this variation in the ability of the biotypes to produce disease in humans is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Hemagglutinins",
"    </span>",
"    &nbsp;&mdash;&nbsp;V. cholerae produces several hemagglutinins (HA) which may act as adhesion factors. As an example, the classical and El Tor biotypes make a soluble HA protease",
"    <span class=\"nowrap\">",
"     (HA/P),",
"    </span>",
"    the product of the hap gene.",
"    <span class=\"nowrap\">",
"     HA/P",
"    </span>",
"    does not have a major effect on virulence, even though it has been demonstrated to activate cholera toxin by nicking the A subunit [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/15\">",
"     15",
"    </a>",
"    ], play a role in the detachment of V. cholerae from the intestinal epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/16\">",
"     16",
"    </a>",
"    ], and inactivate the filamentous phage CTXphi [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6697671\">",
"     'Cholera toxin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The cell-associated hemagglutinins include the mannose-sensitive HA (MSHA) expressed by El Tor strains, the fucose-sensitive HA expressed by classical strains, and the mannose-fucose-resistant HA (MFRHA) made by both biotypes. The genes encoding mrhA and mrhB have been cloned and sequenced, and have been correlated with MFRHA activity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. A mutant strain lacking MFRHA activity has a marked impairment in its ability to persist in the infant mouse gut and cannot compete with the wild-type organism [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/19\">",
"     19",
"    </a>",
"    ]. However, the exact role of MFRHA in colonization is not known.",
"   </p>",
"   <p>",
"    The MSHA pilus is a member of the type 4a family of pili. The entire MSHA gene locus, consisting of 16 open reading frames, has been defined [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/21\">",
"     21",
"    </a>",
"    ]. The MSHA is not required for colonization of the mouse or human intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/22-24\">",
"     22-24",
"    </a>",
"    ], but has been shown to act as a receptor for the V. cholerae O139 filamentous bacteriophage 493 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/25\">",
"     25",
"    </a>",
"    ]. MSHA has been proposed to play a role in the survival of EI Tor V. cholerae in the aquatic environment outside the human host and to be required for biofilm formation on abiotic surfaces [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/21,26\">",
"     21,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Accessory colonization factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;An accessory colonization factor (ACF) is encoded by the acf gene cluster, which lies downstream of the tcp gene cluster within the TCP pathogenicity island [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/11\">",
"     11",
"    </a>",
"    ]. Mutations in these genes lead to reduced colonization in the suckling mouse model, but the way in which ACF enhances colonization is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Porin-like proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several porin-like outer membrane proteins have been implicated in colonization with V. cholerae. Antibodies to these proteins protect against infection by reducing intestinal colonization [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     rfb-encoded enzymes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rfb genes of V. cholerae encode enzymes used in lipopolysaccharide biosynthesis. A strain with a deletion in rfbB showed a severe colonization defect despite having normal TCP production [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Chitin-binding protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;The N-acetylglucosamine-binding protein (eg, chitin-binding protein) appears to be important for colonization of V. cholerae in the environment and human intestine. The gbpA gene of V. cholerae encodes the N-acetylglucosamine-binding protein. A V. cholerae mutant strain with a deletion in gbpA was defective in attachment to human epithelial cells in a tissue culture model and in colonization in a mouse model [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/33\">",
"     33",
"    </a>",
"    ]. In addition, the mutant showed a 10-fold reduction in attachment to exoskeletons of zooplankton as compared to a wild type strain. These studies suggest that the chitin-binding protein plays a role in V. cholerae environmental survival and human infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Virulence factor production",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6697671\">",
"    <span class=\"h3\">",
"     Cholera toxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following attachment and colonization of the small intestinal epithelium, V. cholerae produces its major virulence factor, cholera toxin (CT). CT is a heterodimeric protein of one catalytic A subunit and five B subunits (",
"    <a class=\"graphic graphic_figure graphicRef69278 \" href=\"UTD.htm?31/56/32644\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/34\">",
"     34",
"    </a>",
"    ]. The B subunit pentamer binds holotoxin to the enterocyte surface receptor, the ganglioside GM1 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/35\">",
"     35",
"    </a>",
"    ]. The A subunit is proteolytically cleaved to produce A1 and A2 fragments linked by a disulfide bond. The A1 fragment is the active enzyme; the A2 subunit attaches A1 to the B subunit pentamer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/34\">",
"     34",
"    </a>",
"    ]. The toxin is inactive if the A subunit is not proteolytically cleaved or is mutated in the ADP-ribosyltransferase active center [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following binding of holotoxin to GM1 and internalization, A1 catalyzes the ADP-ribosylation of a GTP-binding protein, leading to persistent activation of adenylate cyclase [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. The increase of cAMP in the intestinal mucosa leads to increased chloride secretion and decreased sodium absorption, producing the massive fluid and electrolyte loss characteristic of the disease (",
"    <a class=\"graphic graphic_figure graphicRef69278 \" href=\"UTD.htm?31/56/32644\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT may also lead to increased prostaglandin production, which adds to gastrointestinal loss of water and electrolytes. The following observations are compatible with a role for prostaglandins in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The effects of cholera toxin on fluid secretion in animals are inhibited by drugs that decrease prostaglandin synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CT-induced fluid accumulation in the intestine in rabbits correlates more closely with the levels of prostaglandin than with the levels of cAMP [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with cholera have increased prostaglandin E2 concentrations in intestinal samples [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The CT structural genes, ctxAB, are transcribed in an operon, with ctxB immediately downstream of ctxA, overlapping by four nucleotides [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/45\">",
"     45",
"    </a>",
"    ]. The B subunit is more highly expressed, probably because of translational control, correlating with the 5:1 ratio of B subunit to A subunit in the mature toxin [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/45\">",
"     45",
"    </a>",
"    ]. There are small differences in the amino acid sequences encoded by the toxin genes of the El Tor and the classical biotypes. Classical strains contain two identical, nontandem copies of the toxin genes; 70 percent of El Tor strains have a single copy, with the rest having two or more tandemly repeated copies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/46\">",
"     46",
"    </a>",
"    ]. Amplification of toxin gene copy number in El Tor strains occurs during intestinal passage in animals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Location of cholera toxin genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genes encoding ctxAB are located on the genome of a lysogenic filamentous bacteriophage, called CTXphi [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/47\">",
"     47",
"    </a>",
"    ]. The 6.9 kbp CTXphi genome is composed of a 4.5-kbp core region and a 2.4-kbp region called RS2 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/47\">",
"     47",
"    </a>",
"    ]. The genes in the core region, in addition to ctxAB, are cep, orfU, ace, and zot, which are essential for the formation of the CTXphi particle. Genes in RS2 are called rstR, rstA2, and rstB2, which act in the integration, replication, regulation, and biotype-specific immunity of CTXphi [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In V. cholerae of the El Tor biotype, the CTXphi can integrate into the chromosome at a specific 18 bp sequence called attRS; in classical V. cholerae strains or El Tor strains lacking the CTXphi and attRS site, CTXphi remains as a circular extrachromosomal replicative form (RF) of the phage DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. On the chromosome of CTXphi lysogens, the prophage is often flanked by 2.7 kbp RS1 regions that are similar to the RS2 regions but also encode another gene, rstC [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TCP is the bacterial cell receptor for CTXphi [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/47\">",
"     47",
"    </a>",
"    ]. Thus, the expression of TCP, a virulence factor for infection, is required for V. cholerae to acquire an additional virulence factor, CTXphi.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Regulation of virulence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many V. cholerae virulence genes are coordinately regulated in response to environmental signals. Although the conditions that affect toxin production in the human intestine are not known, in vitro factors increasing toxin production are low temperature (25 to 30&ordm;C), osmolarity (NaCl concentration of 50 to 60 mmol), high aeration, acidic pH (6.5), and the presence of certain amino acids (asparagine, serine, glutamate, and arginine), phosphate, and trace elements [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several virulence factors are regulated coordinately with cholera toxin in response to these environmental factors. The regulatory cascade controlling virulence genes in V. cholerae was initially believed to be under the sole control of ToxR, a 32-kDa transmembrane protein [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/51\">",
"     51",
"    </a>",
"    ], and has thus been called the ToxR regulon [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/50,52\">",
"     50,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The gene downstream of toxR is toxS, which encodes a 19-kDa periplasmic protein. ToxS interacts with ToxR and increases its activity and stability [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. ToxR and ToxS work synergistically with TcpP and TcpH, two proteins whose genes lie within the tcp gene cluster on the TCP pathogenicity island, to regulate transcription of toxT, which also lies within the tcp gene cluster [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. toxT transcription is from two different promoters; one is activated in part by TcpP and TcpH, while the other is activated by ToxR itself [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ToxT is a 32-kDa protein, which is a member of the AraC family of transcriptional activators [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. ToxT activates transcription of ctxAB, as well as the tcp genes, the acf genes, and the aldA gene. There are both ToxT-dependent and ToxT-independent branches of the ToxR regulon [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/60\">",
"     60",
"    </a>",
"    ]; transcription of the genes encoding two major outer membrane proteins, OmpT and OmpU, is regulated directly by ToxR, as are genes involved in motility and chemotaxis.",
"   </p>",
"   <p>",
"    ToxR has different activities if it is expressed in Escherichia coli or in its native host, V. cholerae. In experimental systems in E. coli, ToxR acts as a transcriptional activator of ctxAB by binding to a 7-bp repetitive region in the ctxAB promoter [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/61\">",
"     61",
"    </a>",
"    ]; the more tandem repeats that are present, the more toxin is produced [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/45\">",
"     45",
"    </a>",
"    ]. In V. cholerae, however, ToxR does not directly activate the ctxAB promoter, but acts to control toxin expression through activation of toxT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/60\">",
"     60",
"    </a>",
"    ]. The difference in the ability of ToxR to activate ctxAB in E. coli and in V. cholerae is not yet understood.",
"   </p>",
"   <p>",
"    The proteins involved in directly sensing the environmental changes that regulate gene expression are not known. Production of TcpP and TcpH is controlled by environmental changes; transcription of the tcpPH genes is regulated by temperature and pH in a ToxR-independent manner [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/56\">",
"     56",
"    </a>",
"    ]. The ability of",
"    <span class=\"nowrap\">",
"     TcpP/H",
"    </span>",
"    to activate ToxT is significantly reduced when the growth medium contains a high NaCl concentration; both exogenous and endogenous sodium appear to affect virulence factors in V. cholerae in a complex fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The regulatory protein AphA is required for activation of the tcpPH promoter, and may act to regulate the expression of tcpPH in response to environmental changes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/63\">",
"     63",
"    </a>",
"    ]. It may be that other yet undefined regulatory proteins affect TcpPH",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ToxR expression, or that TcpPH",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ToxR directly sense external signals. However, ToxR expression itself is not influenced by most environmental changes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/61,64\">",
"     61,64",
"    </a>",
"    ]. One exception is the reduced expression of ToxR at high temperatures (37&ordm;C), which may relate to control at the promoter level by the divergently transcribed heat shock gene, htpG [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The response of V. cholerae strains to environmental conditions varies by biotype. Variations in control over the expression of ToxT appear to be important in these biotype differences [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/50,65\">",
"     50,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other genes may also be important in the regulation of virulence genes. The cAMP-CRP system, a global regulator in many bacteria that responds to carbon sources through cAMP expression, also influences the expression of ToxR-regulated virulence genes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/66\">",
"     66",
"    </a>",
"    ]. V. cholerae has a virulence locus, varA, which is a homologue of the conserved global regulatory gene gacA. GacA belongs to the family of two-component signal transducing molecules. Transcription of the varA gene is independent of ToxR; varA mutants produce less TCP and CT, and are attenuated in colonization [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, phage induction and replication may be an additional mechanism for the regulation of CT production in vivo. Expression of CT from the replicative form of CTXphi is largely independent of ToxR and ToxT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Other virulence factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional enterotoxins have been described in V. cholerae. Two of these, Zot (zonula occludens toxin) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/69,70\">",
"     69,70",
"    </a>",
"    ] and Ace (accessory cholera enterotoxin) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/71\">",
"     71",
"    </a>",
"    ], are encoded by genes within the core region of the CTXphi genome. Zot increases the permeability of the small intestinal mucosa by affecting the structure of the intercellular tight junctions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/72\">",
"     72",
"    </a>",
"    ], while Ace increases ion transport across rabbit ileal mucosa and causes fluid secretion in ligated rabbit ileal loops. However, since Ace and Zot are structural proteins required in bacteriophage morphogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/47\">",
"     47",
"    </a>",
"    ], the role of these proteins as toxins is under question.",
"   </p>",
"   <p>",
"    V. cholerae produces four types of heat-stable enterotoxins, which are similar to a toxin produced by some V. cholerae non-O1 strains. This protein is homologous to the ST enterotoxin of enterotoxigenic E. coli at the amino acid level, but not at the nucleotide level [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/73\">",
"     73",
"    </a>",
"    ], suggesting convergent evolution.",
"   </p>",
"   <p>",
"    The ability to acquire iron appears to be important for bacterial virulence, though the role of specific iron transport systems in V. cholerae virulence has been difficult to elucidate. V. cholerae has two partially redundant TonB transport systems; a strain with mutations in both TonB systems demonstrates reduced colonization of infant mice [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/74\">",
"     74",
"    </a>",
"    ]. However, no single iron source appears to be required for virulence [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/75\">",
"     75",
"    </a>",
"    ]. The V. cholerae hemolysin genes are also negatively regulated by iron concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Volunteer studies, however, do not show a difference in the ability of hemolytic and nonhemolytic strains to cause diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Novel technologies have been used to identify V. cholerae genes specifically induced during infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/79-81\">",
"     79-81",
"    </a>",
"    ], including in vivo-induced antigen technology [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/82\">",
"     82",
"    </a>",
"    ], and transcriptional profiling of human-shed V. cholerae [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/83,84\">",
"     83,84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6697843\">",
"    <span class=\"h2\">",
"     Environmental persistence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aquatic bacteria are rarely found in the planktonic or free-swimming phase; they are usually associated with solid surfaces. Biofilm development has been postulated to be critical to the persistence of V. cholerae in the environment, and several factors have been identified that play important roles in biofilm formation. Bacteria move towards a surface using their polar flagella, then make initial contact enhanced by the MSHA type IV pilus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/26\">",
"     26",
"    </a>",
"    ]. An exopolysaccharide, the product of the vps genes, is a major component of the extracellular matrix of the biofilm [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/85\">",
"     85",
"    </a>",
"    ]. Other genes have been identified as playing roles in the maintenance of biofilm architecture and in the activation of biofilm formation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/86,87\">",
"     86,87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of multicellular biofilms in the environmental persistence and infectiousness of V. cholerae was examined by investigators in Bangladesh [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/88\">",
"     88",
"    </a>",
"    ]. Environmental water samples were tested for the presence of toxigenic V. cholerae. Although the organism was rarely found with conventional culture techniques, V. cholerae was isolated using an enrichment technique that allows conditionally viable environmental cells to multiply. The cells were identified in clumps in surface water. Animal studies confirmed that the organisms were virulent. This study suggests that biofilm formation may be a virulence property of V. cholerae that contributes to its ability to persist in the environment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6698048\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Steps in the pathogenesis of V. cholerae infection include transmission of bacteria, intestinal colonization, production of virulence factor, and environmental persistence (",
"      <a class=\"graphic graphic_figure graphicRef69278 \" href=\"UTD.htm?31/56/32644\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16786065\">",
"       'Pathogenesis overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infection with V. cholerae occurs after ingestion of contaminated food or water. Ingested bacteria must survive the gastric acid barrier of the stomach in order to reach the small intestine. V. cholerae are sensitive to gastric acid, and are rapidly killed at pH &lt;2.4. Organisms may survive transit through the stomach by virtue of protection within food, low gastric acidity of a compromised host, rapid gastric emptying, or a large inoculum size. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Colonization of the small intestinal epithelium is necessary for V. cholerae to cause disease. Factors that may contribute to this process include bacterial pili, hemagglutinins, an accessory colonizing factor, porin-like proteins, rfb-encoded enzymes, and a chitin-binding protein. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanisms of intestinal colonization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following colonization of the small intestinal epithelium, V. cholerae produces cholera toxin, a heterodimeric protein composed of one catalytic A subunit and five B subunits (",
"      <a class=\"graphic graphic_figure graphicRef69278 \" href=\"UTD.htm?31/56/32644\">",
"       figure 1",
"      </a>",
"      ). The A subunit is cleaved to produce A1 and A2 fragments linked by a disulfide bond. The B subunit pentamer binds holotoxin to the enterocyte surface receptor, the ganglioside GM1. Following binding of holotoxin to GM1 and internalization, A1 catalyzes the ADP-ribosylation of a GTP-binding protein, leading to persistent activation of adenylate cyclase [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29768/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. The increase of cAMP in the intestinal mucosa leads to increased chloride secretion and decreased sodium absorption, producing the massive fluid and electrolyte loss characteristic of the disease. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Virulence factor production'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biofilm development has been postulated to be critical to the persistence of V. cholerae in the environment, and several factors have been identified that play important roles in biofilm formation. (See",
"      <a class=\"local\" href=\"#H6697843\">",
"       'Environmental persistence'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Butterton, JR, Calderwood, SB. Vibrio cholerae O1. In: Infections of the Gastrointestinal Tract, Blaser, MJ, Smith, PD, Ravdin, JI, et al (Eds), Raven Press, New York 1995. p.649.",
"    </li>",
"    <li>",
"     Snow, J. On the mode of communication of cholera, John Churchill, London 1849.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/3\">",
"      Sack DA, Sack RB, Nair GB, Siddique AK. Cholera. Lancet 2004; 363:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/4\">",
"      Swerdlow DL, Mintz ED, Rodriguez M, et al. Waterborne transmission of epidemic cholera in Trujillo, Peru: lessons for a continent at risk. Lancet 1992; 340:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/5\">",
"      Ries AA, Vugia DJ, Beingolea L, et al. Cholera in Piura, Peru: a modern urban epidemic. J Infect Dis 1992; 166:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/6\">",
"      Fotedar R. Vector potential of houseflies (Musca domestica) in the transmission of Vibrio cholerae in India. Acta Trop 2001; 78:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/7\">",
"      Blow NS, Salomon RN, Garrity K, et al. Vibrio cholerae infection of Drosophila melanogaster mimics the human disease cholera. PLoS Pathog 2005; 1:e8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/8\">",
"      Cash RA, Music SI, Libonati JP, et al. Response of man to infection with Vibrio cholerae. I. Clinical, serologic, and bacteriologic responses to a known inoculum. J Infect Dis 1974; 129:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/9\">",
"      Taylor RK, Miller VL, Furlong DB, Mekalanos JJ. Use of phoA gene fusions to identify a pilus colonization factor coordinately regulated with cholera toxin. Proc Natl Acad Sci U S A 1987; 84:2833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/10\">",
"      Herrington DA, Hall RH, Losonsky G, et al. Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med 1988; 168:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/11\">",
"      Karaolis DK, Johnson JA, Bailey CC, et al. A Vibrio cholerae pathogenicity island associated with epidemic and pandemic strains. Proc Natl Acad Sci U S A 1998; 95:3134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/12\">",
"      Sun DX, Mekalanos JJ, Taylor RK. Antibodies directed against the toxin-coregulated pilus isolated from Vibrio cholerae provide protection in the infant mouse experimental cholera model. J Infect Dis 1990; 161:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/13\">",
"      Sharma DP, Thomas C, Hall RH, et al. Significance of toxin-coregulated pili as protective antigens of Vibrio cholerae in the infant mouse model. Vaccine 1989; 7:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/14\">",
"      Sharma DP, Stroeher UH, Thomas CJ, et al. The toxin-coregulated pilus (TCP) of Vibrio cholerae: molecular cloning of genes involved in pilus biosynthesis and evaluation of TCP as a protective antigen in the infant mouse model. Microb Pathog 1989; 7:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/15\">",
"      Booth BA, Boesman-Finkelstein M, Finkelstein RA. Vibrio cholerae hemagglutinin/protease nicks cholera enterotoxin. Infect Immun 1984; 45:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/16\">",
"      Finkelstein RA, Boesman-Finkelstein M, Chang Y, H&auml;se CC. Vibrio cholerae hemagglutinin/protease, colonial variation, virulence, and detachment. Infect Immun 1992; 60:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/17\">",
"      Kimsey HH, Waldor MK. Vibrio cholerae hemagglutinin/protease inactivates CTXphi. Infect Immun 1998; 66:4025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/18\">",
"      H&auml;se CC, Finkelstein RA. Cloning and nucleotide sequence of the Vibrio cholerae hemagglutinin/protease (HA/protease) gene and construction of an HA/protease-negative strain. J Bacteriol 1991; 173:3311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/19\">",
"      Franzon VL, Barker A, Manning PA. Nucleotide sequence encoding the mannose-fucose-resistant hemagglutinin of Vibrio cholerae O1 and construction of a mutant. Infect Immun 1993; 61:3032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/20\">",
"      Van Dongen WM, De Graaf FK. Molecular cloning of a gene coding for a Vibrio cholerae haemagglutinin. J Gen Microbiol 1986; 132:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/21\">",
"      Marsh JW, Taylor RK. Genetic and transcriptional analyses of the Vibrio cholerae mannose-sensitive hemagglutinin type 4 pilus gene locus. J Bacteriol 1999; 181:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/22\">",
"      Attridge SR, Manning PA, Holmgren J, Jonson G. Relative significance of mannose-sensitive hemagglutinin and toxin-coregulated pili in colonization of infant mice by Vibrio cholerae El Tor. Infect Immun 1996; 64:3369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/23\">",
"      Tacket CO, Taylor RK, Losonsky G, et al. Investigation of the roles of toxin-coregulated pili and mannose-sensitive hemagglutinin pili in the pathogenesis of Vibrio cholerae O139 infection. Infect Immun 1998; 66:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/24\">",
"      Thelin KH, Taylor RK. Toxin-coregulated pilus, but not mannose-sensitive hemagglutinin, is required for colonization by Vibrio cholerae O1 El Tor biotype and O139 strains. Infect Immun 1996; 64:2853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/25\">",
"      Jouravleva EA, McDonald GA, Marsh JW, et al. The Vibrio cholerae mannose-sensitive hemagglutinin is the receptor for a filamentous bacteriophage from V. cholerae O139. Infect Immun 1998; 66:2535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/26\">",
"      Watnick PI, Fullner KJ, Kolter R. A role for the mannose-sensitive hemagglutinin in biofilm formation by Vibrio cholerae El Tor. J Bacteriol 1999; 181:3606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/27\">",
"      Peterson KM, Mekalanos JJ. Characterization of the Vibrio cholerae ToxR regulon: identification of novel genes involved in intestinal colonization. Infect Immun 1988; 56:2822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/28\">",
"      Parsot C, Taxman E, Mekalanos JJ. ToxR regulates the production of lipoproteins and the expression of serum resistance in Vibrio cholerae. Proc Natl Acad Sci U S A 1991; 88:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/29\">",
"      Parsot C, Mekalanos JJ. Structural analysis of the acfA and acfD genes of Vibrio cholerae: effects of DNA topology and transcriptional activators on expression. J Bacteriol 1992; 174:5211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/30\">",
"      Sengupta DK, Sengupta TK, Ghose AC. Antibodies to outer membrane proteins of Vibrio cholerae induce protection by inhibition of intestinal colonization of vibrios. FEMS Microbiol Immunol 1992; 4:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/31\">",
"      Sengupta DK, Sengupta TK, Ghose AC. Major outer membrane proteins of Vibrio cholerae and their role in induction of protective immunity through inhibition of intestinal colonization. Infect Immun 1992; 60:4848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/32\">",
"      Chiang SL, Mekalanos JJ. rfb mutations in Vibrio cholerae do not affect surface production of toxin-coregulated pili but still inhibit intestinal colonization. Infect Immun 1999; 67:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/33\">",
"      Kirn TJ, Jude BA, Taylor RK. A colonization factor links Vibrio cholerae environmental survival and human infection. Nature 2005; 438:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/34\">",
"      Gill DM. The arrangement of subunits in cholera toxin. Biochemistry 1976; 15:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/35\">",
"      Van Heyningen WE, Carpenter CC, Pierce NF, Greenough WB 3rd. Deactivation of cholera toxin by ganglioside. J Infect Dis 1971; 124:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/36\">",
"      Mekalanos JJ, Collier RJ, Romig WR. Enzymic activity of cholera toxin. II. Relationships to proteolytic processing, disulfide bond reduction, and subunit composition. J Biol Chem 1979; 254:5855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/37\">",
"      Yamamoto S, Takeda Y, Yamamoto M, et al. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J Exp Med 1997; 185:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/38\">",
"      Cassel D, Pfeuffer T. Mechanism of cholera toxin action: covalent modification of the guanyl nucleotide-binding protein of the adenylate cyclase system. Proc Natl Acad Sci U S A 1978; 75:2669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/39\">",
"      Gill DM, Meren R. ADP-ribosylation of membrane proteins catalyzed by cholera toxin: basis of the activation of adenylate cyclase. Proc Natl Acad Sci U S A 1978; 75:3050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/40\">",
"      Holmgren J. Actions of cholera toxin and the prevention and treatment of cholera. Nature 1981; 292:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/41\">",
"      Gilman AG. G proteins and dual control of adenylate cyclase. Cell 1984; 36:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/42\">",
"      Wald A, Gotterer GS, Rajendra GR, et al. Effect of indomethacin on cholera-induced fluid movement, unidirectional sodium fluxes, and intestinal cAMP. Gastroenterology 1977; 72:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/43\">",
"      Peterson JW, Ochoa LG. Role of prostaglandins and cAMP in the secretory effects of cholera toxin. Science 1989; 245:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/44\">",
"      Speelman P, Rabbani GH, Bukhave K, Rask-Madsen J. Increased jejunal prostaglandin E2 concentrations in patients with acute cholera. Gut 1985; 26:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/45\">",
"      Mekalanos JJ, Swartz DJ, Pearson GD, et al. Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development. Nature 1983; 306:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/46\">",
"      Mekalanos JJ. Duplication and amplification of toxin genes in Vibrio cholerae. Cell 1983; 35:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/47\">",
"      Waldor MK, Mekalanos JJ. Lysogenic conversion by a filamentous phage encoding cholera toxin. Science 1996; 272:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/48\">",
"      Waldor MK, Rubin EJ, Pearson GD, et al. Regulation, replication, and integration functions of the Vibrio cholerae CTXphi are encoded by region RS2. Mol Microbiol 1997; 24:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/49\">",
"      Kimsey HH, Waldor MK. CTXphi immunity: application in the development of cholera vaccines. Proc Natl Acad Sci U S A 1998; 95:7035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/50\">",
"      Skorupski K, Taylor RK. Control of the ToxR virulence regulon in Vibrio cholerae by environmental stimuli. Mol Microbiol 1997; 25:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/51\">",
"      Miller VL, Mekalanos JJ. Synthesis of cholera toxin is positively regulated at the transcriptional level by toxR. Proc Natl Acad Sci U S A 1984; 81:3471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/52\">",
"      Faruque SM, Albert MJ, Mekalanos JJ. Epidemiology, genetics, and ecology of toxigenic Vibrio cholerae. Microbiol Mol Biol Rev 1998; 62:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/53\">",
"      Miller VL, DiRita VJ, Mekalanos JJ. Identification of toxS, a regulatory gene whose product enhances toxR-mediated activation of the cholera toxin promoter. J Bacteriol 1989; 171:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/54\">",
"      DiRita VJ, Mekalanos JJ. Periplasmic interaction between two membrane regulatory proteins, ToxR and ToxS, results in signal transduction and transcriptional activation. Cell 1991; 64:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/55\">",
"      H&auml;se CC, Mekalanos JJ. TcpP protein is a positive regulator of virulence gene expression in Vibrio cholerae. Proc Natl Acad Sci U S A 1998; 95:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/56\">",
"      Carroll PA, Tashima KT, Rogers MB, et al. Phase variation in tcpH modulates expression of the ToxR regulon in Vibrio cholerae. Mol Microbiol 1997; 25:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/57\">",
"      Yu RR, DiRita VJ. Analysis of an autoregulatory loop controlling ToxT, cholera toxin, and toxin-coregulated pilus production in Vibrio cholerae. J Bacteriol 1999; 181:2584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/58\">",
"      DiRita VJ, Parsot C, Jander G, Mekalanos JJ. Regulatory cascade controls virulence in Vibrio cholerae. Proc Natl Acad Sci U S A 1991; 88:5403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/59\">",
"      Higgins DE, Nazareno E, DiRita VJ. The virulence gene activator ToxT from Vibrio cholerae is a member of the AraC family of transcriptional activators. J Bacteriol 1992; 174:6974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/60\">",
"      Champion GA, Neely MN, Brennan MA, DiRita VJ. A branch in the ToxR regulatory cascade of Vibrio cholerae revealed by characterization of toxT mutant strains. Mol Microbiol 1997; 23:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/61\">",
"      Miller VL, Taylor RK, Mekalanos JJ. Cholera toxin transcriptional activator toxR is a transmembrane DNA binding protein. Cell 1987; 48:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/62\">",
"      H&auml;se CC, Mekalanos JJ. Effects of changes in membrane sodium flux on virulence gene expression in Vibrio cholerae. Proc Natl Acad Sci U S A 1999; 96:3183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/63\">",
"      Skorupski K, Taylor RK. A new level in the Vibrio cholerae ToxR virulence cascade: AphA is required for transcriptional activation of the tcpPH operon. Mol Microbiol 1999; 31:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/64\">",
"      Parsot C, Mekalanos JJ. Expression of ToxR, the transcriptional activator of the virulence factors in Vibrio cholerae, is modulated by the heat shock response. Proc Natl Acad Sci U S A 1990; 87:9898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/65\">",
"      DiRita VJ, Neely M, Taylor RK, Bruss PM. Differential expression of the ToxR regulon in classical and E1 Tor biotypes of Vibrio cholerae is due to biotype-specific control over toxT expression. Proc Natl Acad Sci U S A 1996; 93:7991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/66\">",
"      Skorupski K, Taylor RK. Cyclic AMP and its receptor protein negatively regulate the coordinate expression of cholera toxin and toxin-coregulated pilus in Vibrio cholerae. Proc Natl Acad Sci U S A 1997; 94:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/67\">",
"      Wong SM, Carroll PA, Rahme LG, et al. Modulation of expression of the ToxR regulon in Vibrio cholerae by a member of the two-component family of response regulators. Infect Immun 1998; 66:5854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/68\">",
"      Lazar S, Waldor MK. ToxR-independent expression of cholera toxin from the replicative form of CTXphi. Infect Immun 1998; 66:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/69\">",
"      Fasano A, Baudry B, Pumplin DW, et al. Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc Natl Acad Sci U S A 1991; 88:5242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/70\">",
"      Baudry B, Fasano A, Ketley J, Kaper JB. Cloning of a gene (zot) encoding a new toxin produced by Vibrio cholerae. Infect Immun 1992; 60:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/71\">",
"      Trucksis M, Galen JE, Michalski J, et al. Accessory cholera enterotoxin (Ace), the third toxin of a Vibrio cholerae virulence cassette. Proc Natl Acad Sci U S A 1993; 90:5267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/72\">",
"      Fasano A, Fiorentini C, Donelli G, et al. Zonula occludens toxin modulates tight junctions through protein kinase C-dependent actin reorganization, in vitro. J Clin Invest 1995; 96:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/73\">",
"      Yoshino K, Miyachi M, Takao T, et al. Purification and sequence determination of heat-stable enterotoxin elaborated by a cholera toxin-producing strain of Vibrio cholerae O1. FEBS Lett 1993; 326:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/74\">",
"      Seliger SS, Mey AR, Valle AM, Payne SM. The two TonB systems of Vibrio cholerae: redundant and specific functions. Mol Microbiol 2001; 39:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/75\">",
"      Mey AR, Wyckoff EE, Oglesby AG, et al. Identification of the Vibrio cholerae enterobactin receptors VctA and IrgA: IrgA is not required for virulence. Infect Immun 2002; 70:3419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/76\">",
"      Stoebner JA, Payne SM. Iron-regulated hemolysin production and utilization of heme and hemoglobin by Vibrio cholerae. Infect Immun 1988; 56:2891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/77\">",
"      Williams SG, Manning PA. Transcription of the Vibrio cholerae haemolysin gene, hlyA, and cloning of a positive regulatory locus, hlyU. Mol Microbiol 1991; 5:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/78\">",
"      Levine MM, Kaper JB, Herrington D, et al. Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect Immun 1988; 56:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/79\">",
"      Camilli A, Mekalanos JJ. Use of recombinase gene fusions to identify Vibrio cholerae genes induced during infection. Mol Microbiol 1995; 18:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/80\">",
"      Lee SH, Hava DL, Waldor MK, Camilli A. Regulation and temporal expression patterns of Vibrio cholerae virulence genes during infection. Cell 1999; 99:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/81\">",
"      Osorio CG, Crawford JA, Michalski J, et al. Second-generation recombination-based in vivo expression technology for large-scale screening for Vibrio cholerae genes induced during infection of the mouse small intestine. Infect Immun 2005; 73:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/82\">",
"      Hang L, John M, Asaduzzaman M, et al. Use of in vivo-induced antigen technology (IVIAT) to identify genes uniquely expressed during human infection with Vibrio cholerae. Proc Natl Acad Sci U S A 2003; 100:8508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/83\">",
"      Merrell DS, Butler SM, Qadri F, et al. Host-induced epidemic spread of the cholera bacterium. Nature 2002; 417:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/84\">",
"      Larocque RC, Harris JB, Dziejman M, et al. Transcriptional profiling of Vibrio cholerae recovered directly from patient specimens during early and late stages of human infection. Infect Immun 2005; 73:4488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/85\">",
"      Yildiz FH, Schoolnik GK. Vibrio cholerae O1 El Tor: identification of a gene cluster required for the rugose colony type, exopolysaccharide production, chlorine resistance, and biofilm formation. Proc Natl Acad Sci U S A 1999; 96:4028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/86\">",
"      Bomchil N, Watnick P, Kolter R. Identification and characterization of a Vibrio cholerae gene, mbaA, involved in maintenance of biofilm architecture. J Bacteriol 2003; 185:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/87\">",
"      Karatan E, Duncan TR, Watnick PI. NspS, a predicted polyamine sensor, mediates activation of Vibrio cholerae biofilm formation by norspermidine. J Bacteriol 2005; 187:7434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29768/abstract/88\">",
"      Faruque SM, Biswas K, Udden SM, et al. Transmissibility of cholera: in vivo-formed biofilms and their relationship to infectivity and persistence in the environment. Proc Natl Acad Sci U S A 2006; 103:6350.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2682 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-817E36F31F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_4_29768=[""].join("\n");
var outline_f29_4_29768=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6698048\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16786065\">",
"      PATHOGENESIS OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanisms of intestinal colonization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Pili",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Hemagglutinins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Accessory colonization factor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Porin-like proteins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - rfb-encoded enzymes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Chitin-binding protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Virulence factor production",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6697671\">",
"      - Cholera toxin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Location of cholera toxin genes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Regulation of virulence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Other virulence factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6697843\">",
"      Environmental persistence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6698048\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2682\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2682|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/56/32644\" title=\"figure 1\">",
"      Pathophysiology of V cholerae",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=related_link\">",
"      Overview of Vibrio cholerae infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_4_29769="Psychosocial issues at the end of life";
var content_f29_4_29769=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Psychosocial issues at the end of life",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/4/29769/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/4/29769/contributors\">",
"     Laurie Rosenblatt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/4/29769/contributors\">",
"     Susan D Block, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/4/29769/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/4/29769/contributors\">",
"     Linda Emanuel, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/4/29769/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/4/29769/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/4/29769/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/4/29769/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosocial and spiritual concerns are nearly universal among patients who are conscious as they near the end of life. Understanding these issues and the ways in which they interact with physical distress is essential to assessment and management in end of life care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41208?source=see_link\">",
"     \"Religion, spirituality, and end of life care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREREQUISITES FOR ADDRESSING PSYCHOSOCIAL AND SPIRITUAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of psychosocial and spiritual issues at the end of life presumes control of physical suffering and a secure and supportive relationship between the patient and his or her clinicians.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Control of symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical discomfort is one of the greatest concerns as patients with a terminal illness anticipate dying [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Effective symptom management allows patients and their families to focus on maintaining hope, reaffirming important connections, and attaining a sense of completion. Patients may then preserve to some extent roles and activities that have made life meaningful [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/2,3,5-11\">",
"     2,3,5-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Psychological, social and spiritual factors may exacerbate physical suffering. For instance, depression amplifies pain and other somatic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. When physical, psychological, and spiritual sources of distress are inseparably intermixed causing \"total pain syndrome\", a fully integrated clinical approach that addresses the multiple dimensions of suffering is required [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/52/28490?source=see_link\">",
"     \"Overview of comprehensive patient assessment in palliative care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinician can clarify causes of distress and tailor treatment at the end of life by asking questions such as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Do you have any physical discomfort right now?",
"     </li>",
"     <li>",
"      Is there anything bothering you that we have not addressed?",
"     </li>",
"     <li>",
"      How are you doing in general?",
"     </li>",
"     <li>",
"      Do you worry about pain or discomfort in the future?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     A secure and supportive patient-clinician relationship",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between patient and clinician can be an important source of solace for patients and their families. But like other relationships, it may be subject to strain during the course of a terminal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/15\">",
"     15",
"    </a>",
"    ]. If the patient does not trust the clinician or if the quality of communication between them is poor or has become strained, it will be difficult for the clinician to gauge the patient's adjustment as the disease progresses.",
"   </p>",
"   <p>",
"    The following questions can be posed to assess the state of the treatment relationship:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      How are we doing together?",
"     </li>",
"     <li>",
"      Are there things I could be doing to be helpful that I'm not doing now?",
"     </li>",
"     <li>",
"      Is there anything you would like to change in the way we work together?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Answers to such questions clarify the working relationship and help uncover unrealistic expectations on the part of the patient or family. Patients differ in their need for information. Knowing what level of detail a patient desires and whether it differs from the family's need for information is an important aspect of patient-clinician communication. In addition, the clinician's own feelings may serve to indicate unacknowledged distress [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/16\">",
"     16",
"    </a>",
"    ], problems in the relationship with the patient or family [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/17-20\">",
"     17-20",
"    </a>",
"    ], undiagnosed psychiatric illness (eg, depression), or the clinician's own strained emotions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/3,4,21\">",
"     3,4,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     COMMON ISSUES AT THE END OF LIFE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are some common concerns voiced by patients with terminal illness:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The meaning of the illness",
"     </li>",
"     <li>",
"      Spiritual uncertainty",
"     </li>",
"     <li>",
"      Loss and grief",
"     </li>",
"     <li>",
"      Fear of increasing dependency on others",
"     </li>",
"     <li>",
"      Uncertainty and fear about the future",
"     </li>",
"     <li>",
"      Worries about loved ones",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Keeping these concerns in mind can help the clinician to diagnose, acknowledge, anticipate, and respond effectively to patient and family distress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     The meaning of the illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;When bad things happen, people try to find a reason for the calamity. A patient blaming his or herself for having \"caused\" his or her lung cancer by smoking may find it difficult to accept care from loved ones. Another patient may feel abandoned by God as when dying.",
"   </p>",
"   <p>",
"    By asking a series of open ended questions like the following, the clinician invites the patient and family to describe the unique impact of the illness on their lives by telling their story about what has happened [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      How do you think about what's happened to you?",
"     </li>",
"     <li>",
"      Are you worried about what may have caused this disease?",
"     </li>",
"     <li>",
"      Are there some aspects of this experience that particularly stand out?",
"     </li>",
"     <li>",
"      What's been the hardest part for you? For your family?",
"     </li>",
"     <li>",
"      Are there some particular aspects of all of this that you'd like to talk about?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this way, clinicians can discover theories about what caused the illness, identify factual inaccuracies about the medical situation, and reveal misunderstandings of therapeutic intent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. A sense of the patient's and family's values and experience of illness emerges from these conversations that may also indicate spiritual or existential distress (eg, suffering viewed as punitive or meaningless), disruptions in personal relationships, or the presence of depression",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98972178\">",
"    <span class=\"h2\">",
"     Spiritual beliefs and religious community",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients and their families often call upon spiritual or religious beliefs and community support networks when confronting terminal disease and making decisions about treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/25\">",
"     25",
"    </a>",
"    ]. Many studies focusing on the role of religion and spirituality in coping with cancer have shown that religious belief provides a reserve of personal strength for those nearing the end of life. Spirituality often helps people accommodate to illness [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/26-29\">",
"     26-29",
"    </a>",
"    ], adjust to disability [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/30\">",
"     30",
"    </a>",
"    ], feel less depressed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], and cope [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Spiritual and religious beliefs also play a role in influencing decisions about medical treatments at the end of life, with patients who report stronger positive religious coping being more likely to choose aggressive care. Additional literature demonstrates that patients who feel supported by the medical team experience better quality of life and are less likely to elect aggressive care [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians may be reluctant to talk about spiritual issues with their patients, worrying that patients may consider such discussions intrusive or evangelical. Clinicians sometimes feel overwhelmed and unsure about how to respond if patients turn to them in spiritual distress. Yet it appears that most patients want their physicians and nurses to ask about spiritual concerns [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although a patient's spiritual and existential beliefs are often a source of solace, during the course of serious illness they may also become a source of anguish, particularly if a spiritually secure patient is assailed by doubt or feels abandoned or punished by God [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/40\">",
"     40",
"    </a>",
"    ]. The clinician can address a patient's spiritual concerns by asking some general questions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What are the things in your life that have been most important to you?",
"     </li>",
"     <li>",
"      What do you hope for now?",
"     </li>",
"     <li>",
"      Has faith or spirituality been important to you in the past?",
"     </li>",
"     <li>",
"      Is religion or spirituality helpful to you now?",
"     </li>",
"     <li>",
"      Is there anyone you'd like me to call?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The topic of spiritual issues, which includes a discussion of how several of the major religions deal with death and suffering at the end of life, is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41208?source=see_link\">",
"     \"Religion, spirituality, and end of life care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Loss and grief",
"    </span>",
"    &nbsp;&mdash;&nbsp;Values, spiritual beliefs, personality style, characteristic methods of coping, and family traditions all influence the way a person comes to terms with a terminal prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/41\">",
"     41",
"    </a>",
"    ]. Terminal illness causes patients to confront current and anticipated physical loss as well as changes in role functioning and relationships. As the disease progresses, patients and their families must adjust to these changes and reestablish a new equilibrium [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Grief is an intrinsic part of the human response to loss and often entails a reassessment of the scope of personal accomplishments, mourning for the loss of a desired future, and relinquishing many of the roles that have sustained a sense of purpose. During these difficult transitions, patients struggle to maintain hope. Hope may be preserved when patients and families redefine the goals for care, and are able to preserve dignity within the newly narrowed circumstances.",
"   </p>",
"   <p>",
"    Several models summarize the grieving process as patients move toward death. Kubler-Ross's five stage model of grieving (denial and isolation, anger, bargaining, depression, and finally acceptance) is the best known [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/44\">",
"     44",
"    </a>",
"    ]. Most patients do not move sequentially through these stages, but the model does reflect the range of normal emotional coping responses during terminal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31190?source=see_link\">",
"     \"Grief and bereavement\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More recent research on grief following a death suggests a pattern in which disbelief peaks at one month, yearning at four months, anger at five months, and depression at six months post loss. This suggests that surviving loved ones who continue to have intense or unmitigated negative affects seven or more months post loss might benefit from psychosocial evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dependency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients lose physical and psychological control as illness progresses, triggering shame and terror that may amplify isolation. Increasing need for help with daily functions may be humiliating and even lead patients to think of hastening death. As physical dependency increases, feelings of vulnerability and helplessness add to concerns about becoming a burden to family members in emotional, physical, and financial ways [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As the patient relinquishes some roles and responsibilities, he or she faces a diminishing sphere of control [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/50\">",
"     50",
"    </a>",
"    ]. One consequence may be a transient increase in family turmoil and conflict due to shifting responsibilities.",
"   </p>",
"   <p>",
"    If a patient expresses concern about lack of control, helplessness, and dependency, the clinician might ask:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Do you worry about needing too much care from others?",
"     </li>",
"     <li>",
"      Do you feel you still have choices about how you spend your days?",
"     </li>",
"     <li>",
"      Do you have control of your symptoms?",
"     </li>",
"     <li>",
"      Is your treatment plan in your control?",
"     </li>",
"     <li>",
"      Is there someone in particular you are worried about burdening?",
"     </li>",
"     <li>",
"      What is your relationship with him or her like now?",
"     </li>",
"     <li>",
"      Do you worry that some particular situation will be overwhelming for people who you love and rely on?",
"     </li>",
"     <li>",
"      Do you worry about a particular situation that would completely overwhelm you?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Feelings of intense anger, guilt, boredom, loneliness, and alienation are common for the patient and family members when a patient becomes more dependent. Shame may arise from the intensity of these emotions and patients may become distressed by not feeling like themselves. By encouraging the patient to talk about difficult feelings, the clinician may come to understand the sources of those feelings and provide reassurance about common responses to serious illness. But the clinician does not need to have answers when faced with existential issues that arise during terminal illness. Listening is often enough, and a rush to provide reassurance that &ldquo;there is nothing to worry about&rdquo; actually may increase a patient's sense of isolation.",
"   </p>",
"   <p>",
"    If feelings such as anger threaten the patient's relationships or lead to dangerous behavior, the clinician should directly address the situation and assess the patient for depression, delirium, and other organic mental states as well as asking about developing isolation and abandonment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Uncertainty and fears about the future",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impending death can rouse anxiety about separation from loved ones, fear of helplessness and loss of control, feelings of overwhelming guilt, perceptions of punishment, anticipation of unbearable physical suffering, and terror of abandonment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/51\">",
"     51",
"    </a>",
"    ]. Questions about the exact nature of a patient's fear can help reduce anxiety and avoid misunderstandings.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What frightens you most about what is happening to you now?",
"     </li>",
"     <li>",
"      What is it about your illness that has been the most frightening for you?",
"     </li>",
"     <li>",
"      Do you have particular worries about death or what dying might be like?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Concerns about loved ones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients worry about the physical and emotional toll of their illness on spouses or other family members who assume the role of caregiver. Caregivers may have increased responsibilities for childcare, care of elderly parents, and management of household tasks, as well as care of the patient and the burdens imposed by anticipatory grief [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parents frequently have questions about how to talk to their children about the illness and impending death. Some principles for addressing these concerns are [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/53\">",
"     53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Get to know the child through the parent's eyes. Asking the patient to describe the child is often a good place to start. Age and temperament provide clues to a child's reaction to the parent's illness, and pointing out that the child's prior coping style is likely to emerge in reaction to the illness and treatment can be helpful.",
"     </li>",
"     <li>",
"      Assess the support system. As a general rule, children do well with a regular schedule and as little disruption of normal routines as possible. Older children often rely on peer relationships for support. Providing the school and caretakers with information about the parent's medical situation permits additional support.",
"     </li>",
"     <li>",
"      Encourage the patient to provide information about the illness and treatment. Overhearing bad news is the worst way for children to obtain information because they sense a secret from which they are excluded and begin to imagine what it might be and to worry that they may be responsible. An open direct approach such as naming the disease and giving age-appropriate explanations can avert this problem [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/54,55\">",
"       54,55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Family members often make major life changes in the course of caring for patients with terminal illness. Many families report loss of family savings and income when spouses or others quit work to provide care [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/52,56\">",
"     52,56",
"    </a>",
"    ]. The emotional toll on family members can lead to depression and stress related symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. In addition caregivers may neglect their own health care, missing routine screening appointments or follow-up care for chronic conditions. Patients frequently feel responsible for bringing these burdens on family members, particularly spouses or elderly parents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MEDIATORS OF COPING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Maintaining hope",
"    </span>",
"    &nbsp;&mdash;&nbsp;Terminal illness inevitably evokes great distress in patients and families and clinicians, engendering fear, anxiety, anger, dread, sadness, helplessness, and uncertainty. Hope permits patients and their families to cope with these difficult emotions and helps them endure the stresses of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. However, the desire for hope may conflict with the desire for full disclosure of the prognosis. Patients and families often oscillate between the two, struggling to find a sense of emotional equilibrium. In the face of such struggles and clinical uncertainty about the imminence of death, it is often difficult for clinicians to imagine how hope can be maintained in the face of conversations about death",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    moving beyond curative treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/61\">",
"     61",
"    </a>",
"    ], which ideally should be initiated soon after a diagnosis of advanced cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/62\">",
"     62",
"    </a>",
"    ]. A prospective, longitudinal cohort study of end of life discussions found no evidence that conversations about prognosis were associated with increased emotional distress [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/63\">",
"     63",
"    </a>",
"    ]. Rather, patients who reported discussions with their clinicians were more likely to acknowledge that they were terminally ill and less likely to receive invasive procedures within the last week of life or to die in the intensive care unit.",
"   </p>",
"   <p>",
"    Hope is not dependent upon undoing what cannot be changed or deceiving patients about the future. It is founded on trust, connection, and preservation of dignity, identity, and the sense of self. Clinicians support hope in their patients by exploring what remaining life can still provide and helping the patient reconnect with important relationships and aspects of themselves that may have been disrupted by illness. In addition, hope is supported by the recognition of past accomplishments that permits people to focus on the legacy they will leave behind [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/64-66\">",
"     64-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A novel therapeutic intervention termed \"dignity therapy\" has been developed to address such existential concerns in patients receiving home-based palliative care services . Terminally ill patients explore issues that matter most to them and reflect on the legacy they would like to leave behind for others. These structured interviews are transcribed and edited, and the patient is encouraged to \"bequeath\" a final version of the transcript to a friend or family member. A randomized trial compared dignity therapy versus standard palliative care or client-centered care (supportive psychotherapy that is focussed predominantly on illness-related symptoms and their management) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/67\">",
"     67",
"    </a>",
"    ]. While dignity therapy did not improve distress, the primary endpoint, it was associated with better spiritual wellbeing than client-centered care, and less sadness and depression compared to standard palliative care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38858?source=see_link&amp;anchor=H25#H25\">",
"     \"Assessment and management of depression in palliative care\", section on 'Existential psychotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Trusting, mutually respectful relationships with family members and care providers support hope. The clinician can nurture hope by confronting problems directly, conveying a caring attitude, focusing on achievable short-term goals, and involving the patient as an agent in care. Direct discussion of the patient's feelings of hopelessness and helplessness acknowledges reality while offering a professional relationship within which these feelings may be managed.",
"   </p>",
"   <p>",
"    We find that an approach of \"hoping for the best while preparing for the worst\" permits the patient to acknowledge the gravity of the disease while being able to find meaning and purpose for remaining time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Coping style",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coping style refers to the characteristic ways in which one maintains psychological and social equilibrium. One goal of physical and psychosocial intervention is to improve coping by identifying difficulties that can be ameliorated [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. To assess a patient's coping the following questions are helpful:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      How have you handled difficult times in the past?",
"     </li>",
"     <li>",
"      What, and who, do you depend upon when things go wrong?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Family and social support",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a patient is dying, even well functioning families may prove challenging for clinicians when they become destabilized by grief, helplessness, and exhaustion. In addition, there may be a significant emotional burden on family members who are asked to make decisions for incapacitated adults [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there is limited empirical research, King and Quill use family theory and clinical experience to suggest an assessment of family functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/71\">",
"     71",
"    </a>",
"    ]. A family's resilience under stressful conditions seems dependent on their committed attachment to each other, their ability to communicate and disagree without rupturing the bonds of affection and respect, and a capacity to solve problems and make decisions in a cooperative way [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When a patient is alert near the end of life, opportunities and vulnerabilities arising from the patient's important relationships may be assessed. In addition to some of the questions above, the following questions can be asked:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is there someone special you talk with and confide in?",
"     </li>",
"     <li>",
"      Who are the important people in your life?",
"     </li>",
"     <li>",
"      Who do you rely on?",
"     </li>",
"     <li>",
"      How are your friends and family doing with all this?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    King and Quill suggest some of the following questions to assess family functioning when the patient is unconscious:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      How was (the patient) diagnosed?",
"     </li>",
"     <li>",
"      What happened next?",
"     </li>",
"     <li>",
"      How did each of you find out?",
"     </li>",
"     <li>",
"      What did you do then?",
"     </li>",
"     <li>",
"      What is your relationship like with (the patient)?",
"     </li>",
"     <li>",
"      Is there anyone important to (the patient) who doesn't know?",
"     </li>",
"     <li>",
"      What was",
"      <span class=\"nowrap\">",
"       s/he",
"      </span>",
"      like before",
"      <span class=\"nowrap\">",
"       s/he",
"      </span>",
"      got sick?",
"     </li>",
"     <li>",
"      How do big decisions get made in your family?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Denial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Denial is a psychological mechanism by which a patient rejects either completely or in part the repercussions and effects of an illness (or treatment) thus avoiding painful feelings such as hopelessness, fear, anxiety, grief, and anger. Denial may at times lead to rigid avoidance of difficult new realities, while at other times it may enable the patient to preserve functioning through partial acknowledgment of bad news [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/68,72,73\">",
"     68,72,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Denial is always contextual. The context might be a crisis, such as disease progression, or an attempt to preserve the status quo in familial or treatment relationships. When confronted with a patient's denial, the clinician can consider the following question: Is denial helping the patient to deal with the illness or is it interfering with that patient's ability to seek appropriate care and preserve significant relationships? If denial is interfering with care, relationships or end-of-life planning, the clinician should address it with gentle but direct statements such as: \"I know that thinking about this now is painful, but I want to help you have as much control as possible over this important decision. If we only plan for your survival, we may lose that chance\" [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/69\">",
"     69",
"    </a>",
"    ]. If denial is constructive, enhancing the patient's life without adversely affecting relationships or care, it should not be confronted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Economic circumstances and disparities in medical care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Financial pressures can be an important factor in the ability of patients and their families to cope with terminal illness. To assess a patient's economic circumstances the clinician can ask a simple question: \"Is money a problem?\". (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/52/28490?source=see_link\">",
"     \"Overview of comprehensive patient assessment in palliative care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A disproportionate number of deaths from cancer occur among racial and ethnic minorities. Racial and ethnic minorities receive less definitive primary therapy, conservative as compared to radical therapy, and adjuvant therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/74\">",
"     74",
"    </a>",
"    ]. Minorities with cancer also undergo less cancer screening, receive poorer pain control, are diagnosed at a later stage, and seem to get less end of life care [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/75-79\">",
"     75-79",
"    </a>",
"    ]. These disparities have not been clearly accounted for by clinical differences.",
"   </p>",
"   <p>",
"    In cancer care, it appears that race, in synergy with lower socioeconomic status, limited access to healthcare, cultural beliefs, and low health literacy, perpetuates disparities in health care [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/74,79-81\">",
"     74,79-81",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The will to live may fluctuate at the very end of life as a result of grief, the physical toll taken by the illness,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spiritual, family, and personality issues. Depression, anxiety, or organic mental disorders may contribute to this instability [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/14,82\">",
"     14,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of epidemiologic studies, systematic reviews, and intervention trials found that approximately 50 percent of patients with advanced cancer met criteria for a psychiatric disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/83\">",
"     83",
"    </a>",
"    ]. The most common were adjustment disorders followed by major depression, anxiety disorders (generalized anxiety, panic disorder, and Posttraumatic stress disorder), and less severe depression [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/83-86\">",
"     83-86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patient with a history of psychiatric illness or trouble coping have an increased risk for renewed difficulties at the end of life [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/12,13,87\">",
"     12,13,87",
"    </a>",
"    ]. Considering psychiatric vulnerability is therefore an important part of the clinical assessment. We have found the following questions useful:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Have you ever had trouble with depression? Anxiety? Alcohol use? Drug use?",
"     </li>",
"     <li>",
"      Have there been times when you had trouble coping?",
"     </li>",
"     <li>",
"      Have you ever sought treatment for emotional difficulties?",
"     </li>",
"     <li>",
"      Was the treatment helpful?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;While distress and grief are normal responses to the losses encountered with life-threatening illness, unremitting low mood, guilt, hopelessness, and pervasive loss of interest in activities and relationships often indicate the presence of a depression.",
"   </p>",
"   <p>",
"    The reported prevalence of depression in cancer patients has varied widely, ranging from 3 to 38 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/88-90\">",
"     88-90",
"    </a>",
"    ]. This may be explained by the use of different criteria for the diagnosis of depression, as well as differences in cancer diagnosis and disease stage in the populations studied. The highest rates have been associated with cancers of the pancreas, oropharynx, and breast [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/91\">",
"     91",
"    </a>",
"    ]. Using strict DSM-IV criteria, major depression has been diagnosed in 7 percent and minor depression in 11 percent of patients with advanced cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/92\">",
"     92",
"    </a>",
"    ]; prevalence rates appear to increase as patients become sicker [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. A personal or family history of depression, untreated physical symptoms, substance abuse, and multiple losses place patients at high risk for depression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38858?source=see_link&amp;anchor=H5#H5\">",
"     \"Assessment and management of depression in palliative care\", section on 'Prevalence of depression in palliative care'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38858?source=see_link&amp;anchor=H15#H15\">",
"     \"Assessment and management of depression in palliative care\", section on 'Assessment and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Untreated depression is a major reason that patients seek to hasten death [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/95-100\">",
"     95-100",
"    </a>",
"    ]. Consistent with this, data suggest that depression is associated with an elevated risk of death in patients with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38858?source=see_link&amp;anchor=H3#H3\">",
"     \"Assessment and management of depression in palliative care\", section on 'Burden of depression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who suffer with depression at the end of life should be treated with psychosocial support and effective medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38858?source=see_link&amp;anchor=H20#H20\">",
"     \"Assessment and management of depression in palliative care\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Anxiety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anxiety is often seen as a natural consequence of confrontation with or awareness of mortality. Patients with high levels of anxiety experience intense distress and interference with their functioning. Lower levels of anxiety, on the other hand, may energize the patient and spur adaptation and coping.",
"   </p>",
"   <p>",
"    Anxiety near the end of life may also be the result of a preexisting anxiety disorder, substance abuse, delirium, side-effects of medications (akathisia), or under-treated symptoms (most commonly pain). Significant factors that may contribute to anxiety include concerns about future pain control and the course of the disease, the impact of the illness on family members, separation from loved ones, unfamiliar caretakers, loneliness and isolation. As with depression, a preexisting anxiety disorder increases the possibility that a patient nearing the end of life will also contend with anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/103\">",
"     103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31080?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnosis of psychiatric and psychologic disorders in patients with cancer\", section on 'Anxiety'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with advanced cancer who have an anxiety disorder may experience problems with the physician-patient relationship, with less trust in their physicians, less comfort in asking questions, and concerns that they will be offered futile therapies, and that symptoms will be adequately controlled [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a patient is very anxious and unable to say what exactly is causing the anxiety, it may be helpful to explore memories about others who have died as a way of identifying the cause. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27673?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of psychiatric and psychologic disorders in patients with cancer\", section on 'Anxiety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Personality disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a person is under stress, personality traits, including dysfunctional ones, tend to be amplified. While for most patients such intensification of behaviors does not interfere significantly with their medical care, other patients under stress may behave in demanding, seductive, manipulative, or aggressive ways. In contrast, people with personality disorders display chronic, dysfunctional patterns of behavior in interpersonal relationships and are unable to modulate feelings and behavior. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40824?source=see_link&amp;anchor=H5#H5\">",
"     \"Personality disorders\", section on 'Recognizing personality disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Narcissistic, borderline, and histrionic personality styles most commonly cause difficulty in medical settings. In the cancer population, 2 to 3 percent of individuals show histrionic and borderline styles while less than 1 percent exhibit a narcissistic style.",
"   </p>",
"   <p>",
"    Patients with borderline personality disorder have a provocative and turbulent style characterized by marked mood swings (even moment to moment), impulsivity, recurrent suicidal threats or attempts, and excessive anger. These individuals often oscillate between extremes of idealization and devaluation of important clinicians and provide different feelings and information to different providers (splitting). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10553?source=see_link\">",
"     \"Borderline personality disorder: Epidemiology, clinical features, diagnosis, and differential diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who exhibit a narcissistic interpersonal style are extremely vulnerable to humiliation and to social slights that other patients readily forgive. They present a seemingly tough, extremely independent and controlling outer shell that covers extreme vulnerability and desperate fears of dependency. Clinicians often find these patients demanding, exploitative, and entitled.",
"   </p>",
"   <p>",
"    A patient with a histrionic style may be overly dramatic, seductive, and flood clinicians with overwhelming displays of affect.",
"   </p>",
"   <p>",
"    In a review of psychiatric disorders in advanced cancer, Miovic states, \"Most patients with personality disorders show a mixture of these traits, and their behavior elicits difficult reactions in clinicians (such as feeling overwhelmed, inadequate, disengaged,",
"    <span class=\"nowrap\">",
"     parental/overprotective,",
"    </span>",
"    mistreated, sexually aroused,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    guilty)\" [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Substance abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substance abuse complicates medical care, and mimics",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    magnifies depression and anxiety. The prevalence of alcoholism ranged from 7 to 27 percent in studies in different palliative care settings [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Few data are available about the prevalence of other forms of substance abuse in end-of-life care. However one would expect rates of substance abuse among cancer patients to match those in the general population. A sampling of cancers for which substance abuse is a recognized contributing factor includes squamous cell cancers of the head and neck, pancreatic, hepatic, rectal, and lung cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Delirium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 40 and 85 percent of patients experience delirium in the last weeks of life [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. Delirium is often frightening to patients and distressing for families. It can interfere with the recognition and treatment of other symptoms such as pain. Delirium is frequently confused with depression, psychosis, or anxiety and should be considered as part of the differential diagnosis whenever changes in mood, behavior, or cognition are being evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31080?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis of psychiatric and psychologic disorders in patients with cancer\", section on 'Delirium and dementia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with other symptoms at the end of life, the patients' and families' goals for care should determine the extent of the diagnostic evaluation and the choice of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27673?source=see_link\">",
"     \"Management of psychiatric and psychologic disorders in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a serious or life-threatening illness are confronted by physical, psychological, social, and spiritual challenges to their sense of wholeness, which often increase as illness progresses. The ways in which people respond to these threats to personal integrity range from highly effective strategies for coping to dysfunctional reactions, often in the same person at different times. Patients undergo a period of adjustment in response to these challenges, during which they may deny, withdraw, or become sad and angry at care providers, family members, friends, themselves, or God.",
"   </p>",
"   <p>",
"    Caring for people with advanced illness begins by controlling pain and other physical suffering. Other tasks include assessing the resilience of the patient's relationship with the clinical team and loved ones, identifying the patient's strengths and vulnerabilities, exploring spiritual practices and beliefs, and inquiring about other areas of possible distress (eg, finances, family adjustment, self-esteem). The clinician can help the patient identify sources of meaning and purpose and support the expression of feelings, even difficult ones, including anguish about saying goodbye or worries about failing loved ones by feeling ready to die.",
"   </p>",
"   <p>",
"    The clinician does not need to do this alone, and may call upon chaplains, mental health providers, and palliative care colleagues as needed. By speaking with terminally ill patients about their sense of personal value, important relationships, feelings of hope, the meaning and purpose of their lives, and their goals for what time remains, clinicians can help their patients toward what Avery Weisman describes an appropriate death. \"[A] death one might choose, had one a choice. It means dying in the best possible way, not only retaining vestiges of what made life important and valuable, but surviving with personal significance and self-esteem, in effect an appropriate death is one we can 'live with'\" [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29769/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Approach death: Improving Care at the End of Life, Field MJ, Cassel CK (Eds), National Academy Press, Washington DC 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/2\">",
"      Lynn J. Measuring quality of care at the end of life: a statement of principles. J Am Geriatr Soc 1997; 45:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/3\">",
"      Stewart AL, Teno J, Patrick DL, Lynn J. The concept of quality of life of dying persons in the context of health care. J Pain Symptom Manage 1999; 17:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/4\">",
"      Curtis JR, Wenrich MD, Carline JD, et al. Understanding physicians' skills at providing end-of-life care perspectives of patients, families, and health care workers. J Gen Intern Med 2001; 16:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/5\">",
"      Cassel EJ. The nature of suffering and the goals of medicine. N Engl J Med 1982; 306:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/6\">",
"      Steinhauser KE, Christakis NA, Clipp EC, et al. Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA 2000; 284:2476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/7\">",
"      Hanson LC, Earp JA, Garrett J, et al. Community physicians who provide terminal care. Arch Intern Med 1999; 159:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/8\">",
"      Steinhauser KE, Clipp EC, McNeilly M, et al. In search of a good death: observations of patients, families, and providers. Ann Intern Med 2000; 132:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/9\">",
"      Gilligan T, Raffin TA. Whose death is it, anyway? Ann Intern Med 1996; 125:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/10\">",
"      Singer PA, Martin DK, Kelner M. Quality end-of-life care: patients' perspectives. JAMA 1999; 281:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/11\">",
"      Byock IR. The nature of suffering and the nature of opportunity at the end of life. Clin Geriatr Med 1996; 12:237.",
"     </a>",
"    </li>",
"    <li>",
"     Massie MJ. Depression. In: Handbook of Psychooncology: Psychological care of the Patient with Cancer, Holland JC, Rowland JH (Eds), Oxford University Press, New York 1989. p.283.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/13\">",
"      Breitbart W, Rosenfeld B, Pessin H, et al. Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA 2000; 284:2907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/14\">",
"      Block SD, Billings JA. Patient requests to hasten death. Evaluation and management in terminal care. Arch Intern Med 1994; 154:2039.",
"     </a>",
"    </li>",
"    <li>",
"     Faulkner A, Maguire P. Talking to cancer patients and their relatives, Oxford Medical Publications, Oxford 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/16\">",
"      Block SD. Assessing and managing depression in the terminally ill patient. ACP-ASIM End-of-Life Care Consensus Panel. American College of Physicians - American Society of Internal Medicine. Ann Intern Med 2000; 132:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/17\">",
"      Brightman, BK. Narcissistic issues in the training experience of the psychotherapist. Int J Psychoanal Psychother 1984-1985; 10:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/18\">",
"      Groves JE. Taking care of the hateful patient. N Engl J Med 1978; 298:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/19\">",
"      MAIN TF. The ailment. Br J Med Psychol 1957; 30:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/20\">",
"      Winnicott, DW. Hate in the countertransference. Int J Psychoanalysis 1949; 30:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/21\">",
"      Passik SD, Dugan W, McDonald MV, et al. Oncologists' recognition of depression in their patients with cancer. J Clin Oncol 1998; 16:1594.",
"     </a>",
"    </li>",
"    <li>",
"     Kleinman A. The Illness Narratives: Suffering, Healing &amp; the Human Condition, Basic Books, Inc, New York 1988.",
"    </li>",
"    <li>",
"     Good, MJDV. American Medicine: The Quest for Competence, University of California Press, Los Angeles 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/24\">",
"      Charon R. What narrative competence is for. Am J Bioeth 2001; 1:62.",
"     </a>",
"    </li>",
"    <li>",
"     Handbook of spirituality and world view in clinical practice, Josephson AJ, Peteet JR (Eds), American Psychiatric Publishing, Washington, DC 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/26\">",
"      Levin JS. Religion and health: is there an association, is it valid, and is it causal? Soc Sci Med 1994; 38:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/27\">",
"      Levin JS. How religion influences morbidity and health: reflections on natural history, salutogenesis and host resistance. Soc Sci Med 1996; 43:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/28\">",
"      Idler, E. Religious involvement and the health of the elderly: some hypotheses and an initial test. Soc Forces 1987; 6:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/29\">",
"      McIntosh, D, Spilka, B. Religion and physical health: the role of personal faith and control believers. Res Soc Sci Study Relig 1990; 2:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/30\">",
"      Koenig HG, Cohen HJ, Blazer DG, et al. Religious coping and cognitive symptoms of depression in elderly medical patients. Psychosomatics 1995; 36:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/31\">",
"      Idler, E, Kasl, SV. Religion, disability, depression, and the timing of death. Am J Sociol 1992; 97:1052.",
"     </a>",
"    </li>",
"    <li>",
"     Levin JS, Chatters LM. Research on religion and mental health: an overview of empirical findings and theoretical issues. In: Handbook of Religion and Mental Health, Doenig HG (Ed), Academic Press, San Diego 1998. p.34.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/33\">",
"      Krause N, Van Tran T. Stress and religious involvement among older blacks. J Gerontol 1989; 44:S4.",
"     </a>",
"    </li>",
"    <li>",
"     Koenig HG, McCullough ME, Larson DB. Koenig, HG, McCullough, ME, Larson, DB, Oxford University Press, New York 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/35\">",
"      Phelps AC, Maciejewski PK, Nilsson M, et al. Religious coping and use of intensive life-prolonging care near death in patients with advanced cancer. JAMA 2009; 301:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/36\">",
"      Balboni TA, Paulk ME, Balboni MJ, et al. Provision of spiritual care to patients with advanced cancer: associations with medical care and quality of life near death. J Clin Oncol 2010; 28:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/37\">",
"      Ehman JW, Ott BB, Short TH, et al. Do patients want physicians to inquire about their spiritual or religious beliefs if they become gravely ill? Arch Intern Med 1999; 159:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/38\">",
"      Daaleman TP, Nease DE Jr. Patient attitudes regarding physician inquiry into spiritual and religious issues. J Fam Pract 1994; 39:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/39\">",
"      Schreiber, K. Religion in the physician-patient relationship. JAMA 1991; 266:3062,.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/40\">",
"      Peteet, JR. Religious issues presented by cancer patients seen in psychiatric consultation. J Psychosoc Oncol 1985; 3:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/41\">",
"      Thompson GN, Chochinov HM, Wilson KG, et al. Prognostic acceptance and the well-being of patients receiving palliative care for cancer. J Clin Oncol 2009; 27:5757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/42\">",
"      Levine C, Zuckerman C. The trouble with families: toward an ethic of accommodation. Ann Intern Med 1999; 130:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/43\">",
"      Librach SL, Talbot Y. Understanding Dying Patients and Their Families: Using the family FIRO model. Can Fam Physician 1991; 37:404.",
"     </a>",
"    </li>",
"    <li>",
"     Kubler-Ross E. On Death and Dying, Touchstone Press, New York 1969.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/45\">",
"      Prigerson HG, Jacobs SC. Perspectives on care at the close of life. Caring for bereaved patients: \"all the doctors just suddenly go\". JAMA 2001; 286:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/46\">",
"      Casarett D, Kutner JS, Abrahm J, End-of-Life Care Consensus Panel. Life after death: a practical approach to grief and bereavement. Ann Intern Med 2001; 134:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/47\">",
"      Parkes CM. Bereavement in adult life. BMJ 1998; 316:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/48\">",
"      Maciejewski PK, Zhang B, Block SD, Prigerson HG. An empirical examination of the stage theory of grief. JAMA 2007; 297:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/49\">",
"      Chochinov HM, Kristjanson LJ, Hack TF, et al. Burden to others and the terminally ill. J Pain Symptom Manage 2007; 34:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/50\">",
"      McCorkle R, Ercolano E, Lazenby M, et al. Self-management: Enabling and empowering patients living with cancer as a chronic illness. CA Cancer J Clin 2011; 61:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/51\">",
"      Holland JC. Anxiety and cancer: the patient and the family. J Clin Psychiatry 1989; 50 Suppl:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/52\">",
"      Covinsky KE, Goldman L, Cook EF, et al. The impact of serious illness on patients' families. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. JAMA 1994; 272:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/53\">",
"      Rauch PK, Muriel AC, Cassem NH. Parents with cancer: who's looking after the children? J Clin Oncol 2002; 20:4399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/54\">",
"      Christ GH, Siegel K, Christ AE. Adolescent grief: \"It never really hit me...until it actually happened\". JAMA 2002; 288:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/55\">",
"      Black D. Coping with loss. Bereavement in childhood. BMJ 1998; 316:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/56\">",
"      Emanuel EJ, Fairclough DL, Slutsman J, Emanuel LL. Understanding economic and other burdens of terminal illness: the experience of patients and their caregivers. Ann Intern Med 2000; 132:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/57\">",
"      Higginson I, Wade A, McCarthy M. Palliative care: views of patients and their families. BMJ 1990; 301:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/58\">",
"      Borneman, T. Caring for Cancer Patients at Home: The Effect on Family Caregivers. Home Health Care Management &amp; Practice 1998; 10:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/59\">",
"      Bruhn JG. Therapeutic value of hope. South Med J 1984; 77:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/60\">",
"      Buehler JA. What contributes to hope in the cancer patient? Am J Nurs 1975; 75:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/61\">",
"      Sullivan AM, Lakoma MD, Matsuyama RK, et al. Diagnosing and discussing imminent death in the hospital: a secondary analysis of physician interviews. J Palliat Med 2007; 10:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/62\">",
"      Peppercorn JM, Smith TJ, Helft PR, et al. American society of clinical oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol 2011; 29:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/63\">",
"      Wright, AA, et al. Medical care and emotional distress associated with advanced cancer patients' end-of-life discussions with their physicians (abstract #6505). J Clin Oncol 2008; 26: 6505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/64\">",
"      Quill TE, Arnold RM, Platt F. \"I wish things were different\": expressing wishes in response to loss, futility, and unrealistic hopes. Ann Intern Med 2001; 135:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/65\">",
"      Quill TE. Perspectives on care at the close of life. Initiating end-of-life discussions with seriously ill patients: addressing the \"elephant in the room\". JAMA 2000; 284:2502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/66\">",
"      Chochinov HM, Hack T, Hassard T, et al. Dignity therapy: a novel psychotherapeutic intervention for patients near the end of life. J Clin Oncol 2005; 23:5520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/67\">",
"      Chochinov HM, Kristjanson LJ, Breitbart W, et al. Effect of dignity therapy on distress and end-of-life experience in terminally ill patients: a randomised controlled trial. Lancet Oncol 2011; 12:753.",
"     </a>",
"    </li>",
"    <li>",
"     Weisman AD. On dying and denying: a psychiatric study of terminality, Behavioral Publ Inc, New York 1972.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/69\">",
"      Block SD. Perspectives on care at the close of life. Psychological considerations, growth, and transcendence at the end of life: the art of the possible. JAMA 2001; 285:2898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/70\">",
"      Wendler D, Rid A. Systematic review: the effect on surrogates of making treatment decisions for others. Ann Intern Med 2011; 154:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/71\">",
"      King DA, Quill T. Working with families in palliative care: one size does not fit all. J Palliat Med 2006; 9:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/72\">",
"      Rousseau P. Death denial. J Clin Oncol 2000; 18:3998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/73\">",
"      Ness DE, Ende J. Denial in the medical interview. Recognition and management. JAMA 1994; 272:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/74\">",
"      Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst 2002; 94:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/75\">",
"      McNeill JA, Reynolds J, Ney ML. Unequal quality of cancer pain management: disparity in perceived control and proposed solutions. Oncol Nurs Forum 2007; 34:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/76\">",
"      Mandelblatt JS, Yabroff KR, Kerner JF. Equitable access to cancer services: A review of barriers to quality care. Cancer 1999; 86:2378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/77\">",
"      Cohen LL. Racial/ethnic disparities in hospice care: a systematic review. J Palliat Med 2008; 11:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/78\">",
"      O'Mahony S, McHenry J, Snow D, et al. A review of barriers to utilization of the medicare hospice benefits in urban populations and strategies for enhanced access. J Urban Health 2008; 85:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/79\">",
"      Smith AK, McCarthy EP, Paulk E, et al. Racial and ethnic differences in advance care planning among patients with cancer: impact of terminal illness acknowledgment, religiousness, and treatment preferences. J Clin Oncol 2008; 26:4131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/80\">",
"      Shavers VL, Shavers BS. Racism and health inequity among Americans. J Natl Med Assoc 2006; 98:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/81\">",
"      Kolb B, Wallace AM, Hill D, Royce M. Disparities in cancer care among racial and ethnic minorities. Oncology (Williston Park) 2006; 20:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/82\">",
"      Chochinov HM, Tataryn D, Clinch JJ, Dudgeon D. Will to live in the terminally ill. Lancet 1999; 354:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/83\">",
"      Miovic M, Block S. Psychiatric disorders in advanced cancer. Cancer 2007; 110:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/84\">",
"      Kadan-Lottick NS, Vanderwerker LC, Block SD, et al. Psychiatric disorders and mental health service use in patients with advanced cancer: a report from the coping with cancer study. Cancer 2005; 104:2872.",
"     </a>",
"    </li>",
"    <li>",
"     First M, Spitzer R, Gibbon M, Wiliams J. Structured clinical interview for DSM-IV Axis I disorders-Patient Edition. In: Biomedtrics Research Department, SCID-I/P, Version 2.0, New York State Psychiatric Institute, 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/86\">",
"      Williams JB, Gibbon M, First MB, et al. The Structured Clinical Interview for DSM-III-R (SCID). II. Multisite test-retest reliability. Arch Gen Psychiatry 1992; 49:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/87\">",
"      Muskin PR. The request to die: role for a psychodynamic perspective on physician-assisted suicide. JAMA 1998; 279:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/88\">",
"      Massie MJ. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 2004; :57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/89\">",
"      Akechi T, Okuyama T, Sugawara Y, et al. Major depression, adjustment disorders, and post-traumatic stress disorder in terminally ill cancer patients: associated and predictive factors. J Clin Oncol 2004; 22:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/90\">",
"      Hotopf M, Chidgey J, Addington-Hall J, Ly KL. Depression in advanced disease: a systematic review Part 1. Prevalence and case finding. Palliat Med 2002; 16:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/91\">",
"      McDaniel JS, Musselman DL, Porter MR, et al. Depression in patients with cancer. Diagnosis, biology, and treatment. Arch Gen Psychiatry 1995; 52:89.",
"     </a>",
"    </li>",
"    <li>",
"     Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association, Washington DC 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/93\">",
"      Evans DL, Staab JP, Petitto JM, et al. Depression in the medical setting: biopsychological interactions and treatment considerations. J Clin Psychiatry 1999; 60 Suppl 4:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/94\">",
"      Ciaramella A, Poli P. Assessment of depression among cancer patients: the role of pain, cancer type and treatment. Psychooncology 2001; 10:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/95\">",
"      Chochinov HM, Wilson KG, Enns M, Lander S. Prevalence of depression in the terminally ill: effects of diagnostic criteria and symptom threshold judgments. Am J Psychiatry 1994; 151:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/96\">",
"      Lynch ME. The assessment and prevalence of affective disorders in advanced cancer. J Palliat Care 1995; 11:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/97\">",
"      DeFlorio, M, Massie, MJ. Review of depression in cancer: gender differences. Depression 1995; 3:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/98\">",
"      Kathol RG, Mutgi A, Williams J, et al. Diagnosis of major depression in cancer patients according to four sets of criteria. Am J Psychiatry 1990; 147:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/99\">",
"      Kugaya A, Akechi T, Okamura H, et al. Correlates of depressed mood in ambulatory head and neck cancer patients. Psychooncology 1999; 8:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/100\">",
"      Katon W, Sullivan MD. Depression and chronic medical illness. J Clin Psychiatry 1990; 51 Suppl:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/101\">",
"      Stommel M, Given BA, Given CW. Depression and functional status as predictors of death among cancer patients. Cancer 2002; 94:2719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/102\">",
"      Faller H, B&uuml;lzebruck H, Drings P, Lang H. Coping, distress, and survival among patients with lung cancer. Arch Gen Psychiatry 1999; 56:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/103\">",
"      Stark D, Kiely M, Smith A, et al. Anxiety disorders in cancer patients: their nature, associations, and relation to quality of life. J Clin Oncol 2002; 20:3137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/104\">",
"      Spencer R, Nilsson M, Wright A, et al. Anxiety disorders in advanced cancer patients: correlates and predictors of end-of-life outcomes. Cancer 2010; 116:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/105\">",
"      Chow E, Connolly R, Wong R, et al. Use of the CAGE questionnaire for screening problem drinking in an out-patient palliative radiotherapy clinic. J Pain Symptom Manage 2001; 21:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/106\">",
"      Bruera E, Neumann C, Brenneis C, Quan H. Frequency of symptom distress and poor prognostic indicators in palliative cancer patients admitted to a tertiary palliative care unit, hospices, and acute care hospitals. J Palliat Care 2000; 16:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/107\">",
"      Passik SD, Portenoy RK, Ricketts PL. Substance abuse issues in cancer patients. Part 1: Prevalence and diagnosis. Oncology (Williston Park) 1998; 12:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/108\">",
"      Massie MJ, Holland J, Glass E. Delirium in terminally ill cancer patients. Am J Psychiatry 1983; 140:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/109\">",
"      Minagawa H, Uchitomi Y, Yamawaki S, Ishitani K. Psychiatric morbidity in terminally ill cancer patients. A prospective study. Cancer 1996; 78:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/110\">",
"      Breitbart W, Bruera E, Chochinov H, Lynch M. Neuropsychiatric syndromes and psychological symptoms in patients with advanced cancer. J Pain Symptom Manage 1995; 10:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/111\">",
"      Nicholas LM, Lindsey BA. Delirium presenting with symptoms of depression. Psychosomatics 1995; 36:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29769/abstract/112\">",
"      Weisman AD. Appropriate death and the hospice program. Hosp J 1988; 4:65.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2195 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7CC26F0507-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_4_29769=[""].join("\n");
var outline_f29_4_29769=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREREQUISITES FOR ADDRESSING PSYCHOSOCIAL AND SPIRITUAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Control of symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      A secure and supportive patient-clinician relationship",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      COMMON ISSUES AT THE END OF LIFE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      The meaning of the illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H98972178\">",
"      Spiritual beliefs and religious community",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Loss and grief",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dependency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Uncertainty and fears about the future",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Concerns about loved ones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MEDIATORS OF COPING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Maintaining hope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Coping style",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Family and social support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Denial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Economic circumstances and disparities in medical care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Anxiety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Personality disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Substance abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Delirium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38858?source=related_link\">",
"      Assessment and management of depression in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10553?source=related_link\">",
"      Borderline personality disorder: Epidemiology, clinical features, diagnosis, and differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31080?source=related_link\">",
"      Diagnosis of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31190?source=related_link\">",
"      Grief and bereavement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27673?source=related_link\">",
"      Management of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/52/28490?source=related_link\">",
"      Overview of comprehensive patient assessment in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40824?source=related_link\">",
"      Personality disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41208?source=related_link\">",
"      Religion, spirituality, and end of life care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_4_29770="The role of parenteral and enteral/oral nutritional support in patients with cancer";
var content_f29_4_29770=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The role of parenteral and enteral/oral nutritional support in patients with cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/4/29770/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/4/29770/contributors\">",
"     Aminah Jatoi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/4/29770/contributors\">",
"     Charles L Loprinzi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/4/29770/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/4/29770/contributors\">",
"     Paul J Hesketh, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/4/29770/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/4/29770/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/4/29770/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/4/29770/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight loss is common among cancer patients, and can be attributed to many causes, including mucositis, inability to ingest or absorb adequate calories because of a problem with the alimentary tract, loss of appetite, and metabolic aberrations. Unintentional weight loss is associated with decreased quality of life (QOL) and a poorer prognosis. Furthermore, for patients who are already in a catabolic state, the increased metabolic demands associated with anticancer treatment (particularly surgery) further worsen the problem. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17960?source=see_link\">",
"     \"Clinical features and pathogenesis of cancer cachexia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intuitively, it would seem that caloric repletion, by either the enteral or parenteral route, would be the optimal approach to the treatment of cancer-associated weight loss. However, the routine use of nutritional support in patients with cancer is controversial. Not all patients with malignancy or cancer treatment-associated weight loss benefit from nutritional support. Furthermore, the routine use of nutritional support in patients with advanced incurable cancer is associated with a higher risk of treatment-related complications [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Nevertheless, nutritional support is frequently prescribed for patients with cancer. In fact, malignant disease is the most frequent indication for home",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (TPN), accounting for approximately one-half of all cases in one large series [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of the general use of both parenteral and",
"    <span class=\"nowrap\">",
"     enteral/oral",
"    </span>",
"    nutritional supplementation in cancer patients and detailed discussions of nutritional support related to the perioperative setting, hematopoietic cell transplantation, head and neck cancer, esophageal cancer, and in patients with advanced incurable cancers are discussed here. The use of nutritional support in surgical patients and the intensive care unit setting, and the basic principles of enteral and parenteral nutrition are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6664?source=see_link\">",
"     \"Perioperative nutritional support\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=see_link\">",
"     \"Nutrition support in critically ill patients: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21016143\">",
"    <span class=\"h1\">",
"     NUTRITIONAL STATUS AND CANCER OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the",
"    <a class=\"external\" href=\"file://openlibrary.org/books/OL15581615M/Guidelines_for_detection_and_management_of_malnutrition\">",
"     Malnutrition Advisory Group of the British Association for Parenteral and Enteral Nutrition",
"    </a>",
"    , malnutrition is defined as a nutritional status in which a deficiency in energy, protein, or other nutrients causes measurable adverse effects on tissues or body form, function, or clinical outcomes. Malnutrition occurs in 40 to 80 percent of cancer patients and is a major cause of morbidity and mortality in patients with advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. It is particularly frequent in patients with digestive and upper aerodigestive tract tumors. Malnutrition may be related to an inability to ingest or absorb nutrients because of a problem with the alimentary tract related to the primary disease process (ie, obstructing esophageal tumor) or cancer treatment (ie, combined modality therapy for head and neck cancer, which may cause severe oral mucositis), or the cancer-associated",
"    <span class=\"nowrap\">",
"     anorexia/cachexia",
"    </span>",
"    syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17960?source=see_link\">",
"     \"Clinical features and pathogenesis of cancer cachexia\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Whatever the cause, malnutrition in cancer patients is associated with poorer overall survival in various malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/6-8\">",
"     6-8",
"    </a>",
"    ], as well as reduced benefit from surgical [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/9,10\">",
"     9,10",
"    </a>",
"    ] and medical therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], a poorer tumor response to chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/6,7,12\">",
"     6,7,12",
"    </a>",
"    ], increased chemotherapy-related toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/11,13,14\">",
"     11,13,14",
"    </a>",
"    ], and poorer quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/7,15-17\">",
"     7,15-17",
"    </a>",
"    ]. It is important to point out that although several investigators refer to &ldquo;malnutrition&rdquo; in cancer patients, the provision of calories is often not the most appropriate response to this situation, as caloric supplementation can lead to complications and no reversal of the clinical picture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H590424\">",
"    <span class=\"h2\">",
"     Screening for nutritional status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous scores are available for nutritional status evaluation of cancer patients. One simple to use and objective tool is the Nutritional Risk Index (NRI), which has been validated in various clinical settings, including gastrointestinal cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. The NRI can be calculated as (=1.519 x serum albumin level",
"    <span class=\"nowrap\">",
"     [g/L]",
"    </span>",
"    + 0.417 X current",
"    <span class=\"nowrap\">",
"     weight/usual",
"    </span>",
"    weight X 100) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/18\">",
"     18",
"    </a>",
"    ]. Based on the NRI, patients can be classified as having no malnutrition (NRI &gt;97.5), moderate malnutrition (97.5 &ge; NRI &ge; 83.5), or severe malnutrition (NRI &lt;83.5).",
"   </p>",
"   <p>",
"    Additional issues related to screening for nutritional status are addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/12/31946?source=see_link&amp;anchor=H2#H2\">",
"     \"Geriatric nutrition: Nutritional issues in older adults\", section on 'Screening for nutritional status'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS AND BENEFITS OF NUTRITIONAL SUPPORT IN CANCER PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no widely accepted guidelines for when to initiate nutritional support in cancer patients. While decisions about nutrition support are relatively easy for malnourished patients who have a potentially curable cancer but are unable to meet their nutrient needs for prolonged periods (eg, because of complete dysphagia or intestinal failure), they are more difficult when nutritional intake is closer to meeting needs, when the likely period of inadequate intake is uncertain, or in situations where the malignancy is treatable but incurable and the patient is unable to take in sufficient nutrients. In these settings, decision-making is more complex, especially given that providing nutrition support is not without risk.",
"   </p>",
"   <p>",
"    This lack of consensus as to specific indications for nutritional support in patients with cancer is reflected in the vagueness of available guidelines from expert groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      International guidelines on the nutritional management of patients with cancer from the European Society for Clinical Nutrition and Metabolism (ESPEN), the American Dietetic Association, the American Society for Parenteral and Enteral Nutrition, and the Dietitians Association of Australia recommend that nutritional intervention be started in malnourished patients or those in whom difficulties with eating are anticipated [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/21-24\">",
"       21-24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the United Kingdom (UK), the National Institute for Health and Clinical Excellence (NICE) recommends that health care professionals consider oral nutritional support to improve nutritional intake for people who can swallow safely and who are malnourished or at risk of malnutrition (",
"      <a class=\"external\" href=\"file://www.nice.org.uk/nicemedia/live/10978/29981/29981.pdf\">",
"       NICE guidelines for nutritional support for adults",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Guidelines from the",
"      <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"       National Comprehensive Cancer Network (NCCN)",
"      </a>",
"      suggest consideration of nutritional support, as appropriate, in patients who have an estimated life expectancy of months to years, but not those with a life expectancy measured in weeks to months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evidence to support benefit from either parenteral or",
"    <span class=\"nowrap\">",
"     enteral/oral",
"    </span>",
"    nutritional intervention in patients with cancer is limited:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review of the literature by the American Gastroenterological Association (AGA) identified 26 randomized trials of parenteral nutritional support in cancer patients, including 19 in those receiving chemotherapy, three in patients being treated with radiation therapy (RT), and four in those undergoing stem cell transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/2\">",
"       2",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Key observations included the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In 19 trials with 1050 patients, the use of parenteral nutrition did not significantly improve mortality.",
"     </li>",
"     <li>",
"      In eight trials that included 333 patients where information was available regarding overall complications, there was a statistically significant 40 percent increase in the total complication rate in the treated group. The incidence of infectious complications was significantly increased by 16 percent.",
"     </li>",
"     <li>",
"      In 15 assessable trials that included 910 patients where tumor response data were provided, the tumor response rate was significantly lower (by an absolute value of 7 percent) in patients receiving parenteral nutrition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subsequent to this analysis, two randomized trials evaluating early institution of parenteral nutritional support in malnourished patients receiving palliative anticancer treatment with chemotherapy or RT concluded that body weight was maintained, and quality and life and survival were significantly improved by the addition of parenteral nutrition to oral enteral nutritional supplementation [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. However, both trials were small (82 and 152 patients, respectively), limited by heterogeneous study populations and different anticancer treatments, and likely subject to publication bias (ie, publication of only &ldquo;positive&rdquo; studies).",
"     </li>",
"     <li>",
"      At least four systematic reviews have addressed the role of",
"      <span class=\"nowrap\">",
"       enteral/oral",
"      </span>",
"      nutritional support in cancer patients, none of which demonstrate a survival benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/1,27-29\">",
"       1,27-29",
"      </a>",
"      ]. The most recent and largest of these included 13 randomized trials of oral nutritional intervention (dietary advice, oral nutritional supplements, or both) totaling 1414 participants with a variety of cancer types [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/27\">",
"       27",
"      </a>",
"      ]. Trials were included if they were undertaken in adults who were clearly malnourished (although the definitions of malnourished differed according to trial), or judged to be at risk for malnutrition on the basis of their clinical condition, receiving active anticancer treatment or palliative care, and were comparing oral nutritional intervention versus usual care.",
"      <br/>",
"      <br/>",
"      Key observations included the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      All trials were judged to be of low to moderate quality and at risk for bias.",
"     </li>",
"     <li>",
"      There was considerable clinical (cancer site and stage, length and type of dietetic intervention, baseline nutritional status) and statistical heterogeneity among the trials. Only four defined baseline nutritional status as an inclusion criterion; six included both well-nourished and malnourished patients.",
"     </li>",
"     <li>",
"      Nutritional intervention was associated with statistically significant improvements in weight (mean difference 1.8 kg) and energy intake (mean difference 432 kcal) compared with routine care; however, these differences were no longer apparent when the data from trials that contributed the most to statistical heterogeneity were removed from the analysis.",
"     </li>",
"     <li>",
"      Nutritional intervention provided significant benefit for some aspects of quality of life (emotional functioning, dyspnea, loss of appetite, global quality of life) but had no impact on mortality (relative risk for death in the intervention group 1.06, 95% CI 0.92-1.22).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that oral nutritional interventions might improve some aspects of quality of life in patients with cancer who are malnourished or at risk for malnutrition, but they do not appear to improve cancer outcomes.",
"   </p>",
"   <p>",
"    In summary, benefit from nutritional support in patients with cancer, particularly parenteral nutritional support, can be expected in those patients who are likely to die sooner from starvation than from cancer, with the underlying malignancy being the prime factor in determining outcomes. The best patients for consideration of nutritional intervention have a potentially curable disease or look forward to the promise of a long disease-free period after cancer treatment. The following sections will describe the use of and evidence for the benefit of nutritional support in specific clinical scenarios.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     THE PERIOPERATIVE SETTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative malnutrition is associated with poor postoperative outcomes in patients undergoing surgery for cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. Although multiple studies have failed to demonstrate a survival benefit from perioperative nutrition support in patients undergoing major cancer surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/34-37\">",
"     34-37",
"    </a>",
"    ], others have documented fewer operative complications, and a shorter length of hospital stay in malnourished patients who receive nutritional support [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/18,38-40\">",
"     18,38-40",
"    </a>",
"    ]. Studies have evaluated both parenteral and enteral nutrition. The following represents the range of findings:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Parenteral nutrition",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Veterans Affairs (VA) Cooperative Study, 395 malnourished patients who required laparotomy or noncardiac thoracotomy (65 percent of whom had cancer) were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"      (TPN) for seven days preoperatively and three days postoperatively or no TPN [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/18\">",
"       18",
"      </a>",
"      ]. Overall, patients receiving TPN had a higher rate of infectious complications (14 versus 6 percent) and a nonsignificant reduction in 30 day mortality (7.3 versus 4.9 percent). However, in the severely malnourished subgroup (n = 24), those treated with TPN had significantly fewer noninfectious complications than controls (43 versus 5 percent).",
"     </li>",
"     <li>",
"      In a second trial, 124 patients with hepatocellular carcinoma undergoing partial hepatectomy were randomly assigned to 14 days of preoperative cyclical TPN or a control group not receiving IV artificial feeding [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/39\">",
"       39",
"      </a>",
"      ]. Both groups included patients with only mild malnutrition, as indicated by the fact that fewer than 20 percent of patients in either group had sustained a &gt;10 percent weight loss, and the median serum albumin was greater than 40",
"      <span class=\"nowrap\">",
"       g/L",
"      </span>",
"      in both groups. There was no difference in mortality when compared to controls, but supplemental TPN was associated with less postoperative morbidity (34 versus 54 percent), better liver function, less ascites, and a reduction in the need for diuretics.",
"     </li>",
"     <li>",
"      Data from studies of postoperative TPN alone are less favorable. One study of patients undergoing pancreatic resection for malignancy found that those who received postoperative TPN had higher rates of major complications including fistulae, abscesses, peritonitis, and anastomotic breakdown (45 versus 23 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/34\">",
"       34",
"      </a>",
"      ]. The rate of infectious complication was also higher in the TPN group, predominantly due to intraabdominal abscesses that were thought to be secondary to increased bacterial translocation from lack of enteral feeding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6664?source=see_link\">",
"       \"Perioperative nutritional support\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      On the other hand, a meta-analysis that included 2211 critically ill or surgical patients (only some of whom had cancer) enrolled in 26 randomized trials failed to document a significant impact of TPN on either mortality or complication rates [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these data suggest that parenteral nutrition decreases postoperative complications when administered to patients undergoing surgery for cancer, but does not appear to provide a survival benefit with the possible exception of those who have intestinal failure (short bowel syndrome, severe intestinal dysmotility, selected patients with inoperable bowel obstruction) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/42\">",
"     42",
"    </a>",
"    ]. Furthermore, there are risks (eg, bloodstream infections) associated with its use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/58/8102?source=see_link&amp;anchor=H12#H12\">",
"     \"Nutrition support in critically ill patients: Parenteral nutrition\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the decision is made to utilize TPN in a patient who has been malnourished for days to weeks, the patient should be watched carefully for refeeding syndrome, which is characterized by potentially life-threatening metabolic derangements [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/43\">",
"     43",
"    </a>",
"    ]. Prevention and treatment of refeeding syndrome involves the use of thiamine, phosphate salts, and management of fluid status, and glucose as well as electrolyte levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=see_link&amp;anchor=H252082#H252082\">",
"     \"Eating disorders: Treatment\", section on 'Refeeding syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Enteral nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malnourished patients undergoing major surgery for GI malignancies may have fewer complications when postoperative feeding is accomplished by the enteral, rather than parenteral, route, although the data are conflicting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial randomly assigned 317 malnourished patients to either postoperative enteral or parenteral nutritional support, both starting the morning after surgery, and continuing until oral intake was adequate [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/44\">",
"       44",
"      </a>",
"      ]. Although the incidence of adverse effects related to feeding (eg, abdominal distention or cramping) was greater in the enteral group (35 versus 14 percent), the incidence of postoperative complications was significantly less in this group (34 versus 49 percent), as was the length of hospital stay (15 versus 13.4 days).",
"     </li>",
"     <li>",
"      However, conflicting data have been reported by others. In one report, 30 patients undergoing a Whipple procedure for pancreatic cancer who received postoperative enteral nutritional support were compared with 32 who did not [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/45\">",
"       45",
"      </a>",
"      ]. Enteral nutrition was associated with a significantly higher frequency of delayed gastric emptying (57 versus 16 percent), a longer duration of nasogastric tube decompression and hospital stay, but no improvement in postoperative complications.",
"      <br/>",
"      <br/>",
"      Although this trial was much smaller than the study discussed above, its conclusions raise questions as to how much benefit is really conferred with the use of postoperative feeding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6664?source=see_link\">",
"       \"Perioperative nutritional support\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Immunonutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the complex interactions between nutrition, mucosal barrier function, immunoregulation, and severe illness become clearer, there is hope that unique forms of nutritional support might provide benefit for specific disease states. Many new formulas contain nutrients previously considered to be nonessential but which, under conditions of critical illness, become \"conditionally essential\". Examples of these nutrient substrates include arginine, RNA nucleotides, and omega-3 fatty acids.",
"   </p>",
"   <p>",
"    Enteral formulas that are supplemented with L-arginine, RNA nucleotides, and omega-3 fatty acids are often referred to as immunonutrition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=see_link&amp;anchor=H935222#H935222\">",
"     \"Nutrition support in critically ill patients: An overview\", section on 'Enteral nutrition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefits of immunonutrition have been addressed in multiple meta-analyses, all of which have concluded that enteral immunonutrition reduces perioperative complications and shortens hospital stay compared to standard enteral nutrition but does not impact mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, one meta-analysis of 21 randomized controlled trials addressing the impact of immunonutrition published between 1985 and 2009 involved 2730 patients undergoing upper or lower gastrointestinal surgery, predominantly for cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/46\">",
"     46",
"    </a>",
"    ]. Although there were varying control groups, the use of immunonutrition significantly reduced overall complications when used before surgery (odds ratio [OR] 0.48, 95% CI 0.34 to 0.69), both before and after operation (HR 0.39, 0.28 to 0.54) or after surgery (OR 0.46, 0.25 to 0.84). Immunonutrition also was associated with significantly shorter hospital stay (mean difference about two days) but there was no influence on mortality (OR for death 0.90, 0.46 to 1.76).",
"   </p>",
"   <p>",
"    Although these data would seem compelling, several of the studies included in these analyses represented multiple papers from just four authors, and it is unclear whether the subjects that were reported were all unique individuals.&nbsp;Furthermore, the heterogeneity of individual studies, cost issues, and lack of strong data to indicate an improvement in mortality must be considered in decision-making. Finally, the lack of comparison to unfed controls means that one cannot determine whether immunonutrition is beneficial or standard enteral nutrition is harmful. Thus, the quality of the evidence to support these conclusions is low.",
"   </p>",
"   <p>",
"    In contrast to these data in critically ill and surgical patients, with only few exceptions, multiple randomized trials in patients with advanced metastatic cancer and cancer-associated",
"    <span class=\"nowrap\">",
"     anorexia/cachexia",
"    </span>",
"    have not provided evidence that supplementation with eicosapentaenoic acid improves clinical outcomes. This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5113?source=see_link&amp;anchor=H14#H14\">",
"     \"Pharmacologic management of cancer anorexia/cachexia\", section on 'Eicosapentaenoic acid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar large scale studies with L-arginine and RNA nucleotides have not been published in patients with advanced cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HEMATOPOIETIC CELL TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients who undergo allogeneic hematopoietic cell transplantation (HCT) develop significant mucositis and have difficulty maintaining adequate caloric intake. The degree of mucositis is related to the particular cytotoxic regimen. Oral intake may be further compromised by the development of acute graft versus host disease (GVHD) affecting the alimentary tract. Parenteral nutritional support is commonly administered prophylactically to such patients until they are able to maintain adequate oral nutritional intake, which usually does not occur until the bone marrow recovers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38250?source=see_link\">",
"     \"Oral toxicity associated with chemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29306?source=see_link&amp;anchor=H598154#H598154\">",
"     \"Supportive care after hematopoietic cell transplantation\", section on 'Mucositis and nutritional support'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Total parenteral nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial support for the routine use of TPN during HCT was provided by an older study that randomly assigned 137 previously well-nourished patients undergoing HCT for a variety of different malignancies (predominantly acute leukemia) to either prophylactic TPN or intravenous maintenance fluids (5 percent dextrose, electrolytes, minerals, trace elements, and vitamins) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/49\">",
"     49",
"    </a>",
"    ]. Treatment was initiated during cytoreductive chemotherapy, and continued for four weeks following transplantation. Compared to controls, patients receiving TPN had significantly better overall and disease-free survival, and a longer time to relapse. This difference was despite 61 percent of control patients eventually starting TPN because of a decline in nutritional status.",
"   </p>",
"   <p>",
"    In part because this study was performed a number of years ago, many questions regarding nutritional support in the setting of HCT remain unanswered. The care of patients undergoing HCT has undergone marked change over the last 20 years. Hospital stays are shorter, and with other improvements in supportive care (eg, better antiemetics, use of recombinant hematopoietic growth factors, better prophylaxis against GVHD), and the increasing use of autologous transplantation, the appropriate use of TPN in transplant patients is deserving of future trials.",
"   </p>",
"   <p>",
"    Other studies have not provided firm support for the routine use of TPN in patients undergoing HCT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 57 patients undergoing HCT were randomly assigned to prophylactic TPN or to an enteral feeding program [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/50\">",
"       50",
"      </a>",
"      ]. TPN was associated with significantly more days of diuretic use, more frequent hyperglycemic episodes, and more catheter-related complications. This study was smaller than the trial referenced above, but nonetheless suggests that the role of TPN in patients undergoing HCT deserves further investigation.",
"     </li>",
"     <li>",
"      In a second trial, 258 patients who were discharged following marrow infusion were randomly assigned to either TPN or intravenous hydration [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/51\">",
"       51",
"      </a>",
"      ]. TPN did not influence the rate of hospital readmission, relapse rate or overall survival [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/51\">",
"       51",
"      </a>",
"      ]. In fact, patients undergoing TPN had a longer median time to resume &gt;85 percent of their caloric requirement (16 versus 10 days), suggesting that the administration of TPN suppressed the return of normal appetite. Furthermore, nutrition-related costs were 2.3-fold greater in the TPN group. Although this study did not examine the issue of whether prophylactic TPN is indicated in patients who receive HCT, it does suggest that after hospital discharge, TPN may not be viewed as necessary in all patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One study attempted to define specific subgroups of patients with hematologic malignancies undergoing intensive cytotoxic chemotherapy with or without HCT who were likely to require TPN [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/52\">",
"     52",
"    </a>",
"    ]. The following criteria were used to define the need for TPN:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe malnutrition at admission",
"     </li>",
"     <li>",
"      A prolonged period (7 to 10 days) of minimal oral intake",
"     </li>",
"     <li>",
"      Clinical weight loss during treatment exceeding 10 percent of body weight",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using these definitions, TPN was judged to be necessary in only 55 percent of patients undergoing HCT, ranging from 37 percent of autologous recipients, to 92 percent of those receiving an HLA mismatched allograft (the latter being associated with a higher rate of GVHD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further studies will be required to determine whether TPN should be used based upon need, or prophylactically in all patients regardless of nutritional status. Until then, it seems prudent to administer TPN to patients undergoing HCT who have severe mucositis or gastrointestinal manifestations of graft versus host disease, when a long period of insufficient oral intake is anticipated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Glutamine supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glutamine is an important precursor for nucleotide synthesis, and an important fuel source for rapidly dividing cells, such as the lining epithelia of the GI tract. Furthermore, glutamine is postulated to facilitate healing of the GI mucosa following damage by either RT or chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/53\">",
"     53",
"    </a>",
"    ]. Although considered a nonessential amino acid, glutamine is a conditionally essential amino acid during periods of stress [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/54\">",
"     54",
"    </a>",
"    ]. It is not usually included in TPN formulations due to stability issues.",
"   </p>",
"   <p>",
"    Animals sustained on TPN develop atrophy of the gut, an effect that may be ameliorated by glutamine supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. These data have led to the study of glutamine supplementation, both parenterally and enterally, in patients undergoing hematopoietic cell transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Parenteral supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least two trials suggest potential benefit from parenteral glutamine supplementation in patients undergoing hematopoietic cell transplantation (HCT) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 45 patients undergoing allogeneic HCT for hematologic malignancies were randomly assigned to parenteral TPN with glutamine supplementation (0.57",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day) or an isocaloric, isonitrogenous glutamine-free TPN formula [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/57\">",
"       57",
"      </a>",
"      ]. The glutamine-supplemented group had significantly lower infection (13 versus 43 percent) and colonization rates, better nitrogen balance, a decreased incidence of infection, and a shorter length of stay (29 versus 36 days).",
"     </li>",
"     <li>",
"      In a second report, 29 patients with both hematologic and solid malignancies undergoing either allogeneic or autologous HCT were randomly assigned to supplemental parenteral glutamine or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/58\">",
"       58",
"      </a>",
"      ]. Despite finding a similar six day shorter length of hospital stay in the glutamine group, there were no significant differences in the incidence of positive bacterial cultures, clinical infections, or mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It cannot be concluded, based upon these limited data, that there is benefit for parenteral glutamine supplementation in patients undergoing HCT. However, glutamine probably deserves further study in this setting. Of note, parenteral glutamine supplementation may also have a role in the preservation of hepatic function in patients undergoing HCT, but this also requires further study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7081?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment and prevention of hepatic sinusoidal obstruction syndrome following hematopoietic cell transplantation\", section on 'Parenteral glutamine supplementation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Enteral supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the above, at least two trials of oral glutamine supplementation have failed to confirm any benefit in patients undergoing hematopoietic cell transplantation (HCT):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first, 193 patients undergoing autologous or allogeneic HCT were randomly assigned to oral glutamine (1",
"      <span class=\"nowrap\">",
"       gm/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      four times daily) or supplemental glycine (placebo) from days 1 through 28 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/59\">",
"       59",
"      </a>",
"      ]. The glutamine-supplemented group undergoing autologous HCT had significantly less mouth pain and opiate use than controls, but no difference was seen in the allogeneic patients. The authors postulated an interaction with the individual chemotherapy regimens to explain this difference.",
"     </li>",
"     <li>",
"      In a similarly designed second study, 66 patients with either hematologic or solid tumors undergoing allogeneic or autologous HCT were randomly assigned to oral glutamine (30 gm per day) or a glycine placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/60\">",
"       60",
"      </a>",
"      ]. There were no significant differences between the groups in length of hospital stay, number of TPN days, neutrophil recovery time, incidence of positive blood cultures, sepsis, mucositis, or diarrhea. There was only a suggestion of improved long-term survival with glutamine, and a possible reduction in the need for TPN.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the impact of oral glutamine supplementation to prevent gut atrophy and decrease mucositis and infectious complications in patients undergoing HCT remains controversial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     HEAD AND NECK CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head and neck cancer (HNC) is commonly diagnosed at an advanced stage. In addition to the alterations in chewing and swallowing that can accompany specific tumors or their surgical treatment, aggressive chemotherapy and RT can lead to dysphagia, odynophagia, and dehydration, all of which may result in malnutrition, treatment interruption, and morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30407?source=see_link\">",
"     \"Overview of head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link\">",
"     \"Management of late complications of head and neck cancer and its treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/24/3466?source=see_link\">",
"     \"Quality of life in head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Nutritional support during RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective series suggest that patients with HNC who receive nutritional support have less weight loss and fewer hospitalizations for treatment-related complications. As an example, in an observational series of 88 patients with locally advanced HNC treated with accelerated twice daily RT (n = 59) or concurrent chemoradiotherapy (n = 29), 36 had undergone prophylactic percutaneous endoscopic gastrostomy (PEG) tube placement prior to starting therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/62\">",
"     62",
"    </a>",
"    ]. Enterally supplemented patients had significantly less average weight loss during therapy (3.1 versus 7.0 kg), required significantly fewer hospitalizations for dehydration and malnutrition, and had fewer interruptions in their cancer treatment (0 versus 18 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/63/20473?source=see_link\">",
"     \"Percutaneous endoscopic gastrostomy (PEG) tubes: Uses and efficacy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, whether the benefits of enteral nutritional support translate into better outcomes from cancer therapy is unclear. In a randomized trial, 40 patients with inoperable squamous cell carcinoma of the nasopharynx and oropharynx were randomly assigned to oral nutrition or intensive nasogastric tube feedings during RT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/63\">",
"     63",
"    </a>",
"    ]. Despite the significantly higher caloric intake of the NG-supplemented group, and less weight loss during treatment in this group, radiation response rates and overall survival were similar. Slightly more patients who received tube feedings returned to their regular activities after six months of follow-up, compared to controls (62 versus 45 percent). This trial had limited power to find significant differences with its small sample size.",
"   </p>",
"   <p>",
"    For patients who are able to swallow, aggressive oral nutritional support may provide similar benefit to gastrostomy feedings, as illustrated by the following two trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one small trial, patients undergoing RT for HNC were randomly assigned to aggressive oral feeding with nutritional supplements or no additional nutritional support [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/64\">",
"       64",
"      </a>",
"      ]. Treatment-related toxicity necessitated interruption of RT in significantly more patients not receiving nutritional support (5 of 12, compared to 0 of 11). However, radiation outcomes were not reported.",
"     </li>",
"     <li>",
"      A benefit for dietary counseling was suggested in a trial in which 75 patients with HNC undergoing RT were randomly assigned to dietary counseling with regular foods (n = 25), usual diet plus supplements (n = 25), or usual diet only [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/65\">",
"       65",
"      </a>",
"      ]. At three months, patients who received dietary counseling improved their oral intake while those in the other two groups returned to, or below, baseline. This group also had the greatest improvement in anorexia, xerostomia, and dysgeusia at three months. QOL outcomes also favored dietary counseling.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Multimodality treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concurrent or sequential chemotherapy and RT represents a promising approach for patients with advanced HNC, particularly for preservation of organ function. However, combined therapy is associated with enhanced mucosal toxicity; loss of 8 to 10 percent of body weight is common, even with early nutritional support [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In uncontrolled studies of patients undergoing combined modality therapy for HNC, prophylactic nutritional support has been associated with increase in body weight, preservation of pretreatment nutritional status, improved QOL, fewer toxicity-related treatment interruptions, and shorter duration of hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/68-72\">",
"     68-72",
"    </a>",
"    ]. However, as with RT alone, it is unclear whether the enteral nutritional support improves overall outcomes from therapy, especially survival; prospective investigations have not been conducted.",
"   </p>",
"   <p>",
"    There is insufficient evidence to determine the optimal method of enteral feeding in patients with head and neck cancer (HNC) who are receiving multimodality therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/73\">",
"     73",
"    </a>",
"    ]. A single randomized trial comparing gastrostomy (eg, percutaneous endoscopic gastrostomy [PEG]) versus nasogastric tube (NGT) approaches in patients undergoing chemoradiotherapy for HNC (which closed early for slow accrual with only 33 patients eligible for analysis) concluded that there were no significant differences in complication rates or patient assessment of QOL; PEG was 10 times more costly than NGT feedings and the duration of PEG use was significantly longer (139 versus 66 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional data are available from two retrospective comparative studies. In one, gastrostomy feeding was associated with better cosmesis, mobility and QOL [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/69\">",
"     69",
"    </a>",
"    ], while the other suggests that PEG nutritional support was associated with a longer duration of support (28 versus 8 weeks) and more dysphagia after completion of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/70\">",
"     70",
"    </a>",
"    ]. Approximately 8 to 20 percent of long-term survivors become gastrostomy tube-dependent. Preexisting swallowing difficulties and advanced T-stage were associated with an increased risk of prolonged gastrostomy tube dependence.",
"   </p>",
"   <p>",
"    Long-term QOL may be affected by the prolonged presence of PEG tubes following primary surgery for oral and oropharyngeal cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/75\">",
"     75",
"    </a>",
"    ]. Follow-up of 243 patients who had surgery for oropharyngeal cancer noted that those patients with PEG tubes still in place (median 34 months) had a poorer QOL than patients who had their PEG tubes removed (median seven months) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/76\">",
"     76",
"    </a>",
"    ]. The major PEG tube-related problems were not leakage, blockage, or discomfort, but interference with family life, intimate relationships, social activities, and hobbies. It should be noted that these data do not prove that poorer quality of life in the long-term PEG tube patients is necessarily due to the PEG tubes that are present, which could be influenced by the fact that patients with more severe disease (cancer",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    complications of cancer treatment) need to have the PEG tubes in place for a longer time.",
"   </p>",
"   <p>",
"    In the absence of well-conducted, robust clinical data, it is impossible to provide definitive conclusions on whether PEG feedings or NGT feedings are preferable. In our own anecdotal experience, however, the NGT seems less preferable to gastrostomy placement in the eyes of healthcare providers because of discomfort, negative cosmetic effects, fears of erosion of the tubing into surrounding structures as it sits in the nostril and descends beyond the oropharynx, less secure positioning, and even hypothetical concerns for tumor seeding with initial insertion. However, decisions need to be undertaken on a case-by-case basis with input from the patients and other members of the healthcare team.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Perioperative nutritional support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malnourished patients who are undergoing resection for HNC may benefit from perioperative nutritional support. In one report, factors associated with the need for long-term nutritional support included heavy alcohol use, tongue base surgery or pharyngectomy, myocutaneous flap reconstruction, or the need for postoperative RT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of immunonutrition in this setting is controversial as indicated by the following data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one double-blind trial, 136 patients undergoing resection for HNC were randomly assigned to perioperative nutritional supplementation with arginine, omega-3 fatty acids and RNA, or a standard enteral nutritional formula [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/78\">",
"       78",
"      </a>",
"      ]. Patients receiving the supplemented formula had significantly fewer postoperative infectious complications and a higher serum albumin concentration when compared to standard formula.",
"     </li>",
"     <li>",
"      Contrasting results were noted in a second small trial of 49 patients with HNC and a preoperative weight loss &gt;10 percent of body weight, who were randomly assigned to standard postoperative tube-feeding, preoperative plus postoperative tube feeding, or arginine-supplemented preoperative and postoperative tube feeding [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/79\">",
"       79",
"      </a>",
"      ]. Compared with only postoperative feeding, preoperative enteral nutrition with or without arginine supplementation did not significantly improve nutritional status, decrease the incidence of major postoperative complications, or alter survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ESOPHAGEAL CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional issues are important for patients with localized esophageal cancer, many of whom present in a nutritionally depleted state from progressive dysphagia. Some degree of malnutrition is present in up to 80 percent of patients at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32250?source=see_link&amp;anchor=H30#H30\">",
"     \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who undergo multimodality therapy for esophageal or esophagogastric junction (EGJ) cancer often have significantly worse nutritional parameters than do those who only undergo resection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/82\">",
"     82",
"    </a>",
"    ]. The side effects of chemotherapy include nausea, vomiting, and diarrhea; the use of concurrent radiation therapy frequently causes odynophagia that further aggravates preexisting dysphagia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. Malnutrition itself reduces the rate of patient tolerance of a complete chemoradiotherapy regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/85\">",
"     85",
"    </a>",
"    ], and it becomes an even more important issue among patients who are candidates for esophagectomy following chemoradiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/82,86,87\">",
"     82,86,87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=see_link\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39738?source=see_link\">",
"     \"Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients who are able to eat upon initial presentation will require some form of supplementation during the course of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/85,88\">",
"     85,88",
"    </a>",
"    ]. Because of this, some centers advocate routine placement of a feeding tube in all patients undergoing multimodality treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/89,90\">",
"     89,90",
"    </a>",
"    ], although this is not a universal practice.",
"   </p>",
"   <p>",
"    Early evaluation and intervention by a dietitian can identify patients who have nutritional risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/91\">",
"     91",
"    </a>",
"    ], and who may benefit from close nutritional monitoring and potentially from nutritional interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/90,92\">",
"     90,92",
"    </a>",
"    ]. Dietary measures alone (oral nutritional supplements, frequent small meals during treatment with avoidance of abrasive, spicy, or acidic foods) may allow some patients to maintain nutrition through the course of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/80\">",
"     80",
"    </a>",
"    ]. While the use of oral nutritional supplementation does not dramatically alter surgical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/93-96\">",
"     93-96",
"    </a>",
"    ], it improves perioperative weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/97,98\">",
"     97,98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who fail conservative measures may need additional nutritional supplementation. While the evidence base to support the benefit of supplemental feeding is weak, retrospective series suggest that nutritional support may improve the higher mortality associated with preoperative nutritional depletion in patients undergoing neoadjuvant chemoradiotherapy, and prevent further nutritional deterioration [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/99-101\">",
"     99-101",
"    </a>",
"    ]. In a retrospective review of 30 patients who were unable to maintain an oral diet and who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (TPN) during neoadjuvant therapy for esophageal cancer, the patients receiving TPN tolerated higher doses of chemotherapy than did those who did not, and their surgical outcomes were similar to that of patients who were able to maintain an oral diet [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/94\">",
"     94",
"    </a>",
"    ]. Whether the benefit had anything to do with TPN, or was simply a reflection of patient selection bias is unclear.",
"   </p>",
"   <p>",
"    Although randomized trials have failed to demonstrate either improved treatment tolerance, or a survival benefit from nutritional support, they were not restricted to malnourished patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/93-96\">",
"     93-96",
"    </a>",
"    ]. Benefit has been shown when this intervention is restricted to malnourished patients undergoing major cancer surgery. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'The perioperative setting'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Timing of the nutritional support may also be a relevant factor. Many studies have provided only postoperative nutritional support. Others have noted a trend toward a decrease in major postoperative complications in patients with esophageal cancer who were malnourished and who received TPN prior to surgery when compared to those who did not receive TPN or received it only after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6369471\">",
"    <span class=\"h2\">",
"     Special issues related to enteral feeding support",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who need adjunctive nutritional support, enteral nutritional support is generally seen as superior to parenteral nutrition in a patient with a functioning gut. In the postoperative setting, it is associated with fewer complications and more efficacious reversal of malnutrition. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'The perioperative setting'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are some special considerations for enteral feeding support in patients who are being treated for esophageal cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most of the experience with tube feeding in cancer patients comes from the use of percutaneous endoscopic gastrostomy (PEG) tubes. However, PEGs are sometimes avoided in operable patients with esophagus cancer because of the risk of injuring the gastroepiploic artery, thus rendering the stomach unusable as a replacement conduit for the esophagus. However, others have shown that PEG placement is safe in the setting of esophageal cancer, and that it does not compromise the stomach or esophagogastric anastomosis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/90\">",
"       90",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Placement of a jejunostomy (J) tube avoids potential injury to the stomach. J tubes can be placed using either an open or a laparoscopic technique. J tubes can also be placed via a percutaneous endoscopic technique, but compared to PEG tubes, rates of moderate to severe complications are higher (2 to 10 percent), and success rates are lower (approximately 70 percent). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33592?source=see_link\">",
"       \"Enteral feeding: Gastric versus post-pyloric\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21016357\">",
"    <span class=\"h1\">",
"     END OF LIFE AND CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The great majority of patients in the terminal phase of an advanced illness such as cancer experience reduced oral intake before death, either voluntarily or because they are unable to take in sufficient nutrients and fluids for a variety of reasons, such as loss of appetite, nausea, vomiting, dysphagia, generalized weakness, gastrointestinal tract obstruction, or impaired cognition. While nutrient supplementation might appear ideal to control or reverse malnutrition, several clinical trials have failed to demonstrate a positive effect in reversing weight loss, improving quality of life, or prolonging survival. Several groups such as the Working Group for Developing Guidelines for Parenteral Nutrition of the German Association for Nutritional Medicine, the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    , and the American Society of Parenteral Nutrition specifically recommend against routine administration of parenteral nutrition in patients with advanced cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/21,103,104\">",
"     21,103,104",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/34/13866?source=see_link\">",
"     \"End of life care: Stopping nutrition and hydration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, in highly selected patients (eg, high-grade bowel obstruction or malabsorption from advanced cancer) who might otherwise have a prognosis that is measured in several months or years, home parenteral nutritional support may be considered after extensive deliberation among the healthcare staff, the patient, and family members [",
"    <a class=\"abstract\" href=\"UTD.htm?29/4/29770/abstract/42,105\">",
"     42,105",
"    </a>",
"    ]. Even under such circumstances, however, the use of parenteral nutrition is the exception rather than the rule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/40/1667?source=see_link\">",
"       \"Patient information: Managing loss of appetite and weight loss with cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malnutrition occurs in 40 to 80 percent of cancer patients and is a major cause of morbidity and mortality in patients with advanced disease. It is particularly frequent in patients with digestive and upper aerodigestive tract tumors. Malnutrition is associated with poorer overall survival in various malignancies, as well as reduced benefit from cancer therapy, increased chemotherapy-related toxicity, and poorer quality of life.",
"      <br/>",
"      <br/>",
"      In some cases, malnutrition may be related to inability to ingest or absorb nutrients because of the primary disease process or its treatment, but in other cases, it is attributable to cancer-associated",
"      <span class=\"nowrap\">",
"       anorexia/cachexia",
"      </span>",
"      syndrome. (See",
"      <a class=\"local\" href=\"#H21016143\">",
"       'Nutritional status and cancer outcomes'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Use of the term &ldquo;malnutrition&rdquo; does not indicate that the provision of nutrition is the answer to this set of circumstances.",
"     </li>",
"     <li>",
"      Nutritional support may improve outcomes in selected cancer patients. However, due to the paucity of evidence demonstrating benefit, the indiscriminate use of enteral or parenteral nutrition in well-nourished or mildly malnourished patients with cancer should be avoided. Oral nutritional interventions might improve some aspects of quality of life in patients with cancer who are malnourished or at risk for malnutrition, but they do not appear to improve survival.",
"     </li>",
"     <li>",
"      Parenteral or enteral nutritional supplementation may be an appropriate option for cancer patients who meet",
"      <strong>",
"       both",
"      </strong>",
"      of the following criteria (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications and benefits of nutritional support in cancer patients'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      They are either notably malnourished or at risk of becoming so during cancer treatment.",
"     </li>",
"     <li>",
"      They have a potentially curable disease or look forward to the promise of a long disease-free period after cancer treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Given the results of available randomized trials, we recommend that adjunctive nutritional therapy for cancer patients be limited to the following circumstances (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Malnourished patients who are undergoing major abdominal surgery (see",
"      <a class=\"local\" href=\"#H5\">",
"       'The perioperative setting'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      During hematopoietic cell transplantation for patients who have severe mucositis or gastrointestinal manifestations of graft versus host disease, when a long period of insufficient oral intake is anticipated (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Hematopoietic cell transplantation'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      During combined modality therapy for head and neck cancer (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Head and neck cancer'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The role of nutritional support in patients with localized esophageal cancer who are undergoing concurrent chemotherapy and RT followed by surgery is less clear. Although some centers advocate routine placement of a feeding tube in all patients undergoing multimodality treatment, this is not a universal practice. The use of nutritional support in these patients should be decided on a case-by-case basis. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Esophageal cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enteral formulas that are supplemented with L-arginine, RNA nucleotides, and omega-3 fatty acids are often referred to as immunonutrition. Given the limitations of the available data and the higher cost of immunonutrition, we suggest that immunonutrition not be routinely chosen over standard formulas for enteral nutritional support (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Immunonutrition'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      Although there is controversy as to when parenteral nutritional support is indicated, it is justified in a malnourished patient undergoing cancer surgery when enteral nutrition is not a viable option, where there is a strong possibility that a patient may be cured of his or her malignancy or attain a substantial improvement in survival as a result of cancer therapy. Even under these circumstances, the benefits of parenteral nutrition must be counterbalanced by the risks associated with its use. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/58/8102?source=see_link&amp;anchor=H12#H12\">",
"       \"Nutrition support in critically ill patients: Parenteral nutrition\", section on 'Complications'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If the decision is made to utilize TPN in a patient who has been malnourished for days to weeks, the patient should be watched carefully for refeeding syndrome, which is characterized by potentially life-threatening metabolic derangements. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Parenteral nutrition'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=see_link&amp;anchor=H252082#H252082\">",
"       \"Eating disorders: Treatment\", section on 'Refeeding syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is little if any justification for the use of nutritional support in patients with advanced cancer who are terminally ill and who have an estimated life span that is measured in weeks to a few months. We recommend against the use of TPN for most patients in this setting (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Among patients with advanced incurable cancers, TPN appears to be justified only if the patient has trouble with nutrition because of intestinal failure (eg, short bowel syndrome or unresectable obstruction) but otherwise has a prognosis that would likely be measured in term of many months or years. (See",
"      <a class=\"local\" href=\"#H21016357\">",
"       'End of life and cancer'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102159813\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to recognize Dr. Darlene Kelly, who contributed to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/1\">",
"      Koretz RL, Avenell A, Lipman TO, et al. Does enteral nutrition affect clinical outcome? A systematic review of the randomized trials. Am J Gastroenterol 2007; 102:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/2\">",
"      Koretz RL, Lipman TO, Klein S, American Gastroenterological Association. AGA technical review on parenteral nutrition. Gastroenterology 2001; 121:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/3\">",
"      Howard L. Home parenteral nutrition: survival, cost, and quality of life. Gastroenterology 2006; 130:S52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/4\">",
"      Nitenberg G, Raynard B. Nutritional support of the cancer patient: issues and dilemmas. Crit Rev Oncol Hematol 2000; 34:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/5\">",
"      Lees J. Incidence of weight loss in head and neck cancer patients on commencing radiotherapy treatment at a regional oncology centre. Eur J Cancer Care (Engl) 1999; 8:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/6\">",
"      Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980; 69:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/7\">",
"      Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 1998; 34:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/8\">",
"      Senesse P, Assenat E, Schneider S, et al. Nutritional support during oncologic treatment of patients with gastrointestinal cancer: who could benefit? Cancer Treat Rev 2008; 34:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/9\">",
"      Jagoe RT, Goodship TH, Gibson GJ. The influence of nutritional status on complications after operations for lung cancer. Ann Thorac Surg 2001; 71:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/10\">",
"      Rey-Ferro M, Casta&ntilde;o R, Orozco O, et al. Nutritional and immunologic evaluation of patients with gastric cancer before and after surgery. Nutrition 1997; 13:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/11\">",
"      Barret M, Malka D, Aparicio T, et al. Nutritional status affects treatment tolerability and survival in metastatic colorectal cancer patients: results of an AGEO prospective multicenter study. Oncology 2011; 81:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/12\">",
"      Salas S, Deville JL, Giorgi R, et al. Nutritional factors as predictors of response to radio-chemotherapy and survival in unresectable squamous head and neck carcinoma. Radiother Oncol 2008; 87:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/13\">",
"      Aslani A, Smith RC, Allen BJ, et al. The predictive value of body protein for chemotherapy-induced toxicity. Cancer 2000; 88:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/14\">",
"      van Eys J. Effect of nutritional status on responses to therapy. Cancer Res 1982; 42:747s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/15\">",
"      Hammerlid E, Wirblad B, Sandin C, et al. Malnutrition and food intake in relation to quality of life in head and neck cancer patients. Head Neck 1998; 20:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/16\">",
"      Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME. Cancer: disease and nutrition are key determinants of patients' quality of life. Support Care Cancer 2004; 12:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/17\">",
"      Tian J, Chen JS. Nutritional status and quality of life of the gastric cancer patients in Changle County of China. World J Gastroenterol 2005; 11:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/18\">",
"      Perioperative total parenteral nutrition in surgical patients. The Veterans Affairs Total Parenteral Nutrition Cooperative Study Group. N Engl J Med 1991; 325:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/19\">",
"      Ryu SW, Kim IH. Comparison of different nutritional assessments in detecting malnutrition among gastric cancer patients. World J Gastroenterol 2010; 16:3310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/20\">",
"      Kim JY, Wie GA, Cho YA, et al. Development and validation of a nutrition screening tool for hospitalized cancer patients. Clin Nutr 2011; 30:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/21\">",
"      August DA, Huhmann MB, American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors. A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. JPEN J Parenter Enteral Nutr 2009; 33:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/22\">",
"      Arends J, Bodoky G, Bozzetti F, et al. ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. Clin Nutr 2006; 25:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/23\">",
"      Bauer JD, Ash S, Davidson WL, et al.. Evidence-based guidelines for the nutritional management of cancer cachexia and chronic kiendy disease. Nutr Dietetics 2006; 63:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/24\">",
"      Robien K, Levin R, Pritchett E, et al. American Dietetic Association: standards of practice and standards of professional performance for registered dietitians (generalist, specialty, and advanced) in oncology nutrition care. J Am Diet Assoc 2006; 106:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/25\">",
"      Shang E, Weiss C, Post S, Kaehler G. The influence of early supplementation of parenteral nutrition on quality of life and body composition in patients with advanced cancer. JPEN J Parenter Enteral Nutr 2006; 30:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/26\">",
"      Hasenberg T, Essenbreis M, Herold A, et al. Early supplementation of parenteral nutrition is capable of improving quality of life, chemotherapy-related toxicity and body composition in patients with advanced colorectal carcinoma undergoing palliative treatment: results from a prospective, randomized clinical trial. Colorectal Dis 2010; 12:e190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/27\">",
"      Baldwin C, Spiro A, Ahern R, Emery PW. Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2012; 104:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/28\">",
"      Elia M, Van Bokhorst-de van der Schueren MA, Garvey J, et al. Enteral (oral or tube administration) nutritional support and eicosapentaenoic acid in patients with cancer: a systematic review. Int J Oncol 2006; 28:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/29\">",
"      Halfdanarson TR, Thordardottir E, West CP, Jatoi A. Does dietary counseling improve quality of life in cancer patients? A systematic review and meta-analysis. J Support Oncol 2008; 6:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/30\">",
"      Gregg JR, Cookson MS, Phillips S, et al. Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer. J Urol 2011; 185:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/31\">",
"      Kathiresan AS, Brookfield KF, Schuman SI, Lucci JA 3rd. Malnutrition as a predictor of poor postoperative outcomes in gynecologic cancer patients. Arch Gynecol Obstet 2011; 284:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/32\">",
"      Garth AK, Newsome CM, Simmance N, Crowe TC. Nutritional status, nutrition practices and post-operative complications in patients with gastrointestinal cancer. J Hum Nutr Diet 2010; 23:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/33\">",
"      Sungurtekin H, Sungurtekin U, Balci C, et al. The influence of nutritional status on complications after major intraabdominal surgery. J Am Coll Nutr 2004; 23:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/34\">",
"      Brennan MF, Pisters PW, Posner M, et al. A prospective randomized trial of total parenteral nutrition after major pancreatic resection for malignancy. Ann Surg 1994; 220:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/35\">",
"      Detsky AS, Baker JP, O'Rourke K, Goel V. Perioperative parenteral nutrition: a meta-analysis. Ann Intern Med 1987; 107:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/36\">",
"      Smith RC, Hartemink RJ, Hollinshead JW, Gillett DJ. Fine bore jejunostomy feeding following major abdominal surgery: a controlled randomized clinical trial. Br J Surg 1985; 72:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/37\">",
"      M&uuml;ller JM, Keller HW, Brenner U, et al. Indications and effects of preoperative parenteral nutrition. World J Surg 1986; 10:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/38\">",
"      M&uuml;ller JM, Brenner U, Dienst C, Pichlmaier H. Preoperative parenteral feeding in patients with gastrointestinal carcinoma. Lancet 1982; 1:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/39\">",
"      Fan ST, Lo CM, Lai EC, et al. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med 1994; 331:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/40\">",
"      Bozzetti F, Gavazzi C, Miceli R, et al. Perioperative total parenteral nutrition in malnourished, gastrointestinal cancer patients: a randomized, clinical trial. JPEN J Parenter Enteral Nutr 2000; 24:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/41\">",
"      Heyland DK, MacDonald S, Keefe L, Drover JW. Total parenteral nutrition in the critically ill patient: a meta-analysis. JAMA 1998; 280:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/42\">",
"      Hoda D, Jatoi A, Burnes J, et al. Should patients with advanced, incurable cancers ever be sent home with total parenteral nutrition? A single institution's 20-year experience. Cancer 2005; 103:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/43\">",
"      Marinella MA. Refeeding syndrome: an important aspect of supportive oncology. J Support Oncol 2009; 7:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/44\">",
"      Bozzetti F, Braga M, Gianotti L, et al. Postoperative enteral versus parenteral nutrition in malnourished patients with gastrointestinal cancer: a randomised multicentre trial. Lancet 2001; 358:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/45\">",
"      Martignoni ME, Friess H, Sell F, et al. Enteral nutrition prolongs delayed gastric emptying in patients after Whipple resection. Am J Surg 2000; 180:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/46\">",
"      Cerantola Y, H&uuml;bner M, Grass F, et al. Immunonutrition in gastrointestinal surgery. Br J Surg 2011; 98:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/47\">",
"      Marik PE, Zaloga GP. Immunonutrition in high-risk surgical patients: a systematic review and analysis of the literature. JPEN J Parenter Enteral Nutr 2010; 34:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/48\">",
"      Marimuthu K, Varadhan KK, Ljungqvist O, Lobo DN. A meta-analysis of the effect of combinations of immune modulating nutrients on outcome in patients undergoing major open gastrointestinal surgery. Ann Surg 2012; 255:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/49\">",
"      Weisdorf SA, Lysne J, Wind D, et al. Positive effect of prophylactic total parenteral nutrition on long-term outcome of bone marrow transplantation. Transplantation 1987; 43:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/50\">",
"      Szeluga DJ, Stuart RK, Brookmeyer R, et al. Nutritional support of bone marrow transplant recipients: a prospective, randomized clinical trial comparing total parenteral nutrition to an enteral feeding program. Cancer Res 1987; 47:3309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/51\">",
"      Charuhas PM, Fosberg KL, Bruemmer B, et al. A double-blind randomized trial comparing outpatient parenteral nutrition with intravenous hydration: effect on resumption of oral intake after marrow transplantation. JPEN J Parenter Enteral Nutr 1997; 21:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/52\">",
"      Iestra JA, Fibbe WE, Zwinderman AH, et al. Parenteral nutrition following intensive cytotoxic therapy: an exploratory study on the need for parenteral nutrition after various treatment approaches for haematological malignancies. Bone Marrow Transplant 1999; 23:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/53\">",
"      Klimberg VS, Souba WW, Dolson DJ, et al. Prophylactic glutamine protects the intestinal mucosa from radiation injury. Cancer 1990; 66:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/54\">",
"      Buchman AL. Glutamine: commercially essential or conditionally essential? A critical appraisal of the human data. Am J Clin Nutr 2001; 74:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/55\">",
"      Pironi L, Paganelli GM, Miglioli M, et al. Morphologic and cytoproliferative patterns of duodenal mucosa in two patients after long-term total parenteral nutrition: changes with oral refeeding and relation to intestinal resection. JPEN J Parenter Enteral Nutr 1994; 18:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/56\">",
"      O'Dwyer ST, Smith RJ, Hwang TL, Wilmore DW. Maintenance of small bowel mucosa with glutamine-enriched parenteral nutrition. JPEN J Parenter Enteral Nutr 1989; 13:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/57\">",
"      Ziegler TR, Young LS, Benfell K, et al. Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. A randomized, double-blind, controlled study. Ann Intern Med 1992; 116:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/58\">",
"      Schloerb PR, Amare M. Total parenteral nutrition with glutamine in bone marrow transplantation and other clinical applications (a randomized, double-blind study). JPEN J Parenter Enteral Nutr 1993; 17:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/59\">",
"      Anderson PM, Ramsay NK, Shu XO, et al. Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplant 1998; 22:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/60\">",
"      Schloerb PR, Skikne BS. Oral and parenteral glutamine in bone marrow transplantation: a randomized, double-blind study. JPEN J Parenter Enteral Nutr 1999; 23:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/61\">",
"      Pajak TF, Laramore GE, Marcial VA, et al. Elapsed treatment days--a critical item for radiotherapy quality control review in head and neck trials: RTOG report. Int J Radiat Oncol Biol Phys 1991; 20:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/62\">",
"      Lee JH, Machtay M, Unger LD, et al. Prophylactic gastrostomy tubes in patients undergoing intensive irradiation for cancer of the head and neck. Arch Otolaryngol Head Neck Surg 1998; 124:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/63\">",
"      Daly JM, Hearne B, Dunaj J, et al. Nutritional rehabilitation in patients with advanced head and neck cancer receiving radiation therapy. Am J Surg 1984; 148:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/64\">",
"      Nayel H, el-Ghoneimy E, el-Haddad S. Impact of nutritional supplementation on treatment delay and morbidity in patients with head and neck tumors treated with irradiation. Nutrition 1992; 8:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/65\">",
"      Ravasco P, Monteiro-Grillo I, Marques Vidal P, Camilo ME. Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck 2005; 27:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/66\">",
"      Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/67\">",
"      Brockstein B, Haraf DJ, Stenson K, et al. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol 1998; 16:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/68\">",
"      Marcy PY, Magn&eacute; N, Bensadoun RJ, et al. Systematic percutaneous fluoroscopic gastrostomy for concomitant radiochemotherapy of advanced head and neck cancer: optimization of therapy. Support Care Cancer 2000; 8:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/69\">",
"      Magn&eacute; N, Marcy PY, Foa C, et al. Comparison between nasogastric tube feeding and percutaneous fluoroscopic gastrostomy in advanced head and neck cancer patients. Eur Arch Otorhinolaryngol 2001; 258:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/70\">",
"      Mekhail TM, Adelstein DJ, Rybicki LA, et al. Enteral nutrition during the treatment of head and neck carcinoma: is a percutaneous endoscopic gastrostomy tube preferable to a nasogastric tube? Cancer 2001; 91:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/71\">",
"      Assenat E, Thezenas S, Flori N, et al. Prophylactic percutaneous endoscopic gastrostomy in patients with advanced head and neck tumors treated by combined chemoradiotherapy. J Pain Symptom Manage 2011; 42:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/72\">",
"      Beer KT, Krause KB, Zuercher T, Stanga Z. Early percutaneous endoscopic gastrostomy insertion maintains nutritional state in patients with aerodigestive tract cancer. Nutr Cancer 2005; 52:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/73\">",
"      Nugent B, Lewis S, O'Sullivan JM. Enteral feeding methods for nutritional management in patients with head and neck cancers being treated with radiotherapy and/or chemotherapy. Cochrane Database Syst Rev 2013; 1:CD007904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/74\">",
"      Corry J, Poon W, McPhee N, et al. Randomized study of percutaneous endoscopic gastrostomy versus nasogastric tubes for enteral feeding in head and neck cancer patients treated with (chemo)radiation. J Med Imaging Radiat Oncol 2008; 52:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/75\">",
"      Wanklyn P, Cox N, Belfield P. Outcome in patients who require a gastrostomy after stroke. Age Ageing 1995; 24:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/76\">",
"      Rogers SN, Thomson R, O'Toole P, Lowe D. Patients experience with long-term percutaneous endoscopic gastrostomy feeding following primary surgery for oral and oropharyngeal cancer. Oral Oncol 2007; 43:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/77\">",
"      Schweinfurth JM, Boger GN, Feustel PJ. Preoperative risk assessment for gastrostomy tube placement in head and neck cancer patients. Head Neck 2001; 23:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/78\">",
"      Snyderman CH, Kachman K, Molseed L, et al. Reduced postoperative infections with an immune-enhancing nutritional supplement. Laryngoscope 1999; 109:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/79\">",
"      van Bokhorst-De Van Der Schueren MA, Quak JJ, von Blomberg-van der Flier BM, et al. Effect of perioperative nutrition, with and without arginine supplementation, on nutritional status, immune function, postoperative morbidity, and survival in severely malnourished head and neck cancer patients. Am J Clin Nutr 2001; 73:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/80\">",
"      Riccardi D, Allen K. Nutritional Management of Patients With Esophageal and Esophagogastric Junction Cancer. Cancer Control 1999; 6:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/81\">",
"      Larrea J, Vega S, Mart&iacute;nez T, et al. [The nutritional status and immunological situation of cancer patients]. Nutr Hosp 1992; 7:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/82\">",
"      Han-Geurts IJ, Hop WC, Tran TC, Tilanus HW. Nutritional status as a risk factor in esophageal surgery. Dig Surg 2006; 23:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/83\">",
"      Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/84\">",
"      Kassam Z, Wong RK, Ringash J, et al. A phase I/II study to evaluate the toxicity and efficacy of accelerated fractionation radiotherapy for the palliation of dysphagia from carcinoma of the oesophagus. Clin Oncol (R Coll Radiol) 2008; 20:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/85\">",
"      Daly JM, Weintraub FN, Shou J, et al. Enteral nutrition during multimodality therapy in upper gastrointestinal cancer patients. Ann Surg 1995; 221:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/86\">",
"      Windsor A, Braga M, Martindale R, et al. Fit for surgery: an expert panel review on optmising patients prior to surgery, with a particular focus on nutrition. Surgeon 2004; 2:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/87\">",
"      Gibbs J, Cull W, Henderson W, et al. Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study. Arch Surg 1999; 134:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/88\">",
"      Stockeld D, Tennvall J, Wagenius G, et al. A Swedish study of chemoradiation in squamous cell carcinoma of the esophagus. Acta Oncol 2001; 40:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/89\">",
"      Jenkinson AD, Lim J, Agrawal N, Menzies D. Laparoscopic feeding jejunostomy in esophagogastric cancer. Surg Endosc 2007; 21:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/90\">",
"      Margolis M, Alexander P, Trachiotis GD, et al. Percutaneous endoscopic gastrostomy before multimodality therapy in patients with esophageal cancer. Ann Thorac Surg 2003; 76:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/91\">",
"      Murphy PM, Modi P, Rahamim J, et al. An investigation into the current peri-operative nutritional management of oesophageal carcinoma patients in major carcinoma centres in England. Ann R Coll Surg Engl 2006; 88:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/92\">",
"      Odelli C, Burgess D, Bateman L, et al. Nutrition support improves patient outcomes, treatment tolerance and admission characteristics in oesophageal cancer. Clin Oncol (R Coll Radiol) 2005; 17:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/93\">",
"      Bozzetti F, Cozzaglio L, Gavazzi C, et al. Nutritional support in patients with cancer of the esophagus: impact on nutritional status, patient compliance to therapy, and survival. Tumori 1998; 84:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/94\">",
"      Sikora SS, Ribeiro U, Kane JM 3rd, et al. Role of nutrition support during induction chemoradiation therapy in esophageal cancer. JPEN J Parenter Enteral Nutr 1998; 22:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/95\">",
"      Heslin MJ, Latkany L, Leung D, et al. A prospective, randomized trial of early enteral feeding after resection of upper gastrointestinal malignancy. Ann Surg 1997; 226:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/96\">",
"      Reynolds JV, Kanwar S, Welsh FK, et al. 1997 Harry M. Vars Research Award. Does the route of feeding modify gut barrier function and clinical outcome in patients after major upper gastrointestinal surgery? JPEN J Parenter Enteral Nutr 1997; 21:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/97\">",
"      Beattie AH, Prach AT, Baxter JP, Pennington CR. A randomised controlled trial evaluating the use of enteral nutritional supplements postoperatively in malnourished surgical patients. Gut 2000; 46:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/98\">",
"      Smedley F, Bowling T, James M, et al. Randomized clinical trial of the effects of preoperative and postoperative oral nutritional supplements on clinical course and cost of care. Br J Surg 2004; 91:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/99\">",
"      Takagi K, Yamamori H, Morishima Y, et al. Preoperative immunosuppression: its relationship with high morbidity and mortality in patients receiving thoracic esophagectomy. Nutrition 2001; 17:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/100\">",
"      Takagi K, Yamamori H, Toyoda Y, et al. Modulating effects of the feeding route on stress response and endotoxin translocation in severely stressed patients receiving thoracic esophagectomy. Nutrition 2000; 16:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/101\">",
"      Bower MR, Martin RC 2nd. Nutritional management during neoadjuvant therapy for esophageal cancer. J Surg Oncol 2009; 100:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/102\">",
"      Daly JM, Massar E, Giacco G, et al. Parenteral nutrition in esophageal cancer patients. Ann Surg 1982; 196:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/103\">",
"      Arends J, Zuercher G, Dossett A, et al. Non-surgical oncology - Guidelines on Parenteral Nutrition, Chapter 19. Ger Med Sci 2009; 7:Doc09.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/104\">",
"      Bozzetti F, Arends J, Lundholm K, et al. ESPEN Guidelines on Parenteral Nutrition: non-surgical oncology. Clin Nutr 2009; 28:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/4/29770/abstract/105\">",
"      Brard L, Weitzen S, Strubel-Lagan SL, et al. The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients. Gynecol Oncol 2006; 103:176.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2830 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-869C284B9E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_4_29770=[""].join("\n");
var outline_f29_4_29770=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21016143\">",
"      NUTRITIONAL STATUS AND CANCER OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H590424\">",
"      Screening for nutritional status",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS AND BENEFITS OF NUTRITIONAL SUPPORT IN CANCER PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      THE PERIOPERATIVE SETTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Parenteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Enteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Immunonutrition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HEMATOPOIETIC CELL TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Total parenteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Glutamine supplementation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Parenteral supplementation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Enteral supplementation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      HEAD AND NECK CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Nutritional support during RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Multimodality treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Perioperative nutritional support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ESOPHAGEAL CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6369471\">",
"      Special issues related to enteral feeding support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21016357\">",
"      END OF LIFE AND CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102159813\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17960?source=related_link\">",
"      Clinical features and pathogenesis of cancer cachexia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=related_link\">",
"      Eating disorders: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/34/13866?source=related_link\">",
"      End of life care: Stopping nutrition and hydration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33592?source=related_link\">",
"      Enteral feeding: Gastric versus post-pyloric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32250?source=related_link\">",
"      Epidemiology, pathobiology, and clinical manifestations of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/12/31946?source=related_link\">",
"      Geriatric nutrition: Nutritional issues in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=related_link\">",
"      Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/51/39738?source=related_link\">",
"      Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/58/8102?source=related_link\">",
"      Nutrition support in critically ill patients: Parenteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38250?source=related_link\">",
"      Oral toxicity associated with chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30407?source=related_link\">",
"      Overview of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/40/1667?source=related_link\">",
"      Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/63/20473?source=related_link\">",
"      Percutaneous endoscopic gastrostomy (PEG) tubes: Uses and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6664?source=related_link\">",
"      Perioperative nutritional support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5113?source=related_link\">",
"      Pharmacologic management of cancer anorexia/cachexia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/24/3466?source=related_link\">",
"      Quality of life in head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=related_link\">",
"      Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29306?source=related_link\">",
"      Supportive care after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7081?source=related_link\">",
"      Treatment and prevention of hepatic sinusoidal obstruction syndrome following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_4_29771="Melanoma recur temporal pattern";
var content_f29_4_29771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recurrence patterns over time for patients with locoregional recurrence on the melanoma intergroup trial",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Type of recurrence",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Number of patients recurring",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Percentage of patients recurring according to duration of follow-up, in years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Years 1 and 2",
"       </td>",
"       <td class=\"subtitle2\">",
"        Years 3 and 4",
"       </td>",
"       <td class=\"subtitle2\">",
"        Years 5 or more",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Local",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In transit metastases",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        51",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Regional nodal",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        51",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distant",
"       </td>",
"       <td>",
"        158",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        29",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Karakousis, CP, et al. Ann Surg Oncol 1996; 3:466.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_4_29771=[""].join("\n");
var outline_f29_4_29771=null;
var title_f29_4_29772="Coronary angio valve disease";
var content_f29_4_29772=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Coronary angiography to diagnose coronary artery disease in patients with valvular disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general",
"agreement that coronary angiography should be performed in patients",
"with valvular disease in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Before valve surgery (including for infective endocarditis) in patients with chest pain (although angina is a poor marker for coronary disease in patients with aortic stenosis), other objective evidence of ischemia, or a history of coronary disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Before valve surgery in patients at risk for coronary disease defined as men &ge;35 years of age, premenopausal women &ge;35 years of age who have coronary risk factors, and postmenopausal women. Patients undergoing mitral balloon valvotomy do not require coronary angiography solely on the basis of coronary risk factors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; In patients with apparently mild to moderate valve disease who have progressive angina, objective evidence of ischemia, or either asymptomatic or symptomatic left ventricular dysfunction.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; When a pulmonary autograft (Ross procedure) is considered in patients with aortic stenosis or in adolescents or young adults with aortic regurgitation in whom the origin of the coronary arteries was not identified by noninvasive testing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or",
"opinion is in favor of the usefulness of surgery without coronary",
"angiography in patients with valve disease in the following setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Before emergency valve surgery for acute valve regurgitation, aortic root disease, or infective endocarditis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence or",
"opinion is less well established for the usefulness of coronary",
"angiography in patients with valve disease in the following setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Patients in whom cardiac catheterization is performed to confirm the severity of valve lesions before valve surgery who do not have a history of coronary disease, multiple coronary risk factors, or advanced age.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or",
"general agreement that coronary angiography in patients with valve",
"disease is NOT useful in in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Young patients undergoing nonemergent valve surgery who have no need for further hemodynamic assessment by cardiac catheterization who do not have a history of coronary disease, multiple coronary risk factors, or advanced age.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Before valve surgery in patients who are severely hemodynamically unstable.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_4_29772=[""].join("\n");
var outline_f29_4_29772=null;
var title_f29_4_29773="Causes abnormal uterine bleeding teen";
var content_f29_4_29773=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of abnormal uterine bleeding in the adolescent girl",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td>",
"            Anovulatory uterine bleeding",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Pregnancy-related problems",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Threatened, spontaneous, incomplete, missed AB",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Problems with termination procedures",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ectopic pregnancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Gestational trophoblastic disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Pelvic inflammatory disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Endometritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cervicitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Vaginitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Vaginal abnormalities",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Lacerations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Cervical problems",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cervicitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Polyp",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Hemangioma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Uterine problems",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Submucous myoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Congenital anomalies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Polyp",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            IUD",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Breakthrough bleeding",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ovulatory bleeding",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Blood dyscrasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Thrombocytopenia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Clotting disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Liver disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Endocrine disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Anovulatory bleeding",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Thyroid disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Adrenal disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Hyperprolactinemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Polycystic ovary syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ovarian failure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Ovarian problems",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cyst",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Tumor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Endometriosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trauma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Foreign body",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Systemic disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Diabetes mellitus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Renal disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Systemic lupus erythematosus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Medications",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Hormonal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Anticoagulants, platelet inhibitors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Androgens, spironolactone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Antipsychotics",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Emans SJ. Dysfunctional uterine bleeding. In: Pediatric and Adolescent Gynecology, 5th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.270.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_4_29773=[""].join("\n");
var outline_f29_4_29773=null;
var title_f29_4_29774="Gold vs auranofin in RA I";
var content_f29_4_29774=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F60267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F60267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Progression of erosions with gold therapy in rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 421px; height: 338px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Changes in erosion score in hand X-ray of patients RA who were randomized to therapy with myocrisin, auranofin, or placebo. Patients in both gold groups showed clinical improvement by articular index, grip strength, and morning stiffness. However, these clinical benefits were not confirmed by the hand radiograph erosion score which showed a deterioration in many patients.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Capell, HA, Lewis, D, Carey, J, Ann Rheum Dis 1986; 45:705.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_4_29774=[""].join("\n");
var outline_f29_4_29774=null;
var title_f29_4_29775="Self expanding stent CPC";
var content_f29_4_29775=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Self-expanding metal stent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 206px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view after deployment of a self-expanding metal stent in the distal esophagus extending into the stomach.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andres Gelrud, MD and Douglas Pleskow, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_4_29775=[""].join("\n");
var outline_f29_4_29775=null;
